EQAS CATALOG 2027

INSTAND

EXCELLENCE IN QUALITY

We promote quality in medical laboratories by offering a wide range of external quality controls and continuous education.

ΑΡΗΣΜΑΝΤΖΩΡΟΣ ΑΕ

INSTAND

INSTAND International GMBH

Ubierstr. 20, 40223 Duesseldorf, Germany

T +49 [0] 211 876 3529 0

E info@instand-international.com

Represented by:

Chief Executive Officer: Prof. Dr. rer. nat. Ingo Schellenberg

Register:

Registered in the Registry of Associations

Register Court: Amtsgericht Düsseldorf Register

Number: HRB 95353

Sales tax identification number according to § 27a Sales Tax Act:

DE351329066

Version: 09/2026

Dear Colleagues,

INSTAND celebrates its 60th anniversary in 2026. We want to take this opportunity to thank you for your ongoing collaboration. Our success is based, among other things, on our close collaboration with the scientific community, our valued EQAS/PT experts, and laboratory teams worldwide, who ensure the high quality of our EQAS/PT and processes. To mark this special occasion, we have given our catalog a modern layout and optimized its individual sections.

INSTAND e.V., the Society for promoting Quality Assurance in Medical Laboratories e.V., has been conducting EQAS/PT in all areas of in-vitro diagnostics as a reference institution of the German Medical Association since 1970.

As an External Quality Assessment organization, we are **accredited according to DIN EN ISO/IEC 17043**. We offer **over 400 External Quality Assessment (EQA) schemes/Proficiency Tests (PT)** for external quality control in laboratory diagnostics, in accordance with the current version of the German Medical Association (Rili-BÄK) guidelines. For this purpose, we ship around 165,000 sample sets annually to approximately 12,000 participating laboratories in nearly 80 countries.

We have optimized our **2027 INSTAND EQA Scheme Program** to meet the highest quality standards. Our new features at a glance (see page 11 for detailed information):

- **Molecular Genetics:** New EQAS/PT and EQAS/PT with new parameters
- **Immunology**: New EQAS/PT and EQAS/PT with new parameters
- **Virus Diagnostics:** New EQAS/PT
- Participation will have access to our EQAS/PT the **2027 Pricelist,** including shipping costs, on the INSTAND RV-Online.

The current EQAS/PT program is available on the **RV-Online System** and on our **Website**.

We are excited to continue our excellent and pleasant cooperation with you.

Your INSTAND Team

Prof. Dr. med.
Michael Spannagl
President of the Board

Prof. Dr. rer. nat.
Ingo Schellenberg
Vice President of the Board

Prof. Dr. med.
Klaus-Peter Hunfeld
Vice President of the Board

INSTAND ACADEMY

As a medical-scientific society, we offer an extensive program of continued education on various advanced topics. While the majority of our training programs are currently in German, our English program is growing continuously. New information will be posted on our website and on LinkedIn.

All courses are available on our website

SCAN ME

CALIBRATION LABORATORY

Head: Dr. Patricia Kaiser
kaiser@instand-ev.de

Our calibration laboratory is accredited according to DIN EN ISO/IEC 17025 and DIN EN ISO 15195. We use internationally recognized calibration methods for the metrological traceability of measurement results for measurands in the field of laboratory medicine to SI units. In line with the requirements of the Rili-BÄK, target values in serum, plasma, whole blood, urine, and cerebrospinal fluid are determined in our laboratory as an evaluation standard in EQAS at the level of accuracy. In addition, we also offer our expertise in determining target values as a calibration service for the certification of control and calibration materials for external customers. Our calibration procedures and services are listed in the Joint Committee for Traceability in Laboratory Medicine (**JCTLM**) database.

Measurand	Sample Type	Range		Measuring Method	U[a]
Substrates/Metabolites:					
Cholesterol	Serum/Plasma	1-10	mmol/l	GC-IDMS	1.0%
Glucose	Serum/Plasma	1-60	mmol/l	GC-IDMS	1.0%
	Urine/Liquor	0.5-60	mmol/l		1.0%
Uric acid	Serum/Plasma	50-1000	µmol/l	GC-IDMS	1.0%
	Urine	20-2500	µmol/l		1.0%
Urea	Serum/Plasma	0.5-50	mmol/l	GC-IDMS	1.0%
	Urine	0.5-500	mmol/l		1.0%
Creatinine	Serum/Plasma	25-2000	µmol/l	GC-IDMS	1.0%
	Urine	0.05-40	mmol/l		1.0%
Total Bilirubin[b]	Serum/Plasma	7-600	µmol/l	Photometric Absorbance Measurement	2.5%
Total glycerol	Serum/Plasma	0.5-6	mmol/l	GC-IDMS	1.0%
Hormones:					
Cortisol	Serum/Plasma	30-2000	nmol/l	GC-IDMS	1.0%
Estradiol-17ß	Serum/Plasma	37-2500	pmol/l	GC-IDMS	1.0%
Progesterone	Serum/Plasma	0.5-150	nmol/l	GC-IDMS	1.0%
Testosterone	Serum/Plasma	0.7-69	nmol/l	GC-IDMS	1.5%
Thyroxine	Serum/Plasma	6.4-283	nmol/l	GC-IDMS	1.0%
Ions:					
Calcium	Serum/Plasma	0.5-8	mmol/l	ICP-IDMS	1.0%
Chloride	Serum/Plasma	50-150	mmol/l	ICP-IDMS	1.0%
Potassium	Serum/Plasma	1-10	mmol/l	ICP-IDMS	1.0%
	Urine	1-200	mmol/l		1.0%
Lithium	Serum/Plasma	0.1-5	mmol/l	ICP-IDMS	1.0%
Magnesium	Serum/Plasma	0.1-5	mmol/l	ICP-IDMS	1.0%
Sodium	Serum/Plasma	70-200	mmol/l	ICP-MS	1.0%
	Urine	20-300	mmol/l		1.0%
Enzymes:					
Alanine aminotransferase (ALAT)	Serum/Plasma	0.33-6.67	µkat/l	Kinetic spectrophotometry	2.5%
Aspartate aminotransferase (ASAT)	Serum/Plasma	0.33-6.67	µkat/l		2.5%
Creatine kinase (CK)	Serum/Plasma	0.8-24	µkat/l		2.5%
γ-Glutamyl transferase (GGT)	Serum/Plasma	0.33-5	µkat/l		2.5%
Lactate dehydrogenase (LDH)	Serum/Plasma	1-12	µkat/l		2.5%
Glycated Proteins:					
HbA1c	Blood/Hemolysate	29-150	mmol/mol Hb	LC-MS	1.5%
Proteins:					
Total hemoglobin	Blood/Hemolysate	20-200	g/l	Spectrophotometry	1.1%
Total protein	Serum/Plasma	25-130	g/l		1.5%
Drugs:					
Digitoxin	Serum/Plasma	1-100	nmol/l	LC-IDMS	2.5%
Digoxin	Serum Plasma	0.2-20	nmol/l	LC-IDMS	2.5%
Theophylline	Serum/Plasma	5-500	µmol/l	GC-IDMS	1.0%

[a] best measurement capability

[b] applied to be listed as a calibration service by the JCTLM

For more details about our calibration procedures, please visit our **website**.

Service Information

INSTAND e.V.'s Mission and Vision

We promote quality in medical laboratories by offering a wide range of external quality control and continuous education. Our vision is to improve the reliability of measurement results in medical laboratories worldwide. In the Federal Republic of Germany, INSTAND e.V. is listed by the German Medical Association as a reference institution for external quality assurance.

Accreditation

INSTAND e.V.'s versatile EQA program is accredited in all represented disciplines of laboratory diagnostics by the German Accreditation Body (DAkkS) according to DIN EN ISO/IEC 17043.

Terms and Conditions, FAQ

Our "General Terms and Conditions for Participation in INSTAND e.V. EQA Schemes" shall apply to all participants of the INSTAND e.V. EQA schemes. These terms and conditions can be found at:

https://www.instand-ev.de/en/terms-conditions/

We would also be happy to send them to you upon request. We have compiled answers to frequently asked questions in our FAQ: https://www.instand-ev.de/en/faq/

Costumers of the INSTAND International GMBH, please find the terms and conditions here:

https://www.instand-international.com/terms-conditions/

The INSTAND International GMBH FAQ can be found at:

https://www.instand-international.com/faq-1/

Information about the RV-Online Portal

A user account for our RV-Online system is required to participate in INSTAND e.V. EQA schemes:

https://rv-online.instandev.de/index.shtml?lang=en

After signing into RV-Online, you will be able to manage your master data and orders, as well as enter your EQAS results, view reports and retrieve your certificates. On our YouTube channel you will find in-depth videos that explain the various features of RV-Online in English and German.

Fees for each INSTAND e.V. EQAS

Our prices are net prices which do not include VAT or shipping costs. Taxes and custom duties shall be borne by the participant. These prices apply exclusively to orders placed via INSTAND e.V. Prices and services may differ for orders placed via distributors.

You can find our current price catalog on RV-Online.

Scope of services

An EQA scheme includes the sample material, which is used to determine the measurement values by the participant, as well as an evaluation by INSTAND e.V. of the submitted EQAS results. After evaluating the

EQAS, participants who have submitted their results on time will receive an individual report, a general overview where applicable, a certificate of participation, and a certificate if they have passed. In the event the EQAS is not passed, residual samples may be available after completion of the respective EQAS for a fee, so the participant can check your test systems.

Note: Even if the participant orders more than one sample set per EQAS/PT, we will issue certificates for the specific parameter analyzed in each case, provided all results are deemed accurate. We cannot issue certificates for individual instruments.

Using this Catalog

EQAS/PT required/not required by Rili-BÄK (German Medical Association)

This catalog clearly indicates which EQAS/PT are subject to the Rili-BÄK requirement. The EQAS/PT highlighted in orange in the table of contents include parameters for which participation is mandatory, in accordance with the German Medical Association's guidelines on quality assurance for laboratory medical tests (https://www.bundesaerztekammer.de/en/german-medical-association).

The orange highlighting of Rili-BÄK-mandated analytes is also reflected in the EQAS/PT descriptions. The participant can view the new structure in a sample scenario on page 8.

Validity of Certificates

Certificates are dated with the closing date of the EQA scheme. Certificates for parameters which must undergo an EQAS are valid for twice as long as the mandatory EQAS interval. Certificates for parameters which are not subject to an EQAS in accordance with Rili-BÄK are usually valid for 12 months.

Registration / Cancellation Deadlines

Orders can be changed or cancelled up until the respective registration/cancellation deadline. After the registration/cancellation deadline, it is no longer possible to change the order.

Shipment Date

On the day of shipment, the packages will be picked up by the shipping service provider of our choice. Before every delivery, our shipping service provider will send a tracking number by e-mail. This e-mail is always sent to the main user registered with RV-Online. If the samples do not arrive within a very short period of time, customers of INSTAND should contact the customer service (info@instand-international.com) without delay. The sooner we are informed, the better we can respond to delivery delays.

Submission Deadlines

EQAS/PT results must be entered by midnight CET on the closing date. After the closing date, it is no longer possible to correct or change the values.

Prices

For 2027, we are offering a separate price list for our participants. The price list is available on the RV-Online.

Using this Catalog

A detailed explanation using a hypothetical EQAS/PT

1 **Molecular Oncology – PML::RARA qualitative** 2 NEW! 3 **702**

EQAS/PT Properties 7 4 POCT

Samples: 2 samples of 30 µL
Sample Properties: cDNA solution
Max. number of sample sets: 1
Additional Information:
As required by the RiliBÄK, the method used must have a detection limit of at least 5%.

EQAS/PT Experts: 5 6
Prof. Dr. Karl-Anton Kreuzer

Deputy EQAS/PT Experts:
Dr. rer. nat. Eva Lorsy

8 **Requirement for EQAS/PT according to Rili-BAK:** half-yearly
Validity Certificate: 12 months
Parameter / Analytes:
PML::RARA gene fusion

9 **Not subject to Rili-BAK:**
Validity Certificate: 12 months
Parameter / Analytes:
PML::RARA gene fusion

10 **Shipping Information:**
Shipping not cooled

11 **Safety Information:**
Process as patient sample material

12 **CMS-approved**

13

Dates	Q1		Q2	Q3		Q4
		Apr.				Nov.
Registration Deadline:		27-01-08				27-08-06
Sample Shipment:		27-03-09				27-10-05
Closing Date:		27-04-09				27-11-05

Depending on the EQAS/PT, there may be additional specific comments or notes, such as infectivity, suitable measuring devices, etc.

1. Name of the EQAS/PT
2. New EQAS/PT
3. Group number of the EQAS/PT
4. EQAS/PT groups suitable for POCT
5. EQAS/PT Expert / Deputy EQAS/PT Expert
6. Labeling of groups containing infectious sample material in accordance with UN3373, Category B biological substance, or UN2814, Category A infectious substance (only for EQAS/PT 425)
7. Detailed information about the sample material sent
8. Parameters examined in the EQAS/PT: Parameters highlighted in orange indicate compliance with Rili-BÄK requirements, as well as information on the frequency and validity period of the certificate as prescribed by Rili-BÄK.
9. Proficiency tests not subject to Rili-BÄK requirements: Parameters, black
10. Notes on Shipping Information
11. Important Safety Information regarding this EQAS/PT
12. Marking for EQAS/PT programs that are CMS-approved in the U.S. in accordance with CLIA
13. List of relevant dates by quarter. For Q1 and Q3, participants can take part in the EQAS/PT on two different dates each. The month listed for each EQAS/PT date refers to the submission deadline. The number of available dates may vary by EQAS/PT.

EQA Schemes suitable for POCT

The following EQAS/PT include analytes relevant to point-of-care testing (POCT) and are generally suitable for participation using corresponding POCT systems.

Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

The corresponding EQA schemes are tagged in the catalog with:

Also suitable for POCT: POCT + **Only POCT:** POCT

EQAS/PT also suitable for POCT POCT +

No.	EQAS/PT	Sample Material
100	Clinical Chemistry - Conventional Analysis	Lyophilised serum
131	Fecal Diagnostics - Hb, Hb-Hapto-complex	Lyophilised stool
145	HbA1c	Whole blood (EDTA), not stabilized
151	Lipids/Lipoproteins	Lyophilised serum
161	Blood Gas Analysis	Control solution
162	Blood Gas Analysis - Haemoglobin	Control solution
163	Blood Gas Analysis OPTI Systems	Control solution
171	Urine Chemistry Qualitative	Liquid urine
173	Urine Chemistry Quantitative	Lyophilised urine
174	Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative)	Lyophilised urine
176	Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative)	Lyophilised urine
177	Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative)	Lyophilised urine
179	Urine Chemistry Hormones	Lyophilised urine
203	Tricyclic Antidepressants 04 - Qualitative in Serum	Lyophilised serum
204	Tricyclic Antidepressants 05 - Qualitative in Urine	Lyophilised urine
209	Haematology - Blood Cell Count - QBC System	Whole blood (EDTA), not stabilized
211	Haematology - Blood Cell Count	Stabilized control blood
226	Haemostasis - D-Dimer	Lyophilised plasma
240	hsCRP	Serum

292	Tumor Markers	Liquid Serum
293	Tumor Markers - PSA and Testosterone	Liquid Serum
320	Infection Serology - Procalcitonin	Serum
322	Infection Serology - C-Reactive Protein	Serum
335	Virus Immunology - HIV-1/HIV-2 (Ab)	Liquid serum/plasma
337	Virus Immunology - HIV-1 p24 Antigen	Liquid Serum
344	Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, Anti-HBe)	Liquid Serum
346	Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen)	Liquid serum/plasma
350	Virus Immunology - Dengue Viruses (Ab and NS1 Antigen)	Liquid serum (inactivated in case of Dengue Virus RNA positive samples)
352	Virus Immunology - Epstein Barr Virus (Ab)	Liquid Serum
355	Virus Immunology - Hantaviruses (Ab)	Liquid serum (inactivated in case of Hantavirus RNA positive samples)
359	Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus	Lyophilised cell culture material
370	Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses	Lyophilised cell culture material or allantoic fluid
410	Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)	Liquid cell culture material (inactivated)
481	Mycoserology - Cryptococcus neoformans/ - gattii Antigen	Liquid Serum
539	Bacterial Genome Detection - MRSA or cMRSA	Lyophilised cell suspension
545	Bacterial Genome Detection - Clostridium difficile (Toxin Gene)	Lyophilised cell suspension
546	Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci)	Lyophilised ell suspension
612	Haematology - Differential Blood Count (Machine-Based Analysis)	Whole blood (EDTA), not stabilized
760	Myocardial Markers	Lyophilised Serum
761	Myocardial Markers BNP	Serum / Plasma

EQAS/PT only for POCT

No.	EQAS/PT	Sample Material
286	Haemostasis - POCT	Whole blood (Citrat), not stabilized
800	Dry Chemistry - POCT: Glucose	Whole blood
810	Dry Chemistry - POCT: Abaxis Piccolo System	Lyophilised Serum

NEW as of 2027

New as of 2027:

1. We have optimized and modernized our layout for easier navigation.
   - Our experts are listed by full name for each EQAS/PT.
   - A new feature is the breakdown into “Rili-BÄK-mandatory” and “non-Rili-BÄK-mandatory” categories; see also page 8.
   - New symbols (NEW, Safety Notice, POCT Label) for quick reference.
2. CMS-approved EQAS/PT are clearly marked.
3. All shipping information is in a separate field.
4. Our separate 2027 price catalog is now available to you on RV-Online.
5. We expanded our index to make it easier to search for a specific EQAS/PT.

EQAS/PT newly added to the Program

Molecular Genetics

- EQAS/PT 590 Molecular Pathology – PIK3CA and ESR1
- EQAS/PT 670 Molecular Genetics – Factor V-Gene (F5)
- EQAS/PT 671 Molecular Genetics – Factor VII-Gene (F7)
- EQAS/PT 672 Molecular Genetics – Factor VIII-Gene (F8)
- EQAS/PT 673 Molecular Genetics – Factor IX-Gene (F9)
- EQAS/PT 674 Molecular Genetics – Factor X-Gene (F10)
- EQAS/PT 675 Molecular Genetics – Factor XI-Gene (F11)
- EQAS/PT 676 Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG)
- EQAS/PT 677 Molecular Genetics – Factor XIII-Gene (F13A1, F13B)
- EQAS/PT 678 Molecular Genetics – von Willebrand Factor-Gene (VWF)
- EQAS/PT 701 Molecular Genetics – FLT3 (internal tandem duplication)
- EQAS/PT 702Molecular Oncology – PML::RARA qualitative
- EQAS/PT 706 Molecular Genetics – Hereditary Fever Syndroms
- EQAS/PT 726 Molecular Genetics – UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood
- EQAS/PT 728 Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction

Immunology

- EQAS/PT 256 Autoimmune Diseases – Myositis
- EQAS/PT 268 Autoimmune Diseases – Receptor Encephalitis
- EQAS/PT 657 NK-/ and T cell cytotoxicity

Virus Diagnostics

- EQAS/PT 435 Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens

New Parameter for the following EQAS/PT

Molecular Genetics

- EQAS/PT 850: Added new parameters: Bictegravir, Cabotegravir, Doravirine, and Ganciclovir
- EQAS/PT 851: Added new parameters: Brivaracetam and Perampanel
- EQAS/PT 875: Added “Cariprazine” parameter

Immunology

- EQAS/PT 251: Autoimmune Diseases - Connective Tissue Diseases (ANA)
- EQAS/PT 253: Autoimmune Diseases - Hepatic Syndromes
- EQAS/PT 255: Autoimmune Diseases - Connective Tissue Diseases (ENA)
- EQAS/PT 257: Autoimmune Diseases - Vasculitis / Glomerulopathies
- EQAS/PT 259: Autoimmune Diseases - Autoimmune Dermatitis
- EQAS/PT 265: Autoimmune Diseases - Paraneoplastic Neuropath**ies**

Virus Diagnostics

- EQAS/PT 410: Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)

CMS approved EQAS/PT

We submitted the documentation for conformity approval in accordance with the CLIA amendments for the following EQA/PT schemes: 344, 391, 409, 410, 421, 422, 423, 424, 435, 720. The decision of CMS is expected in autumn and the catalogue will be updated accordingly.

TABLE OF CONTENT

EQAS/PT	No.	Page
MOLECULAR GENETICS		
Engraftment- and Chimerism Diagnostics		
Engraftment- and Chimerism Diagnostics	618	26
Immunohematology		
Immunohaematology 06 - Molecular Diagnostic	235	26
Conventional Genetics		
Molecular Genetics - Aldolase B (ALDOB) Variants (A149P, A174D, N334K)	793	27
Molecular Genetics - Alpha-Globin and beta-Globin	794	27
Molecular Genetics - Alpha1-Antitrypsin (SERPINA1) Variants (PiM, PiS, PiZ)	743	28
Molecular Genetics - Angiotensin Converting Enzyme	763	28
Molecular Genetics - Antithrombin (AT3; SERPINC1 Gene)	792	29
Molecular Genetics - Apolipoprotein (APOE) Variants (E2, E3, E4) - Whole Blood	734	29
Molecular Genetics - Apolipoprotein B APOB, R3500Q (HGVS: c.10580G>A; p.Arg3527Gln), R3500W (HGVS: c.10579C>T; p.Arg3527Trp))	771	30
Molecular Genetics - Apolipoprotein E (APOE) Variants (E2, E3, E4)	744	30
Molecular Genetics - AZF (Y-Chromosome Microdeletions)	788	31
Molecular Genetics - BRCA1 BRCA2	779	31
Molecular Genetics - C-C Motif Chemokine Receptor 5	764	32
Molecular Genetics - CFTR Common Mutations	778	32
Molecular Genetics - Collagen Receptor (ITGA2) Variant C807T	739	33
Molecular Genetics - Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency (CY-P21A2 Gene)	773	33
Molecular Genetics - Connexin 26 (GJB2 Gene, GJB6 Gene)	782	34
Molecular Genetics - Copper-Binding Protein ATP7B Variant (H1069Q)	745	34
Molecular Genetics - ctDNA Tumour Panel	752	35
Molecular Genetics - CYP2C9 CYP2C19 VKORC1 TPMT	775	35
Molecular Genetics - CYP2D6 IL28B	777	36
Molecular Genetics - Dihydropyrimidin Dehydrogenase	762	36
Molecular Genetics - Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) (DMD Gene)	780	37
Molecular Genetics - Factor V-Leiden (F5) Variant	740	37
Molecular Genetics - Factor V-Leiden (F5) Variant - Whole Blood	730	38
Molecular Genetics - Fibrinogen Receptor (ITGB3) Variant HPA 1a/1b	749	38
Molecular Genetics - Fragile X Syndrome (FMR1 Gene, CGG Repeats)	781	39
Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C)	741	39
Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) - Whole Blood	733	40
Molecular Genetics - Huntington Disease (HTT Gene, CAG Repeats)	784	40
Molecular Genetics - Lactase-Variant -13910T>C (MCM6 Gene, IVS13 C-T, rs4988235, HGVS: C.1917+326 C>T)	770	41

TABLE OF CONTENT

EQAS/PT	No.	Page
Molecular Genetics - MLH1 MSH2 MSH6 PMS2 (Lynch)	783	41
Molecular Genetics - MTHFR Variants C677T (optional A1298C)	747	42
Molecular Genetics - MTHFR Variants C677T (optional A1298C) - Whole Blood	732	42
Molecular Genetics - NIPT - Determination of Fetal RhD Status	727	43
Molecular Genetics - NOD2	774	43
Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G)	748	44
Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) - Whole Blood	735	44
Molecular Genetics - Prader-Willi (PWS) und Angelman (AS) Syndromes (Chromosome region 15q11-13, SNRPN)	786	45
Molecular Genetics - Protein C (PROC Gene)	790	45
Molecular Genetics - Protein S (PROS1 Gene)	791	46
Molecular Genetics - Prothrombin (F2) Variant G20210A	746	46
Molecular Genetics - Prothrombin (F2) Variant G20210A - Whole Blood	731	47
Molecular Genetics - Spinal Muscular Atrophy (SMN1 and SMN2 Genes)	787	47
Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) Variants	742	48
Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood	726	48
Molecular Genetics – Factor IX-Gene (F9)	673	49
Molecular Genetics – Factor V-Gene (F5)	670	49
Molecular Genetics – Factor VII-Gene (F7)	671	50
Molecular Genetics – Factor VIII-Gene (F8)	672	50
Molecular Genetics – Factor X-Gene (F10)	674	51
Molecular Genetics – Factor XI-Gene (F11)	675	51
Molecular Genetics – Factor XIII-Gene (F13A1, F13B)	677	52
Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG)	676	52
Molecular Genetics – FLT3 (internal tandem duplication)	701	53
Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction	728	53
Molecular Genetics – von Willebrand Factor-Gene (VWF)	678	54
Molecular Oncology – PML::RARA qualitative	702	54
Molecular Pathology – PIK3CA and ESR1	590	55
Oncology		
Molecular Genetics - Hereditary Fever Syndroms	706	56
Molecular Genetics - Ret Proto-Oncogene (Multiple Endocrine Neoplasia Type 2, MEN2, RET Gene)	738	56
Molecular Oncology - AML-Panel (NGS)	798	57
Molecular Oncology - BRAF	795	57
Molecular Oncology - BTK	796	58
Molecular Oncology - KIT	767	58
Molecular Oncology - MYD88	766	59
Molecular Oncology - Myeloproliferative Neoplasia	768	59
Molecular Oncology - SF3B1	797	60
Molecular Oncology - STAT3	769	60
Molecular Oncology - TP53	765	61

TABLE OF CONTENT

EQAS/PT	No.	Page
IMMUNOLOGY		
Allergy Diagnostics		
Allergy Diagnostic	720	62
Autoimmune Diseases		
Autoimmune Diseases - Antiphospholipid Syndrome	275	62
Autoimmune Diseases - Autoimmune Dermatitis	259	63
Autoimmune Diseases - Autoimmune Endocrinopathies	263	63
Autoimmune Diseases - Connective Tissue Diseases (ANA)	251	64
Autoimmune Diseases - Connective Tissue Diseases (ENA)	255	64
Autoimmune Diseases - Diabetes mellitus	261	65
Autoimmune Diseases - Gluten-Sensitive Enteropathies	271	65
Autoimmune Diseases - Hepatic Syndromes	253	66
Autoimmune Diseases - Myasthenia gravis	269	66
Autoimmune Diseases - Myositis	256	67
Autoimmune Diseases - Paraneoplastic Neuropathies	265	67
Autoimmune Diseases - Peripheral Neuropathies	267	68
Autoimmune Diseases - Receptor Encephalitis	268	68
Autoimmune Diseases - Rheumatoid Arthritis	273	69
Autoimmune Diseases - Vasculitis / Glomerulopathies	257	69
Basophil Activation Test	653	70
HLA Typing		
HLA Diagnostics - High resolution, molecular HLA typing class I and II	444	70
HLA Diagnostics - HLA Antibody Screening and Identification	445	71
HLA Diagnostics - HLA Crossmatching	443	71
HLA Diagnostics - HLA Typing Class I and II of Serological Eqivalents	441	72
HLA Diagnostics - HLA-B27 Determination	440	72
HLA Diagnostics - HLA-DQ	772	73
HLA Diagnostics - Low resolution, molecular HLA typing class I and II	442	73
Immunophenotyping		
Immunophenotyping - Cellular Immunodeficiency Diagnostic	651	74
Functional Immunologic Assays		
Interferon Gamma Release Assay (IGRA)	650	75
Lymphozyte Transformation Test (LTT)	656	76
NK-/ and T cell cytotoxicity	657	76
Oxidative Burst / Phagocytosis Test	654	77

TABLE OF CONTENT

EQAS/PT	No.	Page
Complement Analysis		
Complement Analysis - Anti-C1 Inhibitor Autoantibody	250	77
Complement Analysis - Anti-C1q Autoantibody	245	78
Complement Analysis - Anti-factor H (FH) Autoantibody	249	78
Complement Analysis - C3 - Nephritic Factor	248	79
Complement Analysis - Complement activation products	247	79
Complement Analysis - Functions (F) and Proteins (P)	246	80
TRANSFUSION MEDICINE		
Immunohematology		
Immunohaematology 01	231	81
Immunohaematology 02 (incl. Antibody Identification)	232	81
Immunohaematology 03 - Platelet Immunology	233	82
Immunohaematology 04 - Granulocyte Immunology	234	82
Immunohaematology 05 - Machine-Based Analysis	237	83
Immunohaematology 07 - Machine-Based Analysis (incl. AB Quantitation)	238	83
Immunohaematology 08 - Compatibility Testing (Blood Transfusion)	239	84
CLINICAL CHEMISTRY		
Haematology		
CD19 CAR-T-Cells (quantitative)	822	85
CLL-MRD Immunophenotyping	820	86
Haematology - Blood Cell Count	211	86
Haematology - Blood Cell Count - QBC System	209	87
Haematology - Blood Smear Analysis	212	87
Haematology - Bone Marrow Cytology	218	88
Haematology - Differential Blood Count (Machine-Based Analysis)	612	88
Haematology - Free Haemoglobin	236	89
Haematology - Haemoglobinopathies	210	89
Haematology - Immunophenotyping	214	90
Haematology - Lymphocyte differentiation	213	90
Haematology - PNH Diagnostics	616	91
Haematology - Reticulocyte Analysis Machine-Based Analysis	216	91
Haematology - Reticulocyte Analysis Microscopy	215	92
Haematology - Stem/Progenitor Cells (CD34)	217	92
Haematology - Stem/Progenitor Cells (CD34) (stabilized)	660	93
Haematology - T, B and NK cells in cellular products (flow cytometry)	617	93

TABLE OF CONTENT

EQAS/PT	No.	Page
Hemostaseology		
Haemostasis - Apixaban	504	94
Haemostasis - Argatroban	230	94
Haemostasis - AT, Protein C, Protein S, C1-Inhibitor	225	95
Haemostasis - Compact	285	95
Haemostasis - D-Dimer	226	96
Haemostasis - Dabigatran	502	96
Haemostasis - Edoxaban	505	97
Haemostasis - Emicizumab	506	97
Haemostasis - Factor II, V, VII,X	223	98
Haemostasis - Factor IX, XI, XII, XIII	224	98
Haemostasis - Factor VIII, WF	227	99
Haemostasis - FIB, TZ, FSP	222	99
Haemostasis - Fondaparinux	501	100
Haemostasis - Functional APC Resistance	288	100
Haemostasis - LMW Heparin	281	101
Haemostasis - Orgaran	282	101
Haemostasis - POCT	286	102
Haemostasis - PT, INR, aPTT	221	102
Haemostasis - Rivaroxaban	503	103
Haemostasis - ROTEM Sigma	509	103
Haemostasis - TEG/ROTEM	283	104
Haemostasis - UF Heparin	280	104
Hormones		
Adrenal Gland / Pituitary	298	105
Aldosterone	304	105
Calcium Metabolism / Special Thyroid	301	106
Fertility	297	106
Gravidity - 1st Trimester Screening	305	107
Gravidity - 2nd Trimester Screening	306	107
Hematopoetic Growth Factors	626	108
Pancreas/Gastrointestinal Tract	300	108
Preeclampsia Marker	625	109
Steroid Hormones, Thyroid Gland	302	109
Thyroid Gland Antibodies	295	110
Thyroid Hormones	294	110
Virilization	309	111

TABLE OF CONTENT

EQAS/PT	No.	Page
IgG Subclasses		
IgG Subclasses	244	111
Cardiac Marker		
Myocardial Markers	760	112
Myocardial Markers BNP	761	112
Conventional Clinical Chemistry		
ACE (Angiotensin-Converting-Enzyme)	630	113
Amino Acid Analysis	710	113
Ammonia	118	114
Biogenic Amines in Plasma	185	114
Capillary Zone Electrophoresis	102	115
Clinical Chemistry - Conventional Analysis	100	115
Ethanol	700	116
Fructosamine	146	116
G6PDH (Glucose-6 Phosphate Dehydrogenase)	279	117
Gammopathies	243	117
Glucose - Conventional Analysis	111	118
HbA1c	145	118
Lipids/Lipoproteins	151	119
Markers of Ethanol Abuse - Carbohydrate-Deficient Transferrin (CDT)	750	119
Plasma Cell Neoplasia-MRD Immunophenotyping	821	120
Serum Proteins/Electrophoresis	141	120
Cerebrospinal Fluid		
Cerebrospinal Fluid Analysis - CSF Ferritin	467	121
Cerebrospinal Fluid Analysis - Dementia Markers	466	121
Cerebrospinal Fluid Analysis - Free light chains Kappa	468	122
Cerebrospinal Fluid Analysis - Lactate/ Glucose	464	122
Cerebrospinal Fluid Analysis - MRZ Reaction	463	123
Cerebrospinal Fluid Analysis - Neuroborreliosis	465	123
Cerebrospinal Fluid Analysis - Oligoclonal IgG	462	124
Cerebrospinal Fluid Analysis - Protein Analysis	460	124

TABLE OF CONTENT

EQAS/PT	No.	Page
Newborn Analytic		
Neonatal Bilirubin	110	125
Newborn screening	785	125
Pharmaceuticals		
Antiarrhytmics - Amiodaron	190	126
Antibacterials 01 - Teicoplanin	193	126
Antibacterials 02	890	127
Anticonvulsants 01	191	127
Anticonvulsants 02	192	128
Anticonvulsants 03	871	128
Anticonvulsants 04	872	129
Antifungals / Immunosuppressants	602	129
Antifungals and Chloramphenicol	198	130
Antipsychotics/Antidepressives 01	200	130
Antipsychotics/Antidepressives 02	873	131
Antipsychotics/Antidepressives 03	874	131
Antipsychotics/Antidepressives 04	875	132
Antivirals	850	132
Benzodiazepines 01	876	133
Benzodiazepines 02	877	133
Benzodiazepines 03	878	134
Immunosuppressants	601	134
Paracetamol and NSAIDs	194	135
Psychostimulants - ADHS-Treatment	879	135
Psychotherapeutic Drugs 01	860	136
Psychotherapeutic Drugs 02	861	136
Psychotherapeutic Drugs 03	862	137
Psychotherapeutic Drugs 04	863	137
Respiratory Stimulants - Caffeine	870	138
Therapeutic drugs - Antibiotics, Digitoxin, MTX	197	138
Therapeutic drugs - Antiepileptics, Digoxin, Lithium and others	195	139
Tri-/Tetracyclic Antidepressants 03 - Quantitative in Serum	202	139
Tricyclic Antidepressants 01 - Quantitative in Serum	199	140
Tricyclic Antidepressants 02 - Quantitative in Serum	201	140
Tricyclic Antidepressants 04 - Qualitative in Serum	203	141

TABLE OF CONTENT

EQAS/PT	No.	Page
Photometry		
Photometer Controls	181	141
Plasma Proteins		
Cystatin C	242	142
hsCRP	240	142
Infection Serology - C-Reactive Protein	322	143
Plasmaproteins	241	143
POCT		
Blood Gas Analysis	161	144
Blood Gas Analysis - Haemoglobin	162	144
Blood Gas Analysis OPTI Systems	163	145
Dry Chemistry - POCT: Abaxis Piccolo System	810	145
Dry Chemistry - POCT: Glucose	800	146
Trace Elements		
Trace Elements - whole blood	208	146
Trace Elements Plasma	206	147
Trace Elements Serum	207	147
Stool Diagnostics		
Fecal Diagnostics - Calprotectin / Fecal Elastase	130	148
Fecal Diagnostics - Hb, Hb-Hapto-complex	131	148
Tumor Marker		
Tumor Markers	292	149
Tumor Markers - Calcitonin, Pro-GRP, PIVKAII, AFP, AFP-L3	299	149
Tumor Markers - PSA and Testosterone	293	150
Urine Analysis		
Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative)	174	150
Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative)	176	151
Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative)	177	151
Markers of Ethanol Abuse - Ethylglucuronide	751	152
Systematic Toxicological Analysis (STA)	188	152
Trace Elements Urine	205	153

TABLE OF CONTENT

EQAS/PT	No.	Page
Tricyclic Antidepressants 05 - Qualitative in Urine	204	153
Urinary Stone Analyses	500	154
Urine Chemistry Aminolaevulinic Acid / Porphobilinogen	180	154
Urine Chemistry Biogene Amines	175	155
Urine Chemistry Hormones	179	155
Urine Chemistry Porphyrins	178	156
Urine Chemistry Qualitative	171	156
Urine Chemistry Quantitative	173	157
Urine Chemistry Sediment Pictures	172	157
Urine Protein Differentiation	182	158
Vitamins		
Vitamins - Methylmalonic Acid	187	158
Vitamins - Serum	290	159
Vitamins - Vitamin C	296	159
Vitamins - whole blood	291	160
MICROBIOLOGY		
Bacterial Genome Detection		
Bacterial Genome Detection - Bordetella pertussis	532	161
Bacterial Genome Detection - Borrelia burgdorferi	535	161
Bacterial Genome Detection - Carbapenemase-Genes	544	162
Bacterial Genome Detection - Chlamydia pneumoniae	540	162
Bacterial Genome Detection - Chlamydia trachomatis	531	163
Bacterial Genome Detection - Chlamydia trachomatis & Neisseria gonorrhoeae	530	163
Bacterial Genome Detection - Clostridium difficile (Toxin Gene)	545	164
Bacterial Genome Detection - Coxiella burnetii & Bacillus anthracis	542	164
Bacterial Genome Detection - EHEC / STEC	534	165
Bacterial Genome Detection - Francisella tularensis & Brucella spp.	543	165
Bacterial Genome Detection - Helicobacter pylori	533	166
Bacterial Genome Detection - Legionella pneumophila	536	166
Bacterial Genome Detection - Listeria spp.	538	167
Bacterial Genome Detection - MRSA or cMRSA	539	167
Bacterial Genome Detection - Mycoplasma pneumoniae	541	168
Bacterial Genome Detection - PCR/NAT Multiplex Detection Method for Gastrointestinal Pathogens	548	168
Bacterial Genome Detection - Salmonella enterica	537	169
Bacterial Genome Detection - Urogenital Panel	547	169
Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci)	546	170

TABLE OF CONTENT

EQAS/PT	No.	Page
Bacteriological Infection Serology		
Infection Serology - Bartonella Antibodies	326	170
Infection Serology - Bordetella pertussis Antibodies	317	171
Infection Serology - Borrelia burgdorferi Antibodies	332	171
Infection Serology - Brucella Antibodies	327	172
Infection Serology - Campylobacter Antibodies	319	172
Infection Serology - Chlamydia pneumoniae (Chlamydophila) Antibodies	314	173
Infection Serology - Chlamydia trachomatis Antibodies	312	173
Infection Serology - Chlamydia trachomatis Direct Detection (ELISA / PCR)	313	174
Infection Serology - Chlamydia trachomatis Direct Detection (Slide)	316	174
Infection Serology - Coxiella burnetii Antibodies	325	175
Infection Serology - Diphtheria Toxoid Antibodies	318	175
Infection Serology - Francisella tularensis Antibodies	328	176
Infection Serology - Helicobacter pylori Antibodies	334	176
Infection Serology - Leptospira Antibodies	329	177
Infection Serology - Mycoplasma pneumoniae Antibodies	324	177
Infection Serology - Procalcitonin	320	178
Infection Serology - Rheumatoid Factor	323	178
Infection Serology - Rickettsia Antibodies	330	179
Infection Serology - Salmonella Antibodies	331	180
Infection Serology - Streptococcal AB	321	181
Infection Serology - Tetanus Toxoid Antibodies	310	181
Infection Serology - Treponema pallidum Antibodies	311	182
Infection Serology - Yersinia Antibodies	315	183
Human Microbiome		
Bacterial Genome Detection - Molecular Genetic Analysis of the Human Microbiome	580	183
Conventional Bacteriology		
Bacteriology (3 Samples)	411	184
Bacteriology (5 Samples)	412	185
Bacteriology - Gram Stain	413	185
Mycobacteriology		
Mycobacterial Diagnostics - Cultivation	422	186
Mycobacterial Diagnostics - Drug Susceptibility Testing of Mycobacterium tuberculosis	425	186
Mycobacterial Diagnostics - Drug Susceptibility Testing of Nontuberculous Mycobacteria	427	187

TABLE OF CONTENT

EQAS/PT	No.	Page
Mycobacterial Diagnostics - Identification	423	187
Mycobacterial Diagnostics - Microscopy	421	188
Mycobacterial Diagnostics - Molecular Drug Susceptibility Testing of tuberculosis bacteria	426	188
Mycobacterial Diagnostics - NAT Mycobacterium tuberculosis	424	189
Mycology		
Fungal Genome Detection - Pneumocystis jirovecii	560	189
Genome Detection of Dermatophytes	492	190
Mycology Dermatophytes, Yeasts, Mould Fungus	491	190
Mycology Mucorales, Yeasts, Coelomycetes, Hyphomycetes, Basidiomycetes	490	191
Mycoserology - Candida (Antigen and Antibodies)	480	191
Mycoserology - Cryptococcus neoformans/ - gattii Antigen	481	192
Parasite Diagnostics		
Detection of Toxoplasma DNA (PCR)	457	192
Molecular Genetic Detection of Protozoa in Stool	458	193
Parasite Microscopy (Blood)	456	193
Parasite Serology - Amoebiasis and Echinococcosis	455	194
Parasite Serology - Malaria and Schistosomiasis	454	194
Parasite Serology - Toxoplasmosis	452	195
Virtual Parasite Microscopy (Blood)	906	195
Virtual Parasite Detection (Stool)	907	196
VIRUS DIAGNOSTICS		
Virus Genome Detection		
Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)	410	197
Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses	370	198
Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus	359	199
Virus Genome Detection - Adenoviruses	371	199
Virus Genome Detection - BK Polyomavirus (BKPyV / BKV)	364	200
Virus Genome Detection - Borna Viruses	404	200
Virus Genome Detection - Chikungunya Virus	392	201
Virus Genome Detection - Coronaviruses incl. SARS-CoV-2	340	202
Virus Genome Detection - Cytomegalovirus Program 1	365	203
Virus Genome Detection - Cytomegalovirus Program 2 - additional Training Program (can only be ordered with program 365)	368	203

TABLE OF CONTENT

EQAS/PT	No.	Page
Virus Genome Detection - Cytomegalovirus Resistance Determination	349	204
Virus Genome Detection - Dengue Viruses	369	204
Virus Genome Detection - Enteroviruses	372	205
Virus Genome Detection - Epstein Barr Virus	376	205
Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests	430	206
Virus Genome Detection - Hepatitis A Virus	377	206
Virus Genome Detection - Hepatitis B Virus Genotyping	396	207
Virus Genome Detection - Hepatitis B Virus Program 1	361	207
Virus Genome Detection - Hepatitis B Virus Program 2 - additional Training Program (can only be ordered with program 361)	378	208
Virus Genome Detection - Hepatitis B Virus Resistance Determination	397	208
Virus Genome Detection - Hepatitis C Virus Geno-/Subtyping	375	209
Virus Genome Detection - Hepatitis C Virus Program 1	362	209
Virus Genome Detection - Hepatitis C Virus Program 2 - additional Training Program (can only be ordered with program 362)	379	210
Virus Genome Detection - Hepatitis C Virus Resistance Determination	399	210
Virus Genome Detection - Hepatitis D Virus	400	211
Virus Genome Detection - Hepatitis E Virus	380	211
Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2	363	212
Virus Genome Detection - HIV-1 (RNA) Program 2 - additional Training Program (can only be ordered with program 360)	382	212
Virus Genome Detection - HIV-1 (RNA) Program 1	360	213
Virus Genome Detection - HIV-1 Drug Resistance Determination - Standard Program for Protease and Reverse Transcriptase Inhibitors	383	213
Virus Genome Detection - HIV-1 Drug Resistance Determination - additional Program for Integrase Inhibitors and Tropism Determination	384	214
Virus Genome Detection - HIV-2 (RNA)	395	214
Virus Genome Detection - Human Herpesvirus 6 (HHV-6)	405	215
Virus Genome Detection - Human Herpesvirus 8 (HHV-8)	406	215
Virus Genome Detection - Human Metapneumovirus	385	216
Virus Genome Detection - Human Papillomaviruses (HPV)	373	216
Virus Genome Detection - Human Rhinoviruses	393	217
Virus Genome Detection - JC Polyomavirus (JCPyV / JCV)	394	217
Virus Genome Detection - Measles Virus	386	218
Virus Genome Detection - MPXV / Orthopoxviruses	418	219
Virus Genome Detection - Mumps Virus	387	220
Virus Genome Detection - Norovirus	381	220
Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens	435	221
Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests	433	221
Virus Genome Detection - Parainfluenza Viruses	388	222
Virus Genome Detection - Parechovirus	407	222
Virus Genome Detection - Parvovirus B19	367	223

TABLE OF CONTENT

EQAS/PT	No.	Page
Virus Genome Detection - Rabies Virus (Tollwutvirus)	390	223
Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests	431	224
Virus Genome Detection - Respiratory Virus Panel 2	432	225
Virus Genome Detection - Rotaviruses	401	226
Virus Genome Detection - Rubella Virus	389	226
Virus Genome Detection - SARS-CoV-2	409	227
Virus Genome Detection - SARS-CoV-2 sequence analysis	417	227
Virus Genome Detection - Torque Teno Virus (TTV)	408	228
Virus Genome Detection - Varicella Zoster Virus	366	228
Virus Genome Detection - West Nile Virus	391	229
Virus Genome Detection - Zika Virus	403	229
Virus Immunology		
Virus Immunology - Borna Viruses (Ab)	415	230
Virus Immunology - Chikungunya Virus (Ab)	402	230
Virus Immunology - Cytomegalovirus (Ab)	351	231
Virus Immunology - Dengue Viruses (Ab and NS1 Antigen)	350	231
Virus Immunology - Epstein Barr Virus (Ab)	352	232
Virus Immunology - Hantaviruses (Ab)	355	232
Virus Immunology - Hepatitis A Virus (Ab)	343	233
Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, An-	344	233
Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM)	345	234
Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen)	346	234
Virus Immunology - Hepatitis D Virus (Ab)	347	235
Virus Immunology - Hepatitis E Virus (Ab)	348	235
Virus Immunology - Herpes Simplex Viruses (Ab)	354	236
Virus Immunology - HIV-1 p24 Antigen	337	236
Virus Immunology - HIV-1/HIV-2 (Ab)	335	237
Virus Immunology - HTLV-1/HTLV-2 (Ab)	339	237
Virus Immunology - Measles Virus (Ab)	357	238
Virus Immunology - Mumps Virus (Ab)	356	238
Virus Immunology - Parvovirus B19 (Ab)	342	239
Virus Immunology - Rabies Virus (Tollwutvirus) (Ab)	336	239
Virus Immunology - Rubella Virus (Ab)	341	240
Virus Immunology - SARS-CoV-2 (Ab)	416	240
Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab)	358	241
Virus Immunology - Varicella Zoster Virus (Ab)	353	241
Virus Immunology - Zika Virus (Ab)	338	242

MOLECULAR GENETICS

Engraftment- and Chimerism Diagnostics

Engraftment- and Chimerism Diagnostics 618

EQAS/PT Properties
Samples: 5 samples of 1.5 mL
Sample Properties: Whole blood (CPD),not stabilized
Max. Number of Sample Sets: 1
Additional Information:
- Sample from donors, patients before and after transplantation are sent per appointment. Only annual subscription possible!
- EQAS/PT results can only be submitted online!
- Successful participation in both EQAS rounds is necessary for the award of a certificate (10 samples per year).
- **Due to longer shipment times, labs using FISH-Analyses, cannot participate in this EQA.**

EQAS/PT Experts:
Dr. med. Roland Reibke

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick
Prof. Dr. med. Michael Spannagl

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Evaluation and diagnosis Receiver

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-03-12			27-08-13
Sample Shipment:			27-05-11			27-10-12
Closing Date:			27-05-28			27-10-29

Immunohematology

Immunohaematology 06 - Molecular Diagnostic 235

EQAS/PT Properties
Samples: 4 samples
Sample Properties: DNA
Max. number of sample sets: 1
Additional Information:
A list of the alleles necessary for successful participation can be found at:
www.instand-ev.de/mandatory-alleles

EQAS/PT Experts:
Prof. Dr. med. Ulrich Sachs

Deputy EQAS/PT Experts:
Prof. Dr. med. Willy A. Flegel
Dr. med. Christof Weinstock

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Red cells: ABO, MNS, RHD, RHD-Deletion, RHCE, LU, KEL, FY, JK, DI, YT, DO, CO, LW, KN, VEL. Platelets: HPA-1, 2, 3, 4, 5, 6, 9, 15. Granulocytes: HNA-1a, -1b, -1c; HNA-3, HNA-4, HNA-5.

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Conventional Genetics

Molecular Genetics - Aldolase B (ALDOB) Variants (A149P, A174D, N334K) 793

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Aldolase B: A 149 P Aldolase B: A 174 D Aldolase B: N 334 K
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Alpha-Globin and beta-Globin 794

EQAS/PT Properties **Samples:** 2 samples of 40 µL **Sample Properties:** DNA solution (approx. 50 ng/µL)	**EQAS/PT Experts:** Dr. med. Claudia Frömmel **Deputy EQAS/PT Experts:** Dr. Adriana Méndez
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Mutations in the alpha-globin gene (max. 4) • Genotype of the alpha-globin gene (hemoglobinopathy nomenclature) • Evaluation of the alpha-globin gene • Mutations in the beta-globin gene (max. 4) • Beta-globin gene genotype (hemoglobinopathy nomenclature) • Beta-globin gene evaluation • Report with findings from both the alpha- and beta-globin genes • Report
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Alpha1-Antitrypsin (SERPINA1) Variants (PiM, PiS, PiZ) 743

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Alpha-1 antitrypsin S-Locus Alpha-1 antitrypsin Z-Locus	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Angiotensin Converting Enzyme 763

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** Prof. Dr. med. Folker Wenzel **Deputy EQAS/PT Experts:** N.N
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** ACE Insertions/ Deletions (I/D)- Polymorphismus	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Antithrombin (AT3; SERPINC1 Gene) 792

EQAS/PT Properties **Samples:** 2 Samples of 50 µl **Sample Properties:** DNA solution (approx. 15 ng/µL) **Max. number of sample sets:** 1	**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Analysis of the SERPINC1 gene for small base variations (SNVs) and/or copy number variations (CNVs)	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Apolipoprotein (APOE) Variants (E2, E3, E4) - Whole Blood 734

EQAS/PT Properties **Samples:** 2 samples of 0.5 ml **Sample Properties:** Whole blood **Max. number of sample sets:** 3	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Apo E (genotypes 2, 3, 4)	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline: **Sample Shipment:** **Closing Date:**		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01	

Molecular Genetics - Apolipoprotein B APOB, R3500Q (HGVS: c.10580G>A; p.Arg-3527Gln), R3500W (HGVS: c.10579C>T; p.Arg3527Trp)) 771

EQAS/PT Properties
Samples: 2 samples of 40 µl
Sample Properties: DNA solution (approx. 15 ng/µL)
Additional Information:
Annotation for the evaluation: The successful participation requires the correct identification if the variants R3S00Q (HGVS: c.10580G>A; p.Arg3527Gln) und R3500W (HGVS: c.10579C>T; p.Arg3527Trp) are present (homozygous/heterozygous) or not (negative) in the DNA samples.

EQAS/PT Experts:
Dr. rer. nat. Morten O. Christensen

Deputy EQAS/PT Experts:
Dr. med. Günther Kappert

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Apo B-100 (R3500Q; R3500W)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Interpretation of results

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Apolipoprotein E (APOE) Variants (E2, E3, E4) 744

EQAS/PT Properties
Samples: 3 samples of 20 µl
Sample Properties: DNA solution (approx. 20 ng/µL)

EQAS/PT Experts:
Dr. rer. nat. Ralf Flörke

Deputy EQAS/PT Experts:
Dr. med. Günther Kappert

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Apo E (genotypes 2, 3, 4)

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - AZF (Y-Chromosome Microdeletions) 788

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** PD Dr. rer. nat. Julia Hentschel **Deputy EQAS/PT Experts:** MSc. Simone Ahting
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** Y-Chromosome AZFa deletion Y-Chromosome AZFb deletion Y-Chromosome AZFc deletion	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - BRCA1 BRCA2 779

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** Analysis of the BRCA1/BRCA2 genes for small base variations (SNVs) and/or copy number variations (CNVs)	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - C-C Motif Chemokine Receptor 5 764

EQAS/PT Properties
Samples: 2 samples of 40 µl
Sample Properties: DNA solution (approx. 15 ng/µL)

EQAS/PT Experts:
Prof. Dr. med. Folker Wenzel

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
CCR5 gene (Δ32)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Interpretation of results

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - CFTR Common Mutations 778

EQAS/PT Properties
Samples: 2 samples of 40 µl
Sample Properties: DNA solution (approx. 15 ng/µL)
Additional Information:
- CFTR gene (NM_000492.4). The 34 most common variants detected by standard screening methods will be tested. Participants must be able to identify at least the 34 most common variants. See here for a list of mandatory mutations: www.instand-ev.de/cftr-mandatory-mutations
- Exception: Participants who only test the 31 variants of the child guidelines for CF. These participants are requested to communicate this in the comment field. Participants who only test for F508del cannot participate in this EQA scheme.
- Participants who analyze the complete CFTR gene are also welcome to participate. These participants please communicate variants that are not among the 34 most common variants via the comment field. Participants are asked to comment on the possibility of CFTR modulator therapy.

EQAS/PT Experts:
PD Dr. rer. nat. Julia Hentschel

Deputy EQAS/PT Experts:
MSc. Simone Ahting

Requirement for EQAS/PT according to Rili-BÄK: yearly
Validity Certificate: 24 months
Parameter / Analytes:
CFTR gene

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
- ACMG classification
- Interpretation of results / recommendation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Collagen Receptor (ITGA2) Variant C807T 739

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution						**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Collagen receptor GP Ia/IIa (C 807 T)			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency (CYP21A2 Gene) 773

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** Analysis of the CYP21A2 gene for small base variations (SNVs) and/or copy number variations (CNVs)			**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Connexin 26 (GJB2 Gene, GJB6 Gene) 782

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** Analysis of the GJB2 gene for small base variations (SNVs) and/or copy number variations (CNVs)	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** • Analysis of the GJB6 gene for copy number variations (CNVs) • Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Copper-Binding Protein ATP7B Variant (H1069Q) 745

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** ATP 7 B: H 1069 Q	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - ctDNA Tumour Panel NEW! 752

EQAS/PT Properties
Samples: 2 samples of 3 ml (30 ng/ml cfDNA)
Sample Properties: DNA solution
Max. number of sample sets: 1
Additional Information:
Due to the complex nature of sample preparation, INSTAND e.V. reserves the right to no longer supply EQA samples to laboratories that have repeatedly failed to submit results. Link to the list of mutations: www.instand-ev.de/ctDNA_mutations

EQAS/PT Experts:
Prof. Dr. med. Stefan Holdenrieder

Deputy EQAS/PT Experts:
N.N.

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
BRAF V600-variant(s)
EGFR T790M-variant(s)
KRAS Codon 12-variant(s)
KRAS Codon 13-variant(s)
KRAS Codon 61-variant(s)
NRAS Codon 61-variant(s)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
ESR1-variant(s)
PIK3CA-variant(s)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-28			27-11-05

Molecular Genetics - CYP2C9 CYP2C19 VKORC1 TPMT 775

EQAS/PT Properties
Samples: 2 samples of 40 µl
Sample Properties: DNA solution (approx. 15 ng/µL)

EQAS/PT Experts:
Prof. Dr. med. Folker Wenzel

Deputy EQAS/PT Experts:
N.N.

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
CYP2C19*2 Allele: G 681 A
CYP2C19*3 Allele: G 636 A
CYP2C9*2 Allele: C 430 T
CYP2C9*3 Allele: A 1075 C
TPMT (nt. A 719 G) TPMT (nt. G 460 A)
TPMT*2 Allele (nt. G 238 C)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
VKORC1: C 1173 T
VKORC1: G -1639 A

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-28			27-11-05

Molecular Genetics - CYP2D6 IL28B 777

EQAS/PT Properties
Samples: 2 samples of 40 µl
Sample Properties: DNA solution (approx. 15 ng/µL)

EQAS/PT Experts:
Prof. Dr. med. Folker Wenzel

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
CYP2D6 gene Duplication
CYP2D6*3: A2637 del
CYP2D6*4: G 1934 A
CYP2D6*5: complete Deletion
CYP2D6*6: T1795 del

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
IL-28B C/T: rs 12979860

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-28			27-11-05

Molecular Genetics - Dihydropyrimidin Dehydrogenase 762

EQAS/PT Properties
Samples: 2 samples of 40 µl
Sample Properties: DNA solution (approx. 15 ng/µL)

EQAS/PT Experts:
Dr. rer. nat. Susanna Schubert

Deputy EQAS/PT Experts:
PD Dr. rer. nat. Julia Hentschel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
The following variants are tested in this EQA scheme:
Haplotype B3 (c.1236G>A; c.1129-5923C>G)
c.1679T>G
c.1905+1G>A
c.2846A>T

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Assessment of the influence on enzyme function as well as the dose recommendation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-28			27-11-05

Molecular Genetics - Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) (DMD Gene) 780

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** Analysis of the DMD gene for small base variations (SNVs) and/or copy number variations (CNVs)			**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Factor V-Leiden (F5) Variant 740

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL) **Additional Information:** Please note that this EQA scheme is intended for laboratories that test only for the Factor V Leiden SNP. If you perform a complete genetic analysis of the F5 gene, please participate in EQA scheme 670 - Molecular Genetics – Factor V-Gene (F5).						**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Factor V-Leiden			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Factor V-Leiden (F5) Variant - Whole Blood 730

EQAS/PT Properties **Samples:** 2 samples of 0.5 ml **Sample Properties:** Whole blood **Max. number of sample sets:** 3 **Additional Information:** Please note that this EQA scheme is intended for laboratories that test only for the Factor V Leiden SNP. If you perform a complete genetic analysis of the F5 gene, please participate in EQA scheme 670 - Molecular Genetics – Factor V-Gene (F5).	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Factor V-Leiden	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline: **Sample Shipment:** **Closing Date:**		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01	

Molecular Genetics - Fibrinogen Receptor (ITGB3) Variant HPA 1a/1b 749

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Fibrinogen Receptor HPA: 1a, 1b
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Fragile X Syndrome (FMR1 Gene, CGG Repeats) 781

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** FMR1: determination of CGG-repeats in 5‘ UTR	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** • FMR1: determination of the variant category • Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) 741

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** HFE: C 282 Y HFE: H 63 D HFE: S 65 C	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) - Whole Blood 733

EQAS/PT Properties **Samples:** 2 samples of 0.5 ml **Sample Properties:** Whole blood **Max. number of sample sets:** 3	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** HFE: C 282 Y HFE: H 63 D HFE: S 65 C	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
		Apr.			**Oct.**	
Registration Deadline: **Sample Shipment:** **Closing Date:**		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01	

Molecular Genetics - Huntington Disease (HTT Gene, CAG Repeats) 784

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** Determination of CAG-repeats	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Lactase-Variant -13910T>C (MCM6 Gene, IVS13 C-T, rs4988235, HGVS: C.1917+326 C>T) 770

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Laktase-Gene (LCT) (-13910 C>T; HGVS: c.1917+326C>T)	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - MLH1 MSH2 MSH6 PMS2 (Lynch) 783

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** PD Dr. rer. nat. Julia Hentschel **Deputy EQAS/PT Experts:** MSc. Simone Ahting
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** MLH1 gene MSH2 gene MSH6 gene PMS2 gene - gene analysis (SNVs und CNVs)	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** • HNPCC interpretation • Interpretation of results / recommendation
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - MTHFR Variants C677T (optional A1298C) 747

EQAS/PT Properties
Samples: 3 samples of 20 µl
Sample Properties: DNA solution (approx. 20 ng/µL)

EQAS/PT Experts:
Dr. rer. nat. Ralf Flörke

Deputy EQAS/PT Experts:
Dr. med. Günther Kappert

Requirement for EQAS/PT according to Rili-BÄK:: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
MTHFR (A 1298 C) MTHFR (C 677 T)

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-28			27-11-05

Molecular Genetics - MTHFR Variants C677T (optional A1298C) - Whole Blood 732

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Whole blood
Max. number of sample sets: 3

EQAS/PT Experts:
Dr. rer. nat. Ralf Flörke

Deputy EQAS/PT Experts:
Dr. med. Günther Kappert

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
MTHFR (A 1298 C) MTHFR (C 677 T)

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline:		27-01-08			27-07-02	
Sample Shipment:		27-03-09			27-08-31	
Closing Date:		27-04-09			27-10-01	

Molecular Genetics - NIPT - Determination of Fetal RhD Status 727

EQAS/PT Properties **Samples:** 2 samples of 1.5 ml **Sample Properties:** Liquid plasma (Plasma) **Max. number of sample sets:** 1	**EQAS/PT Experts:** Prof. Dr. med. Folker Wenzel **Deputy EQAS/PT Experts:** Prof. Dr. rer. nat. Ingo Schellenberg
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Determination of the fetal RhD status
Shipping Information: • Shipping not cooled • Shipping is limited to EU, Switzerland and UK.	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Molecular Genetics - NOD2 774

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)	**EQAS/PT Experts:** Prof. Dr. med. Folker Wenzel **Deputy EQAS/PT Experts:** N.N.
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** NOD2 mutation(s) NOD2 Nomenclature cDNA
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) 748

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: **Validity Certificate:** 12 months **Parameter / Analytes:** Plasminogenactivator-Inhibitor (PAI-1): 4G, 5G	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) - Whole Blood 735

EQAS/PT Properties **Samples:** 2 samples of 0.5 ml **Sample Properties:** Whole blood **Max. number of sample sets:** 3	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Plasminogenactivator-Inhibitor (PAI-1): 4G, 5G
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline: **Sample Shipment:** **Closing Date:**		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01	

Molecular Genetics - Prader-Willi (PWS) und Angelman (AS) Syndromes (Chromosome region 15q11-13, SNRPN) 786

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** Methylation analysis deletion analysis			**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Protein C (PROC Gene) 790

EQAS/PT Properties **Samples:** 2 Samples of 50 µl **Sample Properties:** DNA solution (approx. 15 ng/µL) **Max. number of sample sets:** 1						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the PROC gene for single-nucleotide variants (SNVs) and/or copy number variations (CNVs) • Interpretation of Results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Protein S (PROS1 Gene) 791

EQAS/PT Properties **Samples:** 2 Samples of 50 µl **Sample Properties:** DNA solution (approx. 15 ng/µL) **Max. number of sample sets:** 1						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the PROS1 gene for single-nucleotide variants (SNVs) and/or copy number variations (CNVs) • Interpretation of Results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Prothrombin (F2) Variant G20210A 746

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Prothrombin G20210A			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Prothrombin (F2) Variant G20210A - Whole Blood 731

EQAS/PT Properties **Samples:** 2 samples of 0.5 ml **Sample Properties:** Whole blood **Max. number of sample sets:** 3	**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Prothrombin G20210A	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline: **Sample Shipment:** **Closing Date:**		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01	

Molecular Genetics - Spinal Muscular Atrophy (SMN1 and SMN2 Genes) 787

EQAS/PT Properties **Samples:** 2 samples of 40 µl **Sample Properties:** DNA solution (approx. 15 ng/µL) **Max. number of sample sets:** 9	**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: yearly **Validity Certificate:** 24 months **Parameter / Analytes:** Determination of the copy numbers of the SMN1 and SMN2 genes SMN2 Gen	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Interpretation of results
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) Variants 742

EQAS/PT Properties **Samples:** 3 samples of 20 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** UDP-G1 UGT1A1*28 UDP-G1 UGT1A1*6			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood NEW! 726

EQAS/PT Properties **Samples:** 2 samples of 0.5 mL **Sample Properties:** Whole blood						**EQAS/PT Experts:** Dr. rer. nat. Ralf Flörke **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** UDP-G1 UGT1A1*28 UDP-G1 UGT1A1*6			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
		Apr.			**Oct.**	
Registration Deadline: **Sample Shipment:** **Closing Date:**		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01	

Molecular Genetics – Factor IX-Gene (F9) NEW! 673

EQAS/PT Properties **Samples:** 2 samples of 50 µL **Sample Properties:** DNA solution (approx. 25 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the F9 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics – Factor V-Gene (F5) NEW! 670

EQAS/PT Properties **Samples:** 2 samples of 80 µL **Sample Properties:** DNA solution (approx. 25 ng/µL) **Additional Information:** • Please note that this EQA scheme is intended for laboratories that perform a complete genetic analysis of the F5 gene. • If you are only testing for the Factor V Leiden SNP, please participate in scheme 730 or 740.						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the F5 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics – Factor VII-Gene (F7) NEW! 671

EQAS/PT Properties **Samples:** 2 samples of 50 µL **Sample Properties:** DNA solution (approx. 25 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the F7 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics – Factor VIII-Gene (F8) NEW! 672

EQAS/PT Properties **Samples:** 2 samples of 100 µL **Sample Properties:** DNA solution (approx. 25 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the F8 gene for intron 1 and intron 22 inversions and/or small nucleotide variations (SNVs) and/or copy number variations (CNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics – Factor X-Gene (F10) NEW! 674

EQAS/PT Properties **Samples:** 2 samples of 50 µL **Sample Properties:** DNA solution (approx. 25 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the F7 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics – Factor XI-Gene (F11) NEW! 675

EQAS/PT Properties **Samples:** 2 samples of 50 µL **Sample Properties:** DNA solution (approx. 25 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the F11 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics – Factor XIII-Gene (F13A1, F13B) NEW! 677

EQAS/PT Properties **Samples:** 2 samples of 80 µL **Sample Properties:** DNA solution (approx. 25 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the F13A1 and F13B genes for small nucleotide variations (SNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG) NEW! 676

EQAS/PT Properties **Samples:** 2 samples of 80 µL **Sample Properties:** DNA solution (approx. 25 ng/µL)						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the FGA, FGB, and FGG genes for small nucleotide variations (SNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics – FLT3 (internal tandem duplication) NEW! 701

EQAS/PT Properties
Samples: 2 samples of 10 µL
Sample Properties: DNA solution (approx. 100 ng/µL)
Max. number of sample sets: 1
Additional Information:
- As required by the RiliBÄK, the method used must have a detection limit of at least 5%.
- Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.

EQAS/PT Experts:
Prof. Dr. Karl-Anton Kreuzer

Deputy EQAS/PT Experts:
Dr. rer. nat. Eva Lorsy

Requirement for EQAS/PT according to Rili-BÄK:
Validity Certificate: 12 months
Parameter / Analytes:
FLT3 internal tandem duplication

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline:	26-11-13			27-04-23		
Sample Shipment:	27-01-12			27-06-22		
Closing Date:	27-02-12			27-07-23		

Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction NEW! 728

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Plasma

EQAS/PT Experts:
Prof. Dr. med. Folker Wenzel

Deputy EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Requirement for EQAS/PT according to Rili-BÄK:
Validity Certificate: 12 months
Parameter / Analytes:
Aneuploidy
Determination of fetal fraction
Determination of fetal sex

Not subject to Rili-BÄK not applicable

Shipping Information:
- Shipping not cooled
- Shipping is limited to EU, Switzerland and UK
- Please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-07-02	
Sample Shipment:		27-03-09			27-08-31	
Closing Date:		27-03-19			27-09-10	

Molecular Genetics – von Willebrand Factor-Gene (VWF) NEW! 678

EQAS/PT Properties
Samples: 2 samples of 100 µL
Sample Properties: DNA solution (approx. 25 ng/µL)

EQAS/PT Experts:
Dr. rer. nat. Morten O. Christensen

Deputy EQAS/PT Experts:
Dr. med. Günther Kappert

Requirement for EQAS/PT according to Rili-BÄK:
Validity Certificate: not applicable
Parameter / Analytes:

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Analysis of the VWF gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs)
- Interpretation of results

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Oncology – PML::RARA qualitative NEW! 702

EQAS/PT Properties
Samples: 2 samples of 30 µL
Sample Properties: cDNA solution
Max. number of sample sets: 1
Additional Information:
As required by the RiliBÄK, the method used must have a detection limit of at least 5%.

EQAS/PT Experts:
Prof. Dr. Karl-Anton Kreuzer

Deputy EQAS/PT Experts:
Dr. rer. nat. Eva Lorsy

Requirement for EQAS/PT according to Rili-BÄK: half-yearly
Validity Certificate: 12 months
Parameter / Analytes:
PML::RARA gene fusion

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Apr.				Nov.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-04-09				27-08-06 27-10-05 27-11-05

Molecular Pathology – PIK3CA and ESR1 NEW! 590

EQAS/PT Properties
Samples: 2 samples of 35 µL
Sample Properties: DNA (approx. 5 ng/µL)
Max. number of sample sets: 1
Additional Information:
This EQA scheme addresses the requirements of EBM codes 19463 (PIK3CA) and 19466 (ESR1), which call for the targeted detection of activating mutations in circulating tumor DNA to guide treatment in advanced breast cancer.

EQAS/PT Experts:
Dr. Harald Bartsch

Deputy EQAS/PT Experts:
N.N.

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
ESR1-variant(s) PIK3CA-variant(s)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
						Nov.
Registration Deadline: Sample Shipment: Closing Date:						27-08-13 27-10-12 27-11-19

Oncology

Molecular Genetics - Hereditary Fever Syndroms NEW! 706

EQAS/PT Properties **Samples:** 2 samples of 40 µL **Sample Properties:** DNA solution (approx. 15 ng/µL)						**EQAS/PT Experts:** Prof. Dr. med. Folker Wenzel **Deputy EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the MEFV, NLRP3, MVK, and TNFRSF1A genes, • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - Ret Proto-Oncogene (Multiple Endocrine Neoplasia Type 2, MEN2, RET Gene) 738

EQAS/PT Properties **Samples:** 2 Samples of 50 µl **Sample Properties:** DNA solution (approx. 15 ng/µL) **Max. number of sample sets:** 1						**EQAS/PT Experts:** Dr. rer. nat. Morten O. Christensen **Deputy EQAS/PT Experts:** Dr. med. Günther Kappert
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** • Analysis of the RET gene for small base variations (SNVs) (complete gene or the exons 5, 8, 10, 11, 13-16) and/or copy number variations (CNVs) • Interpretation of results			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Oncology - AML-Panel (NGS) 798

EQAS/PT Properties
Samples: 1 samples of 10 µl
Sample Properties: DNA solution (approx. 50 ng/µL)

EQAS/PT Experts:
Prof. Dr. Karl-Anton Kreuzer

Deputy EQAS/PT Experts:
Dr. rer. nat. Eva Lorsy

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: not applicable
Parameter / Analytes:
ASXL1 (NM_015338.6) Exon 13 Mutation(s)
ASXL1 Nomenclature
CEBPA (NM_004364.5) Mutation(s)
CEBPA Nomenclature
FLT3 (NM_004119.3) Mutation(s) Exon 20
FLT3 Nomenclature
IDH1 (NM_005896.4) Exon 4 Mutation(s)
IDH1 Nomenclature
IDH2 (NM_002168.4) Exon 4 Mutation(s)
IDH2 Nomenclature
NPM1 (NM_002520.7) Exon 11 Mutation(s)
NPM1 Nomenclature
RUNX1 (NM_001754.5) Mutation(s)
RUNX1 Nomenclature
TP53 (NM_000546.6) Mutation(s)
TP53 Nomenclature

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline:	26-11-13			27-04-23		
Sample Shipment:	27-01-12			27-06-22		
Closing Date:	27-02-12			27-07-23		

Molecular Oncology - BRAF 795

EQAS/PT Properties
Samples: 2 samples of 10 µl
Sample Properties: DNA solution (approx. 20 ng/µL)
Additional Information:
As required by the RiliBÄK, the method used must have a detection limit of at least 5%.

EQAS/PT Experts:
Prof. Dr. Karl-Anton Kreuzer

Deputy EQAS/PT Experts:
Dr. rer. nat. Eva Lorsy

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
BRAF p.V600 BRAF Nomenclature

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline:	26-11-13			27-04-23		
Sample Shipment:	27-01-12			27-06-22		
Closing Date:	27-02-12			27-07-23		

Molecular Oncology - BTK 796

EQAS/PT Properties **Samples:** 2 samples of 10 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	**EQAS/PT Experts:** Prof. Dr. Karl-Anton Kreuzer **Deputy EQAS/PT Experts:** Dr. rer. nat. Eva Lorsy
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** BTK p.C481 BTK Nomenclature
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

Molecular Oncology - KIT 767

EQAS/PT Properties **Samples:** 2 samples of 10 µl **Sample Properties:** DNA solution (approx. 20 ng/µL) **Additional Information:** As required by the RiliBÄK, the method used must have a detection limit of at least 0,1%.	**EQAS/PT Experts:** Prof. Dr. Karl-Anton Kreuzer **Deputy EQAS/PT Experts:** Dr. rer. nat. Eva Lorsy
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** KIT p.D816V	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

Molecular Oncology - MYD88 766

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 10 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	Prof. Dr. Karl-Anton Kreuzer **Deputy EQAS/PT Experts:** Dr. rer. nat. Eva Lorsy
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** MYD88 p.L265P
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

Molecular Oncology - Myeloproliferative Neoplasia 768

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 10 µl **Sample Properties:** DNA solution (approx. 50 ng/µL) **Additional Information:** As required by the RiliBÄK, the method used must have a detection limit of at least 5%.	Prof. Dr. Karl-Anton Kreuzer **Deputy EQAS/PT Experts:** Dr. rer. nat. Eva Lorsy
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** JAK2 p.V617F JAK2 Exon 12 mutation JAK2 Exon 12 nomenclature	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** CALR Exon 9 Mutation(s) CALR Nomenclature MPL p.W515 MPL Nomenclature
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

Molecular Oncology - SF3B1 797

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 10 µl **Sample Properties:** DNA solution (approx. 30 ng/µL)	Prof. Dr. Karl-Anton Kreuzer **Deputy EQAS/PT Experts:** Dr. rer. nat. Eva Lorsy
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** SF3B1 Exon 14-15 Mutation(s) SF3B1 Nomenclature
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

Molecular Oncology - STAT3 769

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 10 µl **Sample Properties:** DNA solution (approx. 20 ng/µL)	Prof. Dr. Karl-Anton Kreuzer **Deputy EQAS/PT Experts:** Dr. rer. nat. Eva Lorsy
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** STAT3 Exon 21 Mutation(s) STAT3 Nomenclature
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

Molecular Oncology - TP53 765

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 10 µl **Sample Properties:** DNA solution (approx. 30 ng/µL) **Additional Information:** As required by the RiliBÄK, the method used must have a detection limit of at least 5%.	Prof. Dr. Karl-Anton Kreuzer **Deputy EQAS/PT Experts:** Dr. rer. nat. Eva Lorsy
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** TP53 Mutation(s) TP53 Nomenclature	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

IMMUNOLOGY

Allergy Diagnostics

Allergy Diagnostic 720

EQAS/PT Properties
Samples: 5 samples of 1.0 or 0.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Deputy EQAS/PT Experts:
Dr. Nathalie Weiss

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Qualitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Quantitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples), determination of total IgE (5 samples)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Information will be updated at the end of autumn.

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Autoimmune Diseases

Autoimmune Diseases - Antiphospholipid Syndrome 275

EQAS/PT Properties
Samples: 2 samples of 0.3 ml
Sample Properties: Serum / Plasma

EQAS/PT Experts:
Dr. rer. nat. Martin Blüthner

Deputy EQAS/PT Experts:
Dr. Marie Mayrhofer

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months / 24 months
Parameter / Analytes:

anti-Cardiolipin (IgG)	anti-ß2-Glycoprotein (IgG)
anti-Cardiolipin (IgM)	anti-ß2-Glycoprotein (IgM)
anti-Cardiolipin (IgA)	anti-ß2-Glycoprotein (IgA)
anti-Cardiolipin (polyvalent)	anti-ß2-Glykoprotein (polyvalent)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline:					27-06-11	
Sample Shipment:					27-08-10	
Closing Date:					27-08-27	

Autoimmune Diseases - Autoimmune Dermatitis 259

EQAS/PT Properties **Samples:** 2 samples of 0.3 ml **Sample Properties:** Serum / Plasma	**EQAS/PT Experts:** Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** anti- Desmosomes anti-Hemidesmosomes anti-Desmoglein 1 anti-Desmoglein 3 anti-BPAg 230 anti-BPAg 180 anti-Desmoplakin I / II anti-Kollagen Typ VII
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: **Sample Shipment:** **Closing Date:**		26-12-18 27-02-23 27-03-12				

Autoimmune Diseases - Autoimmune Endocrinopathies 263

EQAS/PT Properties **Samples:** 2 samples of 0.3 ml **Sample Properties:** Serum / Plasma	**EQAS/PT Experts:** Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** anti-adrenal cortex anti-P450 C21 - Hydroxylase anti-P450 C17 - Hydroxylase anti-P450 ssc - Hydroxylase
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline: **Sample Shipment:** **Closing Date:**					27-06-11 27-08-10 27-08-27	

Autoimmune Diseases - Connective Tissue Diseases (ANA) 251

EQAS/PT Properties
Samples: 2 samples of 0.3 ml
Sample Properties: Serum / Plasma

EQAS/PT Experts:
Dr. rer. nat. Martin Blüthner

Deputy EQAS/PT Experts:
Dr. Marie Mayrhofer

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Autoantibodies against ANA
Autoantibodies against dsDNA

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Collagenosis Screening
anti-DFS70 / LEDGF
Autoantibodies against nucleosomes
Autoantibodies against histones

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	

Autoimmune Diseases - Connective Tissue Diseases (ENA) 255

EQAS/PT Properties
Samples: 2 samples of 0.3 ml
Sample Properties: Serum / Plasma

EQAS/PT Experts:
Dr. rer. nat. Martin Blüthner

Deputy EQAS/PT Experts:
Dr. Marie Mayrhofer

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
anti-U1-snRNP
anti-SmD anti-Sm
anti-SS-A / Ro
anti-SS-A / Ro (52 kD - proteins)
anti-SS-A / Ro (60 kD - proteins)
anti-SS-B / La
anti-Topoisomerase-1 (Scl 70)
anti-CENP A
anti-CENP B
anti-ribosomales P-protein

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline:					27-06-11	
Sample Shipment:					27-08-10	
Closing Date:					27-08-27	

Autoimmune Diseases - Diabetes mellitus 261

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Serum / Plasma	Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** anti-Islet cells - JDFU Diabetes Screen anti-Islet cells (ICA) anti-Insulin (IAA) anti-Glutamic Acid Decarboxylase (GAD) anti-Tyrosine Phosphatase (IA2) anti-Zinc Transporter 8 (ZnT8A)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline: **Sample Shipment:** **Closing Date:**					27-06-11 27-08-10 27-08-27	

Autoimmune Diseases - Gluten-Sensitive Enteropathies 271

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Serum / Plasma	Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** anti-Transglutaminase IgA	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** anti-Gliadin IgG anti-Gliadin IgA anti-deamidated Gliadin IgG anti-deamidated Gliadin IgA anti-Endomysium IgA
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline: **Sample Shipment:** **Closing Date:**		26-12-18 27-02-23 27-03-12			27-06-11 27-08-10 27-08-27	

Autoimmune Diseases - Hepatic Syndromes 253

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Plasma / Serum	Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** anti-Mitochondria anti-Microsomes (LKM 1) anti-smooth muscle anti-Actin anti-Parietal cells anti-H+/K+-ATPase anti-gp210 anti-SLA/LP anti-Sp100 anti-Intrinsic factor
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	

Autoimmune Diseases - Myasthenia gravis 269

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Serum / Plasma	Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** anti-Acetylcholin receptors anti-musclespecific Receptor Tyrosinkinase (MuSK) anti-skeletal muscle anti-Titin anti-calcium channel P/Q
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline:		26-12-18				
Sample Shipment:		27-02-23				
Closing Date:		27-03-12				

Autoimmune Diseases - Myositis NEW! 256

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Serum / Plasma	Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** anti-cN-1A anti-PM / Scl anti-Jo1 (Histidyl-tRNA synthetase) anti-PL7 (Threonyl-tRNA synthetase) anti-PL12 (Alanyl-tRNA synthetase) anti-EJ (Glycyl-tRNA synthetase) anti-OJ (Isoleucyl-tRNA synthetase) anti-KS (Asparaginyl-tRNA synthetase) anti-Mi-2 anti-SRP (IgG) anti-TIF1 anti-SAE1 anti-NXP2 anti-MDA5
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline:					27-06-11	
Sample Shipment:					27-08-10	
Closing Date:					27-08-27	

Autoimmune Diseases - Paraneoplastic Neuropathies 265

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Serum / Plasma	Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** anti-Purkinje cells anti-Neuronal nuclei anti-Yo (CDR62) anti-HuD anti-Ri / Nova 1 anti-Amphiphysin 1 anti-Ta (Ma 2) anti - Glia Cell nuclear Antibody (AGNA) anti-SOX1 anti-ZIC4 anti-Recoverin anti-CRMP5/CV2
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline:		26-12-18				
Sample Shipment:		27-02-23				
Closing Date:		27-03-12				

Autoimmune Diseases - Peripheral Neuropathies 267

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Plasma / Serum	Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** anti-Myelin-associated Glycoprotein (MAG) anti-Asialoganglioside (AGA1) anti-Monosialoganglioside (GM1) anti-Monosialoganglioside (GM2) anti-Monosialoganglioside (GM3) anti-Disialoganglioside (GD1a) anti-Disialoganglioside (GD1b) anti-Quadrosialoganglioside (GQ1b) anti-Trisialoganglioside (GT1b)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12				

Autoimmune Diseases - Receptor Encephalitis NEW! 268

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Plasma / Serum	Dr. rer. nat. Martin Blüthner **Deputy EQAS/PT Experts:** Dr. Marie Mayrhofer
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** anti-MOG anti-Aquaporin 4 anti-CASPR2 anti-LGI1 anti-NMDA receptor anti-GABA-B-Rez. anti-AMPA 1/2
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12				

Autoimmune Diseases - Rheumatoid Arthritis 273

EQAS/PT Properties
Samples: 2 samples of 0.3 ml
Sample Properties: Serum / Plasma

Additional Information:
Additional terms for the rheuma factor see EQA scheme 323 - Infection Serology - Rheumatoid Factor!

EQAS/PT Experts:
Dr. rer. nat. Martin Blüthner

Deputy EQAS/PT Experts:
Dr. Marie Mayrhofer

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Rheumatoid Factor
Rheumatoid Factor (isotypes)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
anti-CCP (cyclic citrulline peptide)
anti-MCV (mutated citrullinated Vimentin)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	

Autoimmune Diseases - Vasculitis / Glomerulopathies 257

EQAS/PT Properties
Samples: 2 samples of 0.3 ml
Sample Properties: Plasma / Serum

EQAS/PT Experts:
Dr. rer. nat. Martin Blüthner

Deputy EQAS/PT Experts:
Dr. Marie Mayrhofer

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
c-ANCA anti-PR3
p-ANCA anti-MPO

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
anti-glomerular basement membrane (GBM)
anti-PLA2R
anti-THSD7A

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	

Basophil Activation Test 653

EQAS/PT Properties
Samples: 2 samples of 2.6 ml
Sample Properties: Whole blood (EDTA), not stabilized
Max. number of sample sets: 1

EQAS/PT Experts:
Prof. Dr. med. Ulrich Sack

Deputy EQAS/PT Experts:
Dr. Uwe Kölsch

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Basophil activation by allergens bee and wasp.

Shipping Information:
- Overnight delivery.
- Cooled shipping
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!
- The stimulants are not sent with the samples!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May		Sep.	Oct.
Registration Deadline:		27-01-08	27-03-12		27-07-02	27-08-13
Sample Shipment:		27-03-02	27-05-11		27-08-31	27-10-12
Closing Date:		27-03-12	27-05-21		27-09-10	27-10-22

HLA Typing

HLA Diagnostics - High resolution, molecular HLA typing class I and II 444

EQAS/PT Properties
Samples: 5 samples of 1.5 mL
Sample Properties: Isolated lymphocytes (buffy coat)
Max. number of sample sets: 1
Additional Information:
- Molecular HLA typing class I and II in high resolution according to standards of the European Federation for Immunogenetics (EFI).
- In addition, HLA-B*57:01 associated with Abacavir hypersensitivity and HLA-DR epitopes associated with rheumatoid arthritis may be reported.
- It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).

EQAS/PT Experts:
Dr.-Ing. Nils Lachmann

Deputy EQAS/PT Experts:
Sükran Zaralioglu

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
HLA-B 57:01 typing of DNA

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
HLA-A typing of DNA (high resolution)
HLA-B typing of DNA (high resolution)
HLA-C typing of DNA (high resolution)
HLA-DPA1 typing of DNA (high resolution)
HLA-DPB1 typing of DNA (high resolution)
HLA-DQA1 typing of DNA (high resolution)
HLA-DQB1 typing of DNA (high resolution)
HLA-DRB 3/4/5 DNA-Typisierung (high resolution)
HLA-DRB1 typing of DNA (Shared Epitope)
HLA-DRB1 typing of DNA (high resolution)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.		Apr.	Aug.		Dec.
Registration Deadline:	26-11-13		27-01-15	27-05-14		27-09-10
Sample Shipment:	27-01-11		27-03-15	27-07-12		27-11-08
Closing Date:	27-02-05		27-04-09	27-08-06		27-12-03

HLA Diagnostics - HLA Antibody Screening and Identification 445

EQAS/PT Properties **Samples:** 5 samples of 1 mL **Sample Properties:** Liquid serum **Max. number of sample sets:** 2	**EQAS/PT Experts:** Dr.-Ing. Nils Lachmann **Deputy EQAS/PT Experts:** Sükran Zaralioglu
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** HLA antibody determination: • HLA antibody screening by complement-dependent cytotoxicity test (CDC) and/or with solid phase immunoassays • antibody identification by CDC and/or antibody identification by solid phase immunoassays (ELISA, Luminex) • solid phase complement binding assays (C1q, C3d, C4d etc.).
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.			Aug.		
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-11 27-02-19			27-05-14 27-07-12 27-08-20		

HLA Diagnostics - HLA Crossmatching 443

EQAS/PT Properties **Samples:** 1 serum set (20 Sera à 100 µL and 2x ACD blood à 8 ml) **Sample Properties:** Liquid serum and platelet-depleted blood (ACD) **Max. number of sample sets:** 1	**EQAS/PT Experts:** Dr.-Ing. Nils Lachmann **Deputy EQAS/PT Experts:** Sükran Zaralioglu
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** HLA crossmatching
Shipping Information: • Shipping not cooled • Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			Apr.			
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-01-15 27-03-15 27-04-16			

HLA Diagnostics - HLA Typing Class I and II of Serological Eqivalents 441

EQAS/PT Properties
Samples: 5 samples of 8 mL
Sample Properties: Platelet-depleted blood (ACD)
Max. number of sample sets: 1
Additional Information:
It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).

EQAS/PT Experts:
Dr.-Ing. Nils Lachmann

Deputy EQAS/PT Experts:
Sükran Zaralioglu

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
HLA Typing of serological equivalents of class I (HLA A, B) and/or HLA class II (HLA-DR, DQ) by serological and/or molecular means on the level of serological equivalents.

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.		Apr.	Aug.		Dec.
Registration Deadline:	26-11-13		27-01-15	27-05-14		27-09-10
Sample Shipment:	27-01-11		27-03-15	27-07-12		27-11-08
Closing Date:	27-02-05		27-04-09	27-08-06		27-12-03

HLA Diagnostics - HLA-B27 Determination 440

EQAS/PT Properties
Samples: 5 blood samples of 3 mL
Sample Properties: Whole blood (EDTA), not stabilized
Max. number of sample sets: 1
Additional Information:
Determination of HLA-B27 by molecular and/or serological means

EQAS/PT Experts:
Dr.-Ing. Nils Lachmann

Deputy EQAS/PT Experts:
Sükran Zaralioglu

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Determination of HLA-B27

Not subject to Rili-BÄK: not applicable

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.		Apr.	Aug.		Dec.
Registration Deadline:	26-11-13		27-01-15	27-05-14		27-09-10
Sample Shipment:	27-01-11		27-03-15	27-07-12		27-11-08
Closing Date:	27-02-05		27-04-09	27-08-06		27-12-03

HLA Diagnostics - HLA-DQ 772

EQAS/PT Properties
Samples: 2 samples of 1-1.5 ml
Sample Properties: Whole blood (EDTA), not stabilized

EQAS/PT Experts:
Dr.-Ing. Nils Lachmann

Deputy EQAS/PT Experts:
Sükran Zaralioglu

Requirement for EQAS/PT according to Rili-BÄK:
Validity Certificate: not applicable
Parameter / Analytes:

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
HLA DQA1*05 HLA DQB1*02 HLA DQB1*03:02

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			Apr.			Dec.
Registration Deadline:			27-01-15			27-09-10
Sample Shipment:			27-03-15			27-11-08
Closing Date:			27-04-09			27-12-03

HLA Diagnostics - Low resolution, molecular HLA typing class I and II 442

EQAS/PT Properties
Samples: 5 samples of 7 mL
Sample Properties: Whole blood (ACD), not stabilized
Max. number of sample sets: 1
Additional Information:
- Molecular HLA typing class I and II in low resolution (1-field).
- It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).

EQAS/PT Experts:
Dr.-Ing. Nils Lachmann

Deputy EQAS/PT Experts:
Sükran Zaralioglu

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
HLA-A DNA Typing (low resolution)
HLA-B DNA Typing (low resolution)
HLA-C DNA Typing (low resolution)
HLA-DPA1 DNA Typing (low resolution)
HLA-DPB1 DNA Typing (low resolution)
HLA-DQA1 DNA Typing (low resolution)
HLA-DQB1 DNA typing (low resolution)
HLA-DRB1 DNA typing (low resolution)
HLA-DRB3,4,5 DNA typing (low resolution)
HLA-DRB3,4,5 DNA typing (phenotypic)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.		Apr.	Aug.		Dec.
Registration Deadline:	26-11-13		27-01-15	27-05-14		27-09-10
Sample Shipment:	27-01-11		27-03-15	27-07-12		27-11-08
Closing Date:	27-02-05		27-04-09	27-08-06		27-12-03

Immunophenotyping

Immunophenotyping - Cellular Immunodeficiency Diagnostic 651

EQAS/PT Properties
Samples: 2 samples of 4 mL
Sample Properties: Whole blood (EDTA), not stabilized
Max. number of sample sets: 1

EQAS/PT Experts:
Prof. Dr. med. Ulrich Sack

Deputy EQAS/PT Experts:
Dr. Uwe Kölsch

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Analysis based on the case description for T-, NK-, and B-cell subpopulations, as well as monocytes and granulocytes, including naive, memory, effector, and activated T cells, TH1/2, TH17, and regulatory cells, with the markers CD11a, CD18, HLA-DR, TCR alpha/beta, TCR gamma/delta, CD45RA/CD45RO, CCR7, and CD31.
- Possible B-cell subpopulations: transitional, naive, non-switched, switched, IgM-only, IgA+, IgG+, CD21low/CD38low, and plasmablasts.
- NK subpopulations based on expression of: CD94, Nkp30, Nkp44, Nkp46, CD56 bright, cytolytic NK, NK-like
- Monocytes: classical/non-classical monocytes
- Granulocytes: expression of CD11a, CD18 on granulocytes
- TCR Vß typing
- Only individual markers or subsets of these markers may also be used.

Shipping Information:
- Shipping not cooled
- Overnight delivery
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-05-28			27-08-13 27-10-12 27-10-22

Functional Immunologic Assays

Interferon Gamma Release Assay (IGRA) 650

EQAS/PT Properties
Samples: 2 samples of approx. 4 ml
Sample Properties: Whole blood (Heparin), not stabilized
Max. number of sample sets: 1
Additional Information:
- Due to high demand three different sets of samples will be sent (Gr. 650 = Gr. 950 or Gr. 951). INSTAND e. V. reassigns the group number you receive before each EQAS/PT shipment. All groups are equivalent!
- Please note: This EQA scheme is based on stimulation with Mycobacterium Tuberculosis antigens and is designed for participants who use a TB Elispot (e.g., T-SPOT®.TB) or a test with pre-stimulation in a tube (e.g. QuantiFeron®-TB Gold Plus) or RIDA-SCREEN® TB Assay.

EQAS/PT Experts:
Prof. Dr. med. Ulrich Sack

Deputy EQAS/PT Experts:
Dr. Uwe Kölsch

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Interferon Gamma Release Assay (IGRA)

Shipping Information:
- Shipping not cooled
- Overnight delivery
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 24 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29

Lymphozyte Transformation Test (LTT) 656

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Whole blood (Heparin), not stabilized
Max. number of sample sets: 1
Additional Information:
This EQA scheme is intended for laboratories that perform lymphocyte proliferation assays to clarify lymphocyte dysfunction. Proliferation can be measured with cell tracer dyes, by 3H-thymidine incorporation or by MTT. Stimulation indices (3H-thymidine method and MTT) or proliferation indices (flow cytometric methods) and an evaluation can be reported.

EQAS/PT Experts:
Dr. Uwe Kölsch

Deputy EQAS/PT Experts:
Prof. Dr. Dr. med. Fabian Hauck

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Proliferation index after stimulation with PHA, PMA/ionomycin, anti-CD3 and anti-CD3/anti-CD28
- Evaluation.

Shipping Information:
- Shipping not cooled
- Shipping within the DACH region only
- Overnight delivery. The samples should ideally be stimulated and measured within 24-36 h after blood collection. The stimulants are not sent with the samples!
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-12 27-05-10 27-06-04			27-07-30 27-09-27 27-10-22

NK-/ and T cell cytotoxicity NEW! 657

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Whole blood (Heparin) not stabilized
Max. number of sample sets: 1

EQAS/PT Experts:
Dr. Uwe Kölsch

Deputy EQAS/PT Experts:
Dr. rer. physiol. Eva-Maria Jacobsen

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
CD107a expression or lysis indices and evaluation

Shipping Information:
- Shipping not cooled
- Shipping is only available in the DACH- region
  Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-12 27-05-10 27-06-04			27-07-30 27-09-27 27-10-22

Oxidative Burst / Phagocytosis Test 654

EQAS/PT Properties
Samples: 4 samples of 2 ml
Sample Properties: Whole blood (Heparin), not stabilized
Max. number of sample sets: 1
Additional Information:
- The samples should ideally be stimulated and measured within 24-36 h after blood collection. The stimulants are not sent with the samples!
- This EQA scheme is intended for laboratories that determine oxygen radical production in granulocytes to clarify a granulocyte dysfunction.

EQAS/PT Experts:
Dr. Uwe Kölsch

Deputy EQAS/PT Experts:
Prof. Dr. Dr. med. Fabian Hauck

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Oxygen radical production in granulocytes after stimulation with PMA and with E. coli (also individually) Stimulation index (DHR) and evaluation (DHR/ NBT) as well as phagocytosis of opsonised E. coli in granulocytes Stimulation index and evaluation.

Shipping Information:
- Shipping not cooled
- Overnight delivery
- Shipping within the DACH region only
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-12 27-05-10 27-06-04			27-07-30 27-09-27 27-10-22

Complement Analysis

Complement Analysis - Anti-C1 Inhibitor Autoantibody 250

EQAS/PT Properties
Samples: 2 samples of 300 µl
Sample Properties: Serum
Max. number of sample sets: 1

EQAS/PT Experts:
Prof. Dr. Zoltan Prohaszka

Deputy EQAS/PT Experts:
Prof. Dr. Michael Kirschfink

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Auto-anti-C1 inhibitor IgA (qualitative)
Auto-anti-C1 inhibitor IgG (qualitative)
Auto-anti-C1 inhibitor IgM (qualitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
						Nov.
Registration Deadline: Sample Shipment: Closing Date:						27-08-06 27-10-05 27-11-05

Complement Analysis - Anti-C1q Autoantibody 245

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 300 µl **Sample Properties:** Serum **Max. number of sample sets:** 1	Prof. Dr. Zoltan Prohaszka **Deputy EQAS/PT Experts:** Prof. Dr. Michael Kirschfink
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Auto-anti C1q (IgG) Auto-anti C1q (IgG) (qualitative)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Nov.
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-26				27-08-06 27-10-05 27-11-05

Complement Analysis - Anti-factor H (FH) Autoantibody 249

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 300 µl **Sample Properties:** Serum **Max. number of sample sets:** 1	Prof. Dr. Zoltan Prohaszka **Deputy EQAS/PT Experts:** Prof. Dr. Michael Kirschfink
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Auto-anti FH-(qualitative) Auto-anti-FH (quantitative)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
						Nov.
Registration Deadline: Sample Shipment: Closing Date:						27-08-06 27-10-05 27-11-05

Complement Analysis - C3 - Nephritic Factor 248

EQAS/PT Properties **Samples:** 2 samples of 300 µl **Sample Properties:** Lyophilised serum **Max. number of sample sets:** 1						**EQAS/PT Experts:** Prof. Dr. Zoltan Prohaszka **Deputy EQAS/PT Experts:** Prof. Dr. Michael Kirschfink
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** C3-nephritic factor (qualitative)			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
						Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**						27-08-06 27-10-05 27-11-05

Complement Analysis - Complement activation products 247

EQAS/PT Properties **Samples:** 2 samples of 300 µl **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 3 **Additional Information:** Participation with one parameter (e.g. sC5b-9) possible						**EQAS/PT Experts:** Prof. Dr. Zoltan Prohaszka **Deputy EQAS/PT Experts:** Prof. Dr. Michael Kirschfink
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** C3a, C3d, Bb, sC5b-9			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
						Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**						27-08-06 27-10-05 27-11-05

Complement Analysis - Functions (F) and Proteins (P) 246

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 ml **Sample Properties:** Lyophilised serum **Max. number of sample sets:** 3 **Additional Information:** Analysis of the total function of the 3 complement activation pathways (classical, alternative and lectin pathways) either by functional ELISA (WIELISA), by haemolytic (CH50, AH50) or by liposome-based assay (classical pathway). Participation with one parameter (e.g. CH50) is possible.	Prof. Dr. Zoltan Prohaszka **Deputy EQAS/PT Experts:** Prof. Dr. Michael Kirschfink

Requirement for EQAS/PT according to Rili-BÄK: not applicable	Not subject to Rili-BÄK **Validity Certificate:** 12 months **Parameter / Analytes:** Classical pathway (F), Alternative pathway (F), Lectin pathway (FH), C1q, (P) C4 (P), C3 (P), C1 Inhibitor (F) (P), Factor H (P), Factor I (P)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Nov.
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-26				27-08-06 27-10-05 27-11-05

TRANSFUSION MEDICINE

Immunohematology

Immunohaematology 01 — 231

EQAS/PT Properties
Samples: 2 x 5 ml serum / 2 x 5 ml erythrocytes suspension
Sample Properties: Serum + Erythrocytes suspension

EQAS/PT Experts:
PD Dr. med. Franz F. Wagner

Deputy EQAS/PT Experts:
Dr. Nathalie Weiss

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
A B 0 - Typing
Rh (D) Factor
A - Subtyping
Rh - Subtyping (without Cw)
Antibody Screening
Direct Antiglobulin Test

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Kell antigen

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May	July		Oct.
Registration Deadline:		26-11-27	27-01-29	27-03-26		27-07-09
Sample Shipment:		27-02-23	27-04-27	27-06-22		27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09		27-10-22

Immunohaematology 02 (incl. Antibody Identification) — 232

EQAS/PT Properties
Samples: 2 x 5 ml serum / 2 x 3 ml serum / 2 x 5 ml erythrocytes suspension
Sample Properties: Serum + Erythrocytes suspension

EQAS/PT Experts:
PD Dr. med. Franz F. Wagner

Deputy EQAS/PT Experts:
Dr. Nathalie Weiss

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
A B 0 - Typing
Rh (D) Factor
A - Subtyping
Rh - Subtyping (without Cw)
Antibody Screening
Direct Antiglobulin Test

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Kell antigen
Antibody identification
AB quantitation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May	July		Oct.
Registration Deadline:		26-11-27	27-01-29	27-03-26		27-07-09
Sample Shipment:		27-02-23	27-04-27	27-06-22		27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09		27-10-22

Immunohaematology 03 - Platelet Immunology 233

EQAS/PT Properties
Samples: 3 serum samples, 2 samples of DNA, 2 samples of platelet suspension
Sample Properties: Serum + Cell suspension + DNA
Max. number of sample sets: 1
Additional Information:
This EQA scheme is intended for laboratories which are able to detect platelet alloantibodies and antigens. The EQA scheme 235 - Immunohaematology 06 - Molecular Diagnostic was designed for laboratories which only want to carry out platelet antigen genotyping.

EQAS/PT Experts:
Prof. Dr. med. Ulrich Sachs

Deputy EQAS/PT Experts:
Dr. med. Hartmut Kroll

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Platelet antibodies
Platelet antigens

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-26			27-09-10	

Immunohaematology 04 - Granulocyte Immunology 234

EQAS/PT Properties
Samples: 3 samples of plasma, 2 samples of DNA
Sample Properties: Plasma + DNA
Max. number of sample sets: 1
Additional Information:
- This EQA scheme includes all HNA specifications. It is dedicated to laboratories which are able to detect granulocyte alloantibodies and antigens. The EQA scheme - 235 Immunohaematology 06 - Molecular Diagnostic was designed for laboratories which only want to perform HNA genotyping.
- Because of the complicated preparation of the samples, INSTAND e.V. reserves the right to no longer supply laboratories with EQAS/PT samples, which have repeatedly not sent back any results.

EQAS/PT Experts:
Dr. Torsten J. Schulze

Deputy EQAS/PT Experts:
N.N.

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
HNA/granulocyte antibodies
HNA/granulocyte (neutrophil) antigens

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-26			27-09-10	

Immunohaematology 05 - Machine-Based Analysis 237

EQAS/PT Properties
Samples: 2 samples of 5 mL
Sample Properties: Whole blood

EQAS/PT Experts:
PD Dr. med. Franz F. Wagner

Deputy EQAS/PT Experts:
Dr. Nathalie Weiss

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
A B 0 - Typing
Rh (D) Factor
A - Subtyping
Rh - Subtyping (without Cw)
Antibody Screening
Direct Antiglobulin Test

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Kell antigen
Antibody identification

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May	July		Oct.
Registration Deadline:		26-11-27	27-01-29	27-03-26		27-07-09
Sample Shipment:		27-02-23	27-04-27	27-06-22		27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09		27-10-22

Immunohaematology 07 - Machine-Based Analysis (incl. AB Quantitation) 238

EQAS/PT Properties
Samples: 2 x 5 ml whole blood + 2 x 5 ml serum
Sample Properties: Whole blood + Serum

EQAS/PT Experts:
PD Dr. med. Franz F. Wagner

Deputy EQAS/PT Experts:
Dr. Nathalie Weiss

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
A B 0 - Typing
Rh (D) Factor
A - Subtyping
Rh - Subtyping (without Cw)
Antibody Screening
Direct Antiglobulin Test

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Kell antigen
Antibody identification
AB quantitation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May	July		Oct.
Registration Deadline:		26-11-27	27-01-29	27-03-26		27-07-09
Sample Shipment:		27-02-23	27-04-27	27-06-22		27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09		27-10-22

Immunohaematology 08 - Compatibility Testing (Blood Transfusion) 239

EQAS/PT Properties	EQAS/PT Experts:
Samples: serum + erythrocytes suspension **Sample Properties:** serum + erythrocytes suspension **Max. number of sample sets:** 1	PD Dr. med. Franz F. Wagner **Deputy EQAS/PT Experts:** Dr. Nathalie Weiss

Requirement for EQAS/PT according to Rili-BÄK: quarterly	Not subject to Rili-BÄK
Validity Certificate: 6 months **Parameter / Analytes:** Antibody Screening	**Validity Certificate:** 12 months / 12 months **Parameter / Analytes:** Blood type check (AB0 without isoagglutinins, RhD) Cross-match
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May	July		Oct.
Registration Deadline:		26-11-27	27-01-29	27-03-26		27-07-09
Sample Shipment:		27-02-23	27-04-27	27-06-22		27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09		27-10-22

CLINICAL CHEMISTRY

Haematology

CD19 CAR-T-Cells (quantitative) 822

EQAS/PT Properties
Samples: 2 samples á 2 ml
Sample Properties: Whole blood(EDTA), stabilized
Max. number of sample sets: 1
Additional Information:
- The number of participants is currently limited to a maximum of 40 per term. Note: The planned date may be postponed if donor availability cannot be realised at short notice.
- Due to the time-consuming nature of sample preparation, INSTAND reserves the right to discontinue supplying interlaboratory comparison samples to laboratories that have repeatedly failed to submit results.

EQAS/PT Experts:
Prof. Dr. Marion Subklewe

Deputy EQAS/PT Experts:
Dr. Gerulf Hänel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
CD19 CAR-T-cells

Shipping Information:
- Shipping not cooled
- Shipping to the DACH region only.
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-07			27-08-27 27-10-26 27-11-05

CLL-MRD Immunophenotyping 820

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Whole blood (EDTA), not stabilized
Max. number of sample sets: 1
Additional Information:
- To successfully participate in the EQAS/PT, your method must have a minimum limit of detection (LoD) of 0.01%.
- Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.
- Because of the complicated preparation of the samples, INSTAND e.V. reserves the right to no longer supply laboratories with EQAS/PT samples, which have repeatedly not sent back any results.

EQAS/PT Experts:
Prof. Dr. Karl-Anton Kreuzer

Deputy EQAS/PT Experts:
Dr. Michaela Patz

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
% CLL-cells
Rating of MRD

Shipping Information:
- Cooled shipping
- Cooled shipping to Germany and Austria only.
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Feb.			Sep.	
Registration Deadline:		26-12-04			27-07-23	
Sample Shipment:		27-02-02			27-09-21	
Closing Date:		27-02-05			27-09-24	

Haematology - Blood Cell Count 211

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Stabilized control blood
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Analysis of Haemoglobin with HemoCue systems is possible!

POCT +

EQAS/PT Experts:
Dr. med. Benedikt Lohr

Deputy EQAS/PT Experts:
Dr. med. Thomas Nebe

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Erythrocytes
Haemoglobin
Haematocrit centrif.
Leucocytes
Haematocrit el.count
Thrombocytes

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
MCV

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Haematology - Blood Cell Count - QBC System 209

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Whole blood (EDTA), not stabilized
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- This EQA scheme is only for participants with hematology systems based on QBC (Quantitative Buffy Coat) technology.

EQAS/PT Experts:
Dr. med. Benedikt Lohr

Deputy EQAS/PT Experts:
Dr. med. Thomas Nebe

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Haematocrit centrif.
Haemoglobin
Leucocytes
Thrombocytes

Not subject to Rili-BÄK: not applicable

Shipping Information:
Cooled shipping
Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Sep.	Oct.
Registration Deadline:	26-11-13		27-03-12		27-07-09	27-08-13
Sample Shipment:	27-01-12		27-05-11		27-09-07	27-10-12
Closing Date:	27-01-22		27-05-21		27-09-17	27-10-22

Haematology - Blood Smear Analysis 212

EQAS/PT Properties
Samples: 2 peripheral blood smears
Sample Properties: Slides
Max. number of sample sets: 1
Additional Information:
plus one special case for internal training purposes

EQAS/PT Experts:
Prof. Dr. med. Dr. phil. Torsten Haferlach

Deputy EQAS/PT Experts:
Prof. Dr. med. Wolfgang Kern

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Blood Cell Differentiation in %

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Diagnostic comment
- Morphology of erythrocytes, leucocytes and platelets

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Haematology - Bone Marrow Cytology 218

EQAS/PT Properties
Samples: Digital slides in a virtual microscope of bone marrow aspirate
Sample Properties: Digital slides
Max. number of sample sets: 1
Additional Information:
Available online in digital microscopy! - No shipment!

EQAS/PT Experts:
Prof. Dr. med. Dr. phil. Torsten Haferlach

Deputy EQAS/PT Experts:
Prof. Dr. med. Winfried Gassmann

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Evaluation and diagnosis

Shipping Information:
No shipment!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		27-02-19			27-08-06	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	

Haematology - Differential Blood Count (Machine-Based Analysis) 612

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Whole blood (EDTA), not stabilized
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Due to high demand, two different sets of samples will be sent (Gr. 612 = Gr. 912). The group number you receive will be set by INSTAND e.V. before each EQAS shipment. Both groups are equivalent.

EQAS/PT Experts:
Dr. med. Benedikt Lohr

Deputy EQAS/PT Experts:
Dr. med. Thomas Nebe

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Erythrocytes
Haematocrit centrif.
Haematocrit el.count
Haemoglobin
Leucocytes
Thrombocytes

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Basophilic Granulocytes
Eosinophilic Granulocytes
Lymphocytes
MCV
Monocytes
Neutrophilic Granulocytes

Shipping Information:
Cooled shipping
Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Sep.	Oct.
Registration Deadline:	26-11-13		27-03-12		27-07-09	27-08-13
Sample Shipment:	27-01-12		27-05-11		27-09-07	27-10-12
Closing Date:	27-01-22		27-05-21		27-09-17	27-10-22

Haematology - Free Haemoglobin 236

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Lyophilised erythrocytes preparation
Additional Information:
The samples are not suitable for methods based on photometric measurements of the oxyhaemoglobin peaks around 540 nm and/or 577 nm. The Harboe method (415 nm peak) is suitable. The quantitative hemolysis index from automated chemistry analysers can also provide a suitable result.

EQAS/PT Experts:
Prof. Dr. med. Nicolas von Ahsen

Deputy EQAS/PT Experts:
N.N.

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Haemoglobin (free)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haematology - Haemoglobinopathies 210

EQAS/PT Properties
Samples: 2 samples of 0.8 mL
Sample Properties: Whole blood, stabilized
Max. number of sample sets: 1

EQAS/PT Experts:
Dr. med. Claudia Frömmel

Deputy EQAS/PT Experts:
Dr. Adriana Méndez

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Hemoglobin analysis with evaluation and presumptive diagnosis

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-04-09			27-08-13
Sample Shipment:			27-06-08			27-10-12
Closing Date:			27-06-25			27-10-29

Haematology - Immunophenotyping 214

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Whole blood (EDTA), not stabilized

EQAS/PT Experts:
Dr. med. Richard Schabath

Deputy EQAS/PT Experts:
Prof. Dr. med. Wolfgang Kern

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Immunophenotyping of leukamias/lymphomas
Immunophenotyping of hematologic neoplasms

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-03-12	27-04-30		27-08-13
Sample Shipment:	27-01-12		27-05-11	27-06-29		27-10-12
Closing Date:	27-01-22		27-05-21	27-07-09		27-10-22

Haematology - Lymphocyte differentiation 213

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Whole blood (EDTA), not stabilized

EQAS/PT Experts:
Prof. Dr. med. Wolfgang Kern

Deputy EQAS/PT Experts:
Dr. med. Richard Schabath

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Lymphocyte-immunophenotyping - peripheral blood:
CD4 pos. lymphocytes with CD3-expression (%)
CD8 pos. lymphocytes with CD3-expression (%)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Lymphocyte-immunophenotyping - peripheral blood:
B-Lymphocytes
CD4 pos. lymphocytes with CD3-expression (/nl)
CD8 pos. lymphocytes with CD3-expression (/nl)
Leucocytes
Lymphocytes
NK-cells without CD3-expression
T-lymphocytes

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.		July		Oct.
Registration Deadline:	26-11-13	27-01-15		27-04-30		27-08-13
Sample Shipment:	27-01-12	27-03-16		27-06-29		27-10-12
Closing Date:	27-01-22	27-03-26		27-07-09		27-10-22

Haematology - PNH Diagnostics 616

EQAS/PT Properties
Samples: 2 samples of 1.5 mL
Sample Properties: Whole blood (EDTA), not stabilized
Additional Information:
Due to high demand 3 different sets of samples will be sent (No. 616 = No. 916 or No. 917). The group number you receive will be set by INSTAND e.V. before each EQAS shipment. All groups are equivalent!

EQAS/PT Experts:
Dr. med. Britta Höchsmann

Deputy EQAS/PT Experts:
Dr. med. Thomas Nebe

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
GPI-deficient cells

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 56 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-03-12			27-07-23
Sample Shipment:			27-05-11			27-09-21
Closing Date:			27-05-28			27-10-08

Haematology - Reticulocyte Analysis Machine-Based Analysis 216

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Whole blood (EDTA), not stabilized

EQAS/PT Experts:
Prof. Dr. med. Kai Gutensohn

Deputy EQAS/PT Experts:
Dr. med. Thomas Nebe

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Concentration of Hb in reticulocytes
Immature reticulocytes
Reticulated Platelets
Reticulocyte production Index (RPI)
Reticulocytes
Reticulocytes concentration

Shipping Information:
- Cooled shipping
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Sep.	Oct.
Registration Deadline:	26-11-13		27-03-12		27-07-09	27-08-13
Sample Shipment:	27-01-12		27-05-11		27-09-07	27-10-12
Closing Date:	27-01-22		27-05-21		27-09-17	27-10-22

Haematology - Reticulocyte Analysis Microscopy 215

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 blood smears for microscopic analysis **Sample Properties:** Slides	Prof. Dr. med. Kai Gutensohn **Deputy EQAS/PT Experts:** Dr. med. Thomas Nebe
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Reticulocytes
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.			July		
Registration Deadline:	26-11-13			27-04-30		
Sample Shipment:	27-01-12			27-06-29		
Closing Date:	27-01-22			27-07-09		

Haematology - Stem/Progenitor Cells (CD34) 217

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 mL **Sample Properties:** Whole blood (EDTA), not stabilized	Prof. Dr. med. Kai Gutensohn **Deputy EQAS/PT Experts:** Prof. Dr. med. Andreas Humpe
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Flow cytometric determination of CD34+ stem and progenitor cells and viability measurements
Shipping Information: • Cooled shipping • Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.		July	Sep.	
Registration Deadline:	26-11-13	27-01-15		27-04-30	27-07-09	
Sample Shipment:	27-01-12	27-03-16		27-06-29	27-09-07	
Closing Date:	27-01-22	27-03-26		27-07-09	27-09-17	

Haematology - Stem/Progenitor Cells (CD34) (stabilized) 660

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Whole blood(EDTA), stabilized
Additional Information:
For determination of CD34+ events plus vital CD34+ events, see Group 217 (native sample material).

EQAS/PT Experts:
Prof. Dr. med. Kai Gutensohn

Deputy EQAS/PT Experts:
Prof. Dr. med. Andreas Humpe

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Flow cytometric analysis of stem and progenitor cells (CD34) without vitality measurement.

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.		July	Sep.	
Registration Deadline:	26-11-13	27-01-15		27-04-30	27-07-09	
Sample Shipment:	27-01-12	27-03-16		27-06-29	27-09-07	
Closing Date:	27-01-22	27-03-26		27-07-09	27-09-17	

Haematology - T, B and NK cells in cellular products (flow cytometry) 617

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Cellular products (CPD)

EQAS/PT Experts:
Prof. Dr. med. Andreas Humpe

Deputy EQAS/PT Experts:
Prof. Dr. med. Kai Gutensohn

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
For flow cytometric determination of T, B and NK cells in cellular products only

Shipping Information:
- Cooled shipping
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-03-12			27-08-13
Sample Shipment:			27-05-11			27-10-12
Closing Date:			27-05-21			27-10-22

Hemostaseology

Haemostasis - Apixaban 504

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2						**EQAS/PT Experts:** Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Apixaban			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Haemostasis - Argatroban 230

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2						**EQAS/PT Experts:** Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Argatroban Thrombin Time aPTT			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.		**May**		**Aug.**	**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Haemostasis - AT, Protein C, Protein S, C1-Inhibitor 225

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Inhibitors (AT, PC, PS)
Antithrombin
C1-Inhibitor
Free Protein S immun. (conc.)
Free Protein S funct. (act.)
Protein S total
Total Protein C

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - Compact 285

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Prothrombintime (PT, INR)
Prothrombintime (PT, Quick)
aPTT

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Antithrombin
D-Dimer (quantitative)
Fibrinogen
Thrombin Time

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - D-Dimer 226

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
D-Dimer (qualitative) D-Dimer (quantitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - Dabigatran 502

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Dabigatran

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Haemostasis - Edoxaban 505

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2						EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK **Validity Certificate:** 12 months **Parameter / Analytes:** Edoxaban			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Haemostasis - Emicizumab 506

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2						EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK **Validity Certificate:** 12 months **Parameter / Analytes:** Emicizumab			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Haemostasis - Factor II, V, VII,X 223

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2	**EQAS/PT Experts:** Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Single factors A (via PT): factor II, factor V, factor VII, factor X
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.		**May**		**Aug.**	**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Haemostasis - Factor IX, XI, XII, XIII 224

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2	**EQAS/PT Experts:** Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Single factors B (via APTT, etc.): factor IX, factor XI, factor XII, factor XIII
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.		**May**		**Aug.**	**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Haemostasis - Factor VIII, WF 227

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Factor VIII akt.
Willebrand fact. Ag
Willebrand fact. CBA
Willebrand fact. RiCof
Willebrand fact. activity

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - FIB, TZ, FSP 222

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Global test II: TZ, FIB, FSP screening FSP screening, using batroxobin time or heparin-independent thrombin time

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - Fondaparinux 501

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2	Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Fondaparinux
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Haemostasis - Functional APC Resistance 288

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 ml **Sample Properties:** Lyophilised plasma	Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** APC resistance Diagnostic comments
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Haemostasis - LMW Heparin 281

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2	**EQAS/PT Experts:** Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** LMW Heparin
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.		**May**		**Aug.**	**Oct.**
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - Orgaran 282

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2	**EQAS/PT Experts:** Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Orgaran
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.		**May**		**Aug.**	**Oct.**
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - POCT 286

EQAS/PT Properties
Samples: 2 samples of 1 ml; Starting reagent of 1 ml
Sample Properties: Whole blood (Citrat), not stabilized
Max. number of sample sets: 2
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Please note the short completion time!
- Due to different detection techniques that are applied, not every sample material can be guarenteed to be suitable for every POCT machine. The machines microINR by Axon Lab as well as Xprecia Stride by Siemens are not suitable for this EQAS!

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. med. Georg Wittmann

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Prothrombintime (PT, INR) Prothrombintime (PT, Quick)
aPTT

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
ACT

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		June		Sep.	Nov.
Registration Deadline:	26-11-13		27-04-16		27-07-30	27-09-10
Sample Shipment:	27-01-12		27-06-15		27-09-28	27-11-09
Closing Date:	27-01-14		27-06-17		27-09-30	27-11-11

Haemostasis - PT, INR, aPTT 221

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2
Additonal Information:
No. 221 is only for measuring in plasma samples. For measurements of whole blood in POCT systems, please register for No. 286!

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Prothrombintime (PT, INR) Prothrombintime (PT, Quick)
aPTT

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Haemostasis - Rivaroxaban 503

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2	Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Rivaroxaban
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Haemostasis - ROTEM Sigma 509

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 x 3 samples of 1 ml **Sample Properties:** Lyophilised plasma **Max. number of sample sets:** 2	Prof. Dr. med. Michael Spannagl **Deputy EQAS/PT Experts:** Dr. rer. biol. hum. Andrea Dick
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Extrinsic: A20 [mm] — Intrinsic: A20 [mm] Extrinsic: CT[s] r[min] — Intrinsic: CT[s] r[min] Extrinsic: MCF [mm] — Intrinsic: MCF [mm]
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Haemostasis - TEG/ROTEM 283

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Extrinsic: A20 [mm]
Extrinsic: CT[s] r[min]
Extrinsic: MCF [mm]
Intrinsic: A20 [mm]
Intrinsic: CT[s] r[min]
Intrinsic: MCF [mm]

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - UF Heparin 280

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma
Max. number of sample sets: 2

EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:
Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Thrombin Time UF Heparin aPTT

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Hormones

Adrenal Gland / Pituitary 298

EQAS/PT Properties **Samples:** 2 samples of 3 ml **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Prof. Dr. med. Peter B. Luppa **Deputy EQAS/PT Experts:** Dr. rer. nat. Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** 1-39 ACTH, DHEA-S, Prolactin DHEA, HGH
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Aldosterone 304

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Prof. Dr. med. Peter B. Luppa **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Aldosterone
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Calcium Metabolism / Special Thyroid 301

EQAS/PT Properties **Samples:** 2 samples of 3 ml **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Prof. Dr. rer. nat. Dr. med. Jürgen Durner **Deputy EQAS/PT Experts:** Prof. Dr. med. Peter B. Luppa
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** 1-84 PTH Calcitonin Thyreoglobulin
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Fertility 297

EQAS/PT Properties **Samples:** 2 samples of 3 ml **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Prof. Dr. med. Folker Wenzel **Deputy EQAS/PT Experts:** Dr. med. Thomas Lutz
Requirement for EQAS/PT according to Rili-BÄK: quarterly **Validity Certificate:** 6 months **Parameter / Analytes:** FSH	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** LH anti-Mullerian hormone
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Gravidity - 1st Trimester Screening 305

EQAS/PT Properties **Samples:** 2 samples of 1 mL **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Prof. Dr. med. Folker Wenzel **Deputy EQAS/PT Experts:** Dr. med. Thomas Lutz
Requirement for EQAS/PT according to Rili-BÄK: quarterly **Validity Certificate:** 6 months **Parameter / Analytes:** Free beta-chain hCG	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** PAPP-A
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
		Mar.	**May**		**Aug.**	**Oct.**
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Gravidity - 2nd Trimester Screening 306

EQAS/PT Properties **Samples:** 2 samples of 1 mL **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Prof. Dr. med. Folker Wenzel **Deputy EQAS/PT Experts:** Dr. med. Thomas Lutz
Requirement for EQAS/PT according to Rili-BÄK: quarterly **Validity Certificate:** 6 months **Parameter / Analytes:** AFP hCG intact hCG intact +beta-hCG free	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
		Mar.	**May**		**Aug.**	**Oct.**
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Hematopoetic Growth Factors 626

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised serum **Max. number of sample sets:** 1						**EQAS/PT Experts:** Prof. Dr. med. Folker Wenzel **Deputy EQAS/PT Experts:** M.Sc. Luisa Toll
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Erythropoietin Thrombopoietin			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Pancreas/Gastrointestinal Tract 300

EQAS/PT Properties **Samples:** 2 samples of 3 ml **Sample Properties:** Lyophilised serum						**EQAS/PT Experts:** Prof. Dr. rer. nat. Dr. med. Jürgen Durner **Deputy EQAS/PT Experts:** Prof. Dr. med. Peter B. Luppa
Requirement for EQAS/PT according to Rili-BÄK: **Validity Certificate:** not applicable **Parameter / Analytes:**			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** C-Peptide Glucagon Pro-insuline Gastrin Insulin			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.		**May**	**July**		**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09		27-08-06 27-10-05 27-10-22

Preeclampsia Marker 625

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 ml **Sample Properties:** Lyophilised serum **Max. number of sample sets:** 1	Prof. Dr. med. Peter B. Luppa **Deputy EQAS/PT Experts:** Dr. rer. nat. Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** PlGF (placental growth factor) sFLT-1 (soluble fms-like tyrosine kinase-1)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Steroid Hormones, Thyroid Gland 302

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 2 ml **Sample Properties:** Liquid serum	Prof. Dr. med. Peter B. Luppa **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: quarterly **Validity Certificate:** 6 months **Parameter / Analytes:** 17-beta-Estradiol, Testosterone Cortisol, free T3 (f-triiodothyronine) Progesterone, free T4 (f-thyroxine) TSH	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** T3 total (triiodothyronine), T4 total (thyroxine)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Thyroid Gland Antibodies 295

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

Deputy EQAS/PT Experts:
Prof. Dr. med. Peter B. Luppa

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
TRAK/THYBIA, anti-TPO, anti-Microsome, anti-Thyroglobuline

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Thyroid Hormones 294

EQAS/PT Properties
Samples: 2 samples of 3 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

Deputy EQAS/PT Experts:
Prof. Dr. med. Peter B. Luppa

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
TSH, free T3 (f-triiodothyronine), free T4 (f-thyroxine)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
T3 total (triiodothyronine), T4 total (thyroxine)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Virilization 309

EQAS/PT Properties **Samples:** 2 samples of 1 mL **Sample Properties:** Lyophilised serum						EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: Dr. med. Thomas Lutz
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK **Validity Certificate:** 12 months **Parameter / Analytes:** 17-Hydroxyprogesterone Androstendion			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.	May		Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12	27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

IgG Subclasses

IgG Subclasses 244

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised serum						EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK **Validity Certificate:** 12 months **Parameter / Analytes:** IgG1 IgG2 IgG3 IgG4			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Cardiac Marker

Myocardial Markers 760

EQAS/PT Properties
Samples: 2 samples of 2 ml
Sample Properties: Lyophilised serum
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Please note that this EQA scheme is not suitable for methods that require whole blood.

EQAS/PT Experts:
Prof. Dr. med. Hannsjörg Baum

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Troponin I
Troponin T

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
CK-MB (activity)
CK-MB (mass)
CK-MB (qualitative)
Myoglobin
Myoglobin (qualitative)
NT-pro BNP
Troponin I (qualitative)
Troponin T (qualitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Myocardial Markers BNP 761

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Serum / Plasma
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 5 Days!

EQAS/PT Experts:
Prof. Dr. med. Hannsjörg Baum

Deputy EQAS/PT Experts:
N.N.

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
BNP

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Conventional Clinical Chemistry

ACE (Angiotensin-Converting-Enzyme) 630

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Liquid serum
Max. number of sample sets: 1

EQAS/PT Experts:
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

Deputy EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
ACE

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May	July		Oct.
Registration Deadline:		26-12-18	27-02-26	27-04-23		27-08-06
Sample Shipment:		27-02-23	27-04-27	27-06-22		27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09		27-10-22

Amino Acid Analysis 710

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma

EQAS/PT Experts:
M. Sc. Irina Keßel

Deputy EQAS/PT Experts:
Dr. Gernot Brauers

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

4-Hydroxyproline (free)
Alanine
Arginine
Argininosuccinic acid
Asparagine
Aspartic acid
Citrulline
Cystathionine
Cysteine-Homocysteine-disulfide
Cystine
Glutamic acid
Glutamine
Glycine
Histidine
Isoleucine
Leucine
Lysine
Methionine
Ornithine
Phenylalanine
Phosphoethanolamine
Proline
Sarcosine
Serine
Taurine
Threonine
Tryptophan
Tyrosine
Valine
allo-Isoleucine
alpha-Aminoadipic acid
b-Alanine proposed diagnosis

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Ammonia 118

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 ml **Sample Properties:** Liquid controls	Dr. rer. nat. Manfred Falck **Deputy EQAS/PT Experts:** Prof. Dr. med. Matthias Nauck
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Ammonia
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Biogenic Amines in Plasma 185

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 5 ml **Sample Properties:** Lyophilised Plasma	Dr. rer. nat Heike Schneider **Deputy EQAS/PT Experts:** Prof. Dr. med. Peter B. Luppa
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** 3-Methoxytyramine, Dopamine, Epinephrine, Metanephrine, Norepinephrine, Normetanephrine, Serotonin
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	

Capillary Zone Electrophoresis 102

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Dr. med. Christoph Niederau

Deputy EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Albumin (electrophoresis)
a1-Globulins
a2-Globulins
beta-Globulins
gamma-Globulins

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Clinical Chemistry - Conventional Analysis 100

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Dr. rer. nat. Manfred Falck

Deputy EQAS/PT Experts:
Dr. med. Christoph Niederau

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
AP
Albumin
Bilirubin
CK
Calcium
Chloride
Cholesterol
Creatinine
GGT
GOT (ASAT)
GPT (ALAT)
Glucose
IgA
IgG
IgM
LDH
Lactate
Lithium
Magnesium
Phosphate
Potassium
Protein
Sodium
Transferrine
Triglycerides
Urea
Uric Acid

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Acid phosphatase
Albumin (electrophoresis)
Aldolase
Bilirubin conj.
CHE
Copper
GLDH
HBDH
Iron
Iron binding capacity
Lipase
Osmolality
Pancreas amylase
Prostatic acid
Posphatase
alpha-Amylase
gamma-Globulins

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Ethanol 700

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 2 ml **Sample Properties:** Liquid serum	Prof. Dr. rer. nat. Ingo Schellenberg **Deputy EQAS/PT Experts:** Dr. rer. nat. Manfred Falck
Requirement for EQAS/PT according to Rili-BÄK: quarterly **Validity Certificate:** 6 months **Parameter / Analytes:** Ethanol	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Fructosamine 146

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 mL **Sample Properties:** Lyophilised serum	Dr. med. Christoph Niederau **Deputy EQAS/PT Experts:** Dr. Patricia Kaiser (PhD)
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Fructosamine
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

G6PDH (Glucose-6 Phosphate Dehydrogenase) 279

EQAS/PT Properties **Samples:** 2 samples of 0.5 ml **Sample Properties:** Lyophilised whole blood	**EQAS/PT Experts:** Dr. Patricia Kaiser (PhD) **Deputy EQAS/PT Experts:** Udo Kramer, Dipl.-Ing. (FH)
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** G6PDH
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
		Mar.			**Aug.**	
Registration Deadline: **Sample Shipment:** **Closing Date:**		26-12-18 27-02-23 27-03-12			27-06-11 27-08-10 27-08-27	

Gammopathies 243

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised plasma	**EQAS/PT Experts:** Dr. med. Christoph Niederau **Deputy EQAS/PT Experts:** N.N
Requirement for EQAS/PT according to Rili-BÄK: **Validity Certificate:** 6 months **Parameter / Analytes:** IgA IgG IgM	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Free light chains type kappa (quantitative) Free light chains type lambda (quantitative) Gammopathies kappa/lambda (ratio)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.		**May**	**July**		**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09		27-08-06 27-10-05 27-10-22

Glucose - Conventional Analysis 111

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Dr. med. Christoph Niederau

Deputy EQAS/PT Experts:
Dr. rer. nat. Manfred Falck

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Glucose

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

HbA1c 145

EQAS/PT Properties
Samples: 2 samples of 0.3 ml
Sample Properties: Whole blood (EDTA), not stabilized
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- The samples must be measured within 2 days of receipt!

POCT +

EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Deputy EQAS/PT Experts:
Udo Kramer, Dipl.-Ing. (FH)

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
HbA1c

Not subject to Rili-BÄK: not applicable

Shipping Information:
- Cooled shipping
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Sep.	Oct.
Registration Deadline:	26-11-20	27-01-15	27-03-12	27-05-07	27-07-09	27-08-20
Sample Shipment:	27-01-19	27-03-16	27-05-11	27-07-06	27-09-07	27-10-19
Closing Date:	27-01-22	27-03-19	27-05-14	27-07-09	27-09-10	27-10-22

Lipids/Lipoproteins 151

EQAS/PT Properties
Samples: 2 samples of 3 mL
Sample Properties: Lyophilised serum
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Dr. med. Christoph Niederau

Deputy EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Apolipoprotein A1, Cholesterol
Apolipoprotein B, Triglycerides

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Apolipoprotein E, Homocystein, Lp (a)
HDL-cholesterol, LDL-cholesterol, Phospholipids

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Markers of Ethanol Abuse - Carbohydrate-Deficient Transferrin (CDT) 750

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Peter B. Luppa

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Asialotransferrin
Asialotransferrin+Disialotransferrin
Disialotransferrin

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Plasma Cell Neoplasia-MRD Immunophenotyping 821

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Whole blood (EDTA), not stabilized
Additional Information:
- To successfully participate in the interlaboratory test, your method must have a minimum limit of detection (LoD) of 0.01%.
- Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.

EQAS/PT Experts:
Prof. Dr. Karl-Anton Kreuzer

Deputy EQAS/PT Experts:
Dr. Michaela Patz

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
% Plasma cell neoplasia-cells Rating of MRD

Shipping Information:
- Cooled shipping
- Cooled shipping to Germany and Austria only.
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			Apr.			Nov.
Registration Deadline:			27-02-19			27-09-17
Sample Shipment:			27-04-20			27-11-16
Closing Date:			27-04-23			27-11-19

Serum Proteins/Electrophoresis 141

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum
Additional Information:
Participants using the method capillary zone electrophoresis please order EQA scheme 102 - Capillary Zone Electrophoresis

EQAS/PT Experts:
Dr. med. Christoph Niederau

Deputy EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Albumin Protein

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Albumin (electrophoresis)
a1-Globulins
a2-Globulins
beta-Globulins
gamma-Globulins

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Cerebrospinal Fluid

Cerebrospinal Fluid Analysis - CSF Ferritin 467

EQAS/PT Properties
Samples: 1 CSF sample of 1 ml
Sample Properties: CSF
Max. number of sample sets: 1
Additional Information:
Neurochemical diagnostics of hemorrhages

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Deputy EQAS/PT Experts:
Prof. Dr. med. Inga Zerr

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Ferritin - CSF

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			

Cerebrospinal Fluid Analysis - Dementia Markers 466

EQAS/PT Properties
Samples: 1 sample of 1 ml
Sample Properties: CSF
Max. number of sample sets: 1
Additional Information:
Neurochemical dementia diagnostics: Support for differential diagnosis of dementia by interpretation of the combined analysis of different marker proteins in CSF.

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Deputy EQAS/PT Experts:
Prof. Dr. med. Inga Zerr

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Amyloid ß Peptid 40 (Aß40)
Amyloid ß Peptid 42 (Aß42)
Amyloid ß Peptid Ratio (Aß 42/40)
PhosphoTau Protein (pTau)
Total Tau Protein (Tau)
p-Tau/ß-Amyloid (1-42) Ratio

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Cerebrospinal Fluid Analysis - Free light chains Kappa 468

EQAS/PT Properties
Samples: 2 sets = CSF + serum of 1 ml
Sample Properties: CSF + serum
Max. number of sample sets: 1
Additional Information:
Neurochemical diagnostics of inflammatory CNS processes

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Deputy EQAS/PT Experts:
Prof. Dr. med. Inga Zerr

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
kappa-free light chains - CSF
kappa-free light chains - serum

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			
Registration Deadline:			27-02-26			
Sample Shipment:			27-04-27			
Closing Date:			27-05-14			

Cerebrospinal Fluid Analysis - Lactate/ Glucose 464

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: CSF + Serum (Lyophilised)
Max. number of sample sets: 1
Additional Information:
Calculation of the CSF/serum ratio of glucose. Interpretation with respect to the reference range.

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Deputy EQAS/PT Experts:
Dr. rer. nat. Thomas Zimmermann

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Glucose - CSF Lactate

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Glucose quotient (CSF/Serum)
Glucose quotient - diagnostic comment
Interpretation of the report
Lactate - diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Cerebrospinal Fluid Analysis - MRZ Reaction 463

EQAS/PT Properties
Samples: 4 samples of 1ml
Sample Properties: Serum / Plasma
Max. number of sample sets: 1
Additional Information:
Detection of titers is not suitable. Evaluation as antibody index and interpretation of combined data.

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Deputy EQAS/PT Experts:
Dr. rer. nat. Thomas Zimmermann

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Antibodies against Measles viruses, Rubella viruses, Varicella zoster viruses, Herpes simplex viruses (1+2). Analysis of virus-specific antibodies in CSF and serum for detection of specific antibody response in central nervous system (MRZ reaction).

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Cerebrospinal Fluid Analysis - Neuroborreliosis 465

EQAS/PT Properties
Samples: 2 samples of 0.5ml
Sample Properties: CSF + Serum
Max. number of sample sets: 1
Additional Information:
Detection of titers is not suitable. Calculation of antibody index (Certificate) and interpretation (Certificate of Participation).

EQAS/PT Experts:
Dr. rer. nat. Thomas Zimmermann

Deputy EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Borrelia IgG Antibody Index (AI) calculation
Interpretation of the report

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Cerebrospinal Fluid Analysis - Oligoclonal IgG 462

EQAS/PT Properties
Samples: 2 samples of 100 µl
Sample Properties: CSF + Serum
Max. number of sample sets: 1
Additional Information:
The acquisition of samples is demanding, as it is not possible to use pooled CSF, i.e. the samples are from individual patients (catheter, drainage, etc.).

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Deputy EQAS/PT Experts:
Dr. rer. nat. Thomas Zimmermann

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Oligoclonal IgG

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Interpretation of the report

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Cerebrospinal Fluid Analysis - Protein Analysis 460

EQAS/PT Properties
Samples: 4 samples of 1ml
Sample Properties: Serum / Plasma
Max. number of sample sets: 1
Additional Information:
Sample volumes in the CSF EQAS/PTs are limited as it is difficult to acquire large volumes of CSF.

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Deputy EQAS/PT Experts:
Dr. rer. nat. Thomas Zimmermann

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Albumin
Albumin - CSF
IgA
IgA - CSF
IgG
IgG - CSF
IgM
IgM - CSF
Protein - CSF

Not subject to Rili-BÄK
Validity Certificate: 6 months
Parameter / Analytes:
Evaluation of CSF/serum quotients in diagrams and age-related interpretation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Newborn Analytic

Neonatal Bilirubin 110

EQAS/PT Properties **Samples:** 2 samples of 2 ml **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Dr. med. Christoph Niederau **Deputy EQAS/PT Experts:** Dr. rer. nat. Manfred Falck
Requirement for EQAS/PT according to Rili-BÄK: quarterly **Validity Certificate:** 6 months **Parameter / Analytes:** Neonatal Bilirubin	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Newborn screening 785

EQAS/PT Properties **Samples:** 2 samples **Sample Properties:** Filter papers, each with 2 dried blood spots **Max. number of sample sets:** 1 **Additional Information:** This EQAS/PT scheme is currently in the planning stages, and we will share details on the website and in the INSTAND e.V. newsletter.	**EQAS/PT Experts:** N.N. **Deputy EQAS/PT Experts:** N.N
Requirement for EQAS/PT according to Rili-BÄK: quarterly **Validity Certificate:** 6 months **Parameter / Analytes:** TSH 17-hydroxy Progesteron IRT PAP	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled Shipping within Germany only!	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
Registration Deadline:						
Sample Shipment:						
Closing Date:						

Pharmaceuticals

Antiarrhytmics - Amiodaron 190

EQAS/PT Properties **Samples:** 2 samples of 3 ml **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat. Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Amiodarone Desethylamiodarone
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Antibacterials 01 - Teicoplanin 193

EQAS/PT Properties **Samples:** 2 samples of 2 ml **Sample Properties:** Lyophilised serum	**EQAS/PT Experts:** Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Teicoplanin
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample materia

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Antibacterials 02 890

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Dr. rer. nat. Heike Schneider

Deputy EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Ampicillin	Meropenem
Cefepime	Piperacillin
Ceftazidime	Sulbactam
Linezolid	Tazobactam

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Anticonvulsants 01 191

EQAS/PT Properties
Samples: 2 samples of 3 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Lamotrigine Levetiracetam Sulthiame

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Anticonvulsants 02 192

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 3 ml **Sample Properties:** Lyophilised serum	Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat. Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** 10-OH-Carbamazepine Carbamazepine-epoxide N-Desmethylmethsuximide
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Anticonvulsants 03 871

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 2.5 ml **Sample Properties:** Lyophilised serum	Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Brivaracetam, Lacosamide Eslicarbazepine, Perampanel Felbamate, Rufinamide
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Anticonvulsants 04 — 872

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 2.5 ml **Sample Properties:** Lyophilised serum	Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Gabapentin, Pregabalin, Tiagabine, Topiramate, Vigabatrin, Zonisamide
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Antifungals / Immunosuppressants — 602

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 1 mL **Sample Properties:** Lyophilised plasma	Prof. Dr. med. Nicolas von Ahsen **Deputy EQAS/PT Experts:** Dr. Patricia Kaiser (PhD)
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Hydroxy-Itraconazole Itraconazole Mycophenolic acid
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline:		26-12-18				27-08-06
Sample Shipment:		27-02-23				27-10-05
Closing Date:		27-03-12				27-10-22

Antifungals and Chloramphenicol 198

EQAS/PT Properties **Samples:** 2 samples of 5 ml (+ 2 samples of 3 ml antibiotics) **Sample Properties:** Lyophilised serum						**EQAS/PT Experts:** Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Chloramphenicol, Fluconazole, Flucytosine, Posaconazole, Voriconazole			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Antipsychotics/Antidepressives 01 200

EQAS/PT Properties **Samples:** 2 samples of 2 ml **Sample Properties:** Lyophilised serum						**EQAS/PT Experts:** Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Clozapine, N-Desmethylclozapine			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.	**Mar.**	**May**	**July**	**Aug.**	**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-01-29	26-12-18 27-02-23 27-03-12	27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09	27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Antipsychotics/Antidepressives 02 873

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Amisulpride	Pipamperone
Desmethylsertraline	Reboxetine
Fluvoxamine	Sertraline
Levomepromazine	Ziprasidone

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Antipsychotics/Antidepressives 03 874

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Desmethylfluoxetine	Mianserine
Fluoxetine	Perazine

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Antipsychotics/Antidepressives 04 875

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Cariprazine
Chlorprotixene
Desmethylolanzapine
Olanzapine
Paroxetine

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Antivirals 850

EQAS/PT Properties
Samples: 2 samples of 1 - 3 ml
Sample Properties: Lyophilised serum
Additional Information:
Please note that some analytes may interfere with the HPLC methods with UV detection. For this reason, the schedule-based composition will be adjusted as shown in the following pdf-download-link: https://www.instand-ev.de/EQA850-Analytes

EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Deputy EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Aciclovir
Atazanavir
Bictegravir
Cabotegravir
Darunavir
Dolutegravir
Doravirine
Efavirenz
Elvitegravir
Etravirine
Ganciclovir
Lopinavir
Maraviroc
Nevirapine
Raltegravir
Ribavirin
Rilpivirin
Ritonavir T
enofovir

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Benzodiazepines 01 876

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Alprazolam
Chlordiazepoxide
Desalkylflurazepam
Diazepam
Nordiazepam
Oxazepam
Trazodone

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Benzodiazepines 02 877

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Clonazepam
Flunitrazepam
Flurazepam
Nitrazepam
Temazepam

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Benzodiazepines 03 878

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 2.5 ml **Sample Properties:** Lyophilised serum	Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Bromazepam Clobazam (Clobazepam) Lorazepam
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Immunosuppressants 601

EQAS/PT Properties	EQAS/PT Experts:
Samples: 4 samples of 1 ml **Sample Properties:** Lyophilised whole blood	Prof. Dr. med. Nicolas von Ahsen **Deputy EQAS/PT Experts:** Dr. Patricia Kaiser (PhD)
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Cyclosporine A Everolimus Sirolimus Tacrolimus
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12				27-08-06 27-10-05 27-10-22

Paracetamol and NSAIDs 194

EQAS/PT Properties	EQAS/PT Experts:
Samples: 4 samples of 1 ml **Sample Properties:** Lyophilised serum	Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Paracetamol Salicylic acid
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Psychostimulants - ADHS-Treatment 879

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 2.5 ml **Sample Properties:** Lyophilised serum	Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Atomoxetine Methylphenidate Ritalinic acid
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Psychotherapeutic Drugs 01 860

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen

Deputy EQAS/PT Experts:
Florian Ridders

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

10-OH-Carbamazepine	O-Desmethylvenlafaxine
Aripiprazole	Perazine
Citalopram	Quetiapine
Lamotrigine	Venlafaxine

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Psychotherapeutic Drugs 02 861

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen

Deputy EQAS/PT Experts:
Florian Ridders

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Amisulpride	O-Desmethylvenlafaxine
Escitalopram	Quetiapine
Mirtazapine	Venlafaxine

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Psychotherapeutic Drugs 03 — 862

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen

Deputy EQAS/PT Experts:
Florian Ridders

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
9-OH-Risperidone / Paliperidone
Clozapine
Duloxetine
Haloperidol
N-Desmethylclozapine
Olanzapine
Quetiapine
Risperidone
Ziprasidone

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Psychotherapeutic Drugs 04 — 863

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen

Deputy EQAS/PT Experts:
Florian Ridders

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Amitriptyline
Clomipramine
Clozapine
Desipramine
Doxepin
Imipramine
Maproptiline
N-Desmethylclozapine
Norclomipramine
Nordoxepin

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Respiratory Stimulants - Caffeine 870

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 2.5 ml **Sample Properties:** Lyophilised serum	Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Caffeine
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Therapeutic drugs - Antibiotics, Digitoxin, MTX 197

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 5 ml **Sample Properties:** Lyophilised serum	Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider Dr. Patricia Kaiser (PhD)
Requirement for EQAS/PT according to Rili-BÄK: quarterly **Validity Certificate:** 6 months **Parameter / Analytes:** Digitoxin Vancomycin	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Amicacin Methotrexate Gentamicin Tobramycin
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29	26-12-18 27-02-23 27-03-12	27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09	27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Therapeutic drugs - Antiepileptics, Digoxin, Lithium and others 195

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider
Dr. Patricia Kaiser (PhD)

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Carbamacepine, Phenytoin, Lithium, Theophylline, Phenobarbital, Valproic Acid

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Digoxin, Ethosuximid, Primidon

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Tri-/Tetracyclic Antidepressants 03 - Quantitative in Serum 202

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Desipramine, Maproptiline, Imipramine, Normaproptiline, Tricyclic Antidepressants - Screen

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Tricyclic Antidepressants 01 - Quantitative in Serum 199

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Amitriptyline
Clomipramine
Norclomipramine
Nortriptyline
Tricyclic Antidepressants - Screen

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Tricyclic Antidepressants 02 - Quantitative in Serum 201

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Doxepin
Nordoxepin
Nortrimipramine
Tricyclic Antidepressants - Screen
Trimipramine

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Tricyclic Antidepressants 04 - Qualitative in Serum 203

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Lyophilised serum
Additional Information:
- May contain the following substances:Amitriptyline, Clomipramine, Desipramine, Doxepin, Imipramine, Norclomipramine, Nordoxepin, Nortrimipramine, Nortriptyline, Trimipramine
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Tricyclic Antidepressants (qualitative)- Screening

Not subject to Rili-BÄK:
Validity Certificate: 12 months
Parameter / Analytes:
Amitriptyline, Clomipramine, Desipramine, Doxepin, Imipramine, Norclomipramine, Nordoxepin, Nortrimipramine, Nortriptyline, Trimipramine

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Photometry

Photometer Controls 181

EQAS/PT Properties
Samples: 2 samples of 6 mL
Sample Properties: Potassium picrate solution

EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Deputy EQAS/PT Experts:
Udo Kramer, Dipl.-Ing. (FH)

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Wavelengths 334, 340, 365, 405 and 436 nm

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Plasma Proteins

Cystatin C 242

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Liquid serum
Max. number of sample sets: 1

EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Deputy EQAS/PT Experts:
Dr. rer. nat. Manfred Falck

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Cystatin C

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

hsCRP 240

EQAS/PT Properties
Samples: 2 samples of 0.4 mL
Sample Properties: Liquid serum
Max. number of sample sets: 1
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Deputy EQAS/PT Experts:
Dr. rer. nat. Manfred Falck

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
hsCRP

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Infection Serology - C-Reactive Protein 322

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
C-Reactive Protein (quantitative)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
C-Reactive Protein (qualitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Plasmaproteins 241

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Liquid plasma

EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Deputy EQAS/PT Experts:
Dr. rer. nat. Manfred Falck

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
C-Reactive Protein (quantitative)
Ferritin
IgA
IgG
IgM
Transferrine

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
C3
C4
Coeruloplasmin
Haptoglobin
Hemopexin
sTfR
a1-Antitrypsine
a1-Glycoprotein
a2-Makroglobulin
Quantitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples)
determination of total IgE (5 samples)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

POCT

Blood Gas Analysis 161

EQAS/PT Properties
Samples: 2 samples of 2.5 ml
Sample Properties: Control solution
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. Peter B. Luppa

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:

Chloride	Potassium	pH
Creatinine	Sodium	pO2
Glucose	Urea	
Lactate	ionized Calcium	
Magnesium	pCO2	

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Blood Gas Analysis - Haemoglobin 162

EQAS/PT Properties
Samples: 2 samples of 2 ml
Sample Properties: Control solution
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Dr. med. Benedikt Lohr

Deputy EQAS/PT Experts:
Dr. med. Thomas Nebe

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Haemoglobin

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Fraction CO-Hb Fraction Met-Hb Fraction O2-Hb

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Blood Gas Analysis OPTI Systems 163

EQAS/PT Properties
Samples: 2 samples of 1.7 ml
Sample Properties: Control solution
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Prof. Dr. med. Peter B. Luppa

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:

Chloride	Sodium	pH
Haemoglobin	Urea	pO2
Lactate	ionized Calcium	
Potassium	pCO2	

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
sO2

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Dry Chemistry - POCT: Abaxis Piccolo System 810

EQAS/PT Properties
Samples: 2 samples of 5 mL
Sample Properties: Lyophilised serum
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT

EQAS/PT Experts:
Dr. rer. nat. Manfred Falck

Deputy EQAS/PT Experts:
Prof. Dr. med. Matthias Nauck

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:

AP	GGT	Potassium
Albumin	GOT (ASAT)	Protein
Bilirubin	GPT (ALAT)	Sodium
CK	Glucose	Triglycerides
Calcium	LDH	Urea
Chloride	Lactate	Uric Acid
Cholesterol	Magnesium	
Creatinine	Phosphate	

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Bilirubin conj.	VLDL-cholesterol
HDL-cholesterol	alpha-Amylase
LDL-cholesterol	tCO2

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Kammel	Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Dry Chemistry - POCT: Glucose 800

EQAS/PT Properties
Samples: 2 samples of 0.5 mL
Sample Properties: Whole blood
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- For point-of-care testing (POCT) devices which work with unit-use reagents and preferably use whole blood as patient sample material.

POCT

EQAS/PT Experts:
Prof. Dr. med. Dipl.-Biol. Astrid Petersmann

Deputy EQAS/PT Experts:
Prof. Dr. med. Matthias Nauck

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Glucose

Not subject to Rili-BÄK: not applicable

Shipping Information:
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Sep.	Oct.
Registration Deadline:	26-11-27	27-01-08	27-03-12	27-05-14	27-07-16	27-08-27
Sample Shipment:	27-01-26	27-03-02	27-05-11	27-07-13	27-09-14	27-10-26
Closing Date:	27-01-29	27-03-05	27-05-14	27-07-16	27-09-17	27-10-29

Trace Elements

Trace Elements - whole blood 208

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised whole blood

EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Deputy EQAS/PT Experts:
Udo Kramer, Dipl.-Ing. (FH)

Requirement for EQAS/PT according to Rili-BÄK:
Validity Certificate: 6 months
Parameter / Analytes:
Magnesium

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Antimony, Arsenic, Cadmium, Chromium, Cobalt, Lead, Manganese, Mercury, Nickel, Selenium, Zinc

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline:		26-12-18				27-08-06
Sample Shipment:		27-02-23				27-10-05
Closing Date:		27-03-19				27-10-29

Trace Elements Plasma 206

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised plasma

EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Deputy EQAS/PT Experts:
Udo Kramer, Dipl.-Ing. (FH)

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Aluminium	Iodine
Arsenic	Iron
Cadmium	Manganese
Chromium	Nickel
Cobalt	Platinum
Copper	Selenium
Fluoride	Zinc
Gold	

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline:		26-12-18				27-08-06
Sample Shipment:		27-02-23				27-10-05
Closing Date:		27-03-19				27-10-29

Trace Elements Serum 207

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Deputy EQAS/PT Experts:
Udo Kramer, Dipl.-Ing. (FH)

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Antimony	Molybdenum
Beryllium	Tin
Bismuth	Vanadium

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline:		26-12-18				27-08-06
Sample Shipment:		27-02-23				27-10-05
Closing Date:		27-03-19				27-10-29

Stool Diagnostics

Fecal Diagnostics - Calprotectin / Fecal Elastase 130

EQAS/PT Properties
Samples: 2 samples of 0.75 ml
Sample Properties: Lyophilised stool
Max. number of sample sets: 1

EQAS/PT Experts:
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

Deputy EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Calprotectin
Calprotectin (qualitative)
Fecal elastase
Fecal elastase (qualitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.		July		Oct.
Registration Deadline:		26-12-18		27-04-23		27-08-06
Sample Shipment:		27-02-23		27-06-22		27-10-05
Closing Date:		27-03-12		27-07-09		27-10-22

Fecal Diagnostics - Hb, Hb-Hapto-complex 131

EQAS/PT Properties
Samples: 2 samples of 0.75 ml
Sample Properties: Lyophilised stool
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

Deputy EQAS/PT Experts:
Prof. Dr. med. Michael Spannagl

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Haemoglobin
Haemoglobin (qualitative)
Hemoglobin-Haptoglobin-complex
Hemoglobin-Haptoglobin-complex (qualitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline:		26-12-18				27-08-06
Sample Shipment:		27-02-23				27-10-05
Closing Date:		27-03-12				27-10-22

Tumor Marker

Tumor Markers 292

EQAS/PT Properties
Samples: 2 samples of 2 ml
Sample Properties: Liquid Serum
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Prof. Dr. med. Stefan Holdenrieder

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:

AFP	PSA, total
CA 15-3	hCG intact
CEA	hCG intact +beta-hCG free

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

CA 125	HER2/new	SCC
CA 19-9	NSE	TPA
CA 72-4	PSA, free	TPS
CYFRA 21-1	ROMA-Score	Thyreoglobulin
HE4	S100	beta-2-Microglobulin

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Tumor Markers - Calcitonin, Pro-GRP, PIVKAII, AFP, AFP-L3 299

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Liquid Serum

EQAS/PT Experts:
Prof. Dr. med. Stefan Holdenrieder

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

AFP	PIVKAII
AFP-L3	Progastrin-releasing
Calcitonin GAAD-Score	Peptide
GALAD-Score	

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Tumor Markers - PSA and Testosterone 293

EQAS/PT Properties
Samples: 2 samples of 2 mL
Sample Properties: Liquid Serum
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. Stefan Holdenrieder

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
PSA, totalTestosterone

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
PSA, free

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Urine Analysis

Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative) 174

EQAS/PT Properties
Samples: 2 samples of 3 ml
Sample Properties: Lyophilised urine
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. med. Christoph Niederau

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Benzoylecgonine (qualitative)
Opiate / Morphin (qualitative)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Amphetamine (qualitative)
Amphetamine (quantitative)
Barbiturate-Phenobarbital (qualitative)
Barbiturate-Phenobarbital (quantitative)
Benzoylecgonine (quantitative)
Opiate / Morphin (quantitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative) 176

EQAS/PT Properties
Samples: 2 samples of 3 ml
Sample Properties: Lyophilised urine
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. med. Christoph Niederau

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Methadone (qualitative)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
(d-)Methamphetamine (quantitative)
(d-)Methamphetamine (qualitative)
Buprenorphine (qualitative)
Buprenorphine (quantitative)
LSD (qualitative)
LSD (quantitative)
Methadone (quantitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative) 177

EQAS/PT Properties
Samples: 2 samples of 3 ml
Sample Properties: Lyophilised urine
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. med. Christoph Niederau

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
EDDP (qualitative)
delta-9-THC-COOH (qualitative)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Benzodiazepine Lorazepam (qualitative)
Benzodiazepine Lorazepam (quantitative)
EDDP (quantitative)
MDMA (qualitative)
MDMA (quantitative)
delta-9-THC-COOH (quantitative)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Markers of Ethanol Abuse - Ethylglucuronide 751

EQAS/PT Properties **Samples:** 2 samples of 1 ml **Sample Properties:** Lyophilised urine	**EQAS/PT Experts:** Prof. Dr. med. Peter B. Luppa **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Ethylglucuronide
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
		Mar.	**May**		**Aug.**	**Oct.**
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Systematic Toxicological Analysis (STA) 188

EQAS/PT Properties **Samples:** 2 samples of 10 ml **Sample Properties:** Lyophilised urine **Max. number of sample sets:** 1 **Additional Information:** • This EQAS/PT scheme is still in the planning stages, and we will announce details on the website and in the INSTAND e.V. newsletter. • From a list of 30 substances, the proof of 6 - 8 substances with chromatographic methods is required in both samples.	**EQAS/PT Experts:** Prof. Dr. med. Werner Steimer **Deputy EQAS/PT Experts:** Dr. rer. nat Heike Schneider
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Chromatographic analysis with identification of the active substance (STA)	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
Registration Deadline:						
Sample Shipment:						
Closing Date:						

Trace Elements Urine 205

EQAS/PT Properties
Samples: 2 samples of 10 ml
Sample Properties: Lyophilised urine

EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Deputy EQAS/PT Experts:
Udo Kramer, Dipl.-Ing. (FH)

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Aluminium	Copper	Manganese
Arsenic	Fluoride	Mercury
Cadmium	Iodine	Nickel
Chromium	Iron	Selenium
Cobalt	Lead	Zinc

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline:		26-12-18				27-08-06
Sample Shipment:		27-02-23				27-10-05
Closing Date:		27-03-19				27-10-29

Tricyclic Antidepressants 05 - Qualitative in Urine 204

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised urine
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. Werner Steimer

Deputy EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Tricyclic Antidepressants (qualitative)- Screening

Not subject to Rili-BÄK:
Validity Certificate: 12 months
Parameter / Analytes:

Amitriptylin	Imipramin	Nortriptylin
Clomipramin	Norclomipramin	Trimipramin
Desipramin	Nordoxepin	
Doxepin	Nortrimipramin	

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Urinary Stone Analyses 500

EQAS/PT Properties **Samples:** 2 samples **Sample Properties:** Urinary stone (powdered)						**EQAS/PT Experts:** Dr. rer. nat. Stefan Neubeck **Deputy EQAS/PT Experts:** Prof. Dr. med. Karl H. Reuner
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** urinary stone analysis (chemical) urinary stone analysis (physical)			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Urine Chemistry Aminolaevulinic Acid / Porphobilinogen 180

EQAS/PT Properties **Samples:** 2 samples of 3 ml **Sample Properties:** Lyophilised urine						**EQAS/PT Experts:** Dr. Patricia Kaiser (PhD) **Deputy EQAS/PT Experts:** Udo Kramer, Dipl.-Ing. (FH)
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Aminolaevulinic acid Porphobilinogen			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Urine Chemistry Biogene Amines 175

EQAS/PT Properties
Samples: 2 samples of 8 ml
Sample Properties: Lyophilised urine

EQAS/PT Experts:
Dr. rer. nat Heike Schneider

Deputy EQAS/PT Experts:
Dr. med. Thomas Lutz

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

3-Methoxytyramine	Metanephrine
5-Hydroxyindolea acid	Norepinephrine
Dopamine	Normetanephrine
Epinephrine	Serotonin
Homovanillic acid	Vanillylmandelic acid

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Urine Chemistry Hormones 179

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised urine
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Deputy EQAS/PT Experts:
Udo Kramer, Dipl.-Ing. (FH)

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Aldosterone Cortisol free hCG intact

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Urine Chemistry Porphyrins 178

EQAS/PT Properties
Samples: 2 samples of 3 ml
Sample Properties: Lyophilised urine

EQAS/PT Experts:
Dr. Patricia Kaiser (PhD)

Deputy EQAS/PT Experts:
Udo Kramer, Dipl.-Ing. (FH)

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Coproporphyrin 1	Hexaporphyrin
Coproporphyrin 3	Pentaporphyrin
Coproporphyrin total	Porphyrins total
Heptaporphyrin	Uroporphorin

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Urine Chemistry Qualitative 171

EQAS/PT Properties
Samples: 2 samples of 10 ml
Sample Properties: Liquid urine
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Dr. Roman Fried

Deputy EQAS/PT Experts:
Dr. med. Christoph Niederau

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:

Albumin - Urine	Nitrite
Ascorbic acid	Protein
Bilirubin	Urobilinogen
Erythrocytes	hCG
Glucose	pH
Ketone bodies	specific gravity
Leucocytes	

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Urine Chemistry Quantitative 173

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised urine
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Dr. Roman Fried

Deputy EQAS/PT Experts:
Dr. rer. nat. Manfred Falck

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Albumin - Urine
Calcium
Creatinine
Glucose
Phosphate
Potassium
Sodium
Urea
Uric Acid
total Protein - Urine

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Chloride
Magnesium
Osmolality
alpha-Amylase

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Urine Chemistry Sediment Pictures 172

EQAS/PT Properties
Samples: Pictures
Sample Properties: Digital slides
Max. number of sample sets: 1
Additional Information:
Available online in the virtual microscope! - No shipment!

EQAS/PT Experts:
Dr. Roman Fried

Deputy EQAS/PT Experts:
Dr. med. Christoph Niederau

Requirement for EQAS/PT according to Rili-BÄK: yearly
Validity Certificate: 24 months
Parameter / Analytes:
Urine sediment

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	27-01-08		27-04-23	27-06-18		27-10-01
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Urine Protein Differentiation 182

EQAS/PT Properties
Samples: 2 samples of 1 mL
Sample Properties: Liquid urine

EQAS/PT Experts:
Dr. Roman Fried

Deputy EQAS/PT Experts:
Dr. rer. nat. Manfred Falck

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Albumin - Urine

Not subject to Rili-BÄK
Validity Certificate: 6 months / 12 months
Parameter / Analytes:
Creatinine
IgG
Retinol binding protein
Transferrine
alpha-1-Microglobulin
alpha-2-macroglobulin
beta-2-Microglobulin

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	

Vitamins

Vitamins - Methylmalonic Acid 187

EQAS/PT Properties
Samples: 2 samples of 1 ml
Sample Properties: Lyophilised plasma

EQAS/PT Experts:
Dr. med. Christoph Niederau

Deputy EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Methylmalonic acid

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Vitamins - Serum 290

EQAS/PT Properties
Samples: 2 samples of 5 ml
Sample Properties: Lyophilised serum

EQAS/PT Experts:
Dr. med. Christoph Niederau

Deputy EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
1,25-OH Cholecalciferol
25-OH CCF (Vitamin D)
Biotin (Vitamin H)
Cobalamin (Vitamin B12)
Folic acid Holotranscobalamine
Pantothenic acid (Vitamin B5)
Pyridoxal-5-phosphate (Vitamin B6)
Retinol (Vitamin A)
Riboflavin (Vitamin B2)
Thiamine total (Vitamin B1)
Tocopherol (Vitamin E)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Vitamins - Vitamin C 296

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Lyophilised plasma

EQAS/PT Experts:
Dr. med. Christoph Niederau

Deputy EQAS/PT Experts:
Prof. Dr. rer. nat. Ingo Schellenberg

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Ascorbic acid (Vitamin C)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Vitamins - whole blood 291

EQAS/PT Properties **Samples:** 2 samples of 2 ml **Sample Properties:** Lyophilised whole blood	**EQAS/PT Experts:** Dr. med. Christoph Niederau **Deputy EQAS/PT Experts:** Prof. Dr. rer. nat. Ingo Schellenberg
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Flavine Adenine Dinucleotide (FAD) Flavine mononucleotid (FMN) Pyridoxal-5-phosphate (Vitamin B6) Riboflavin (Vitamin B2) Thiamine total (Vitamin B1) Thiaminpyrophosphat (TPP)
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
	Jan.		**May**	**July**		**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09		27-08-06 27-10-05 27-10-22

MICROBIOLOGY

Bacterial Genome Detection

Bacterial Genome Detection - Bordetella pertussis 532

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension					**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist	
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** not applicable **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Bordetella pertussis			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Borrelia burgdorferi 535

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension					**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** Dr. med. Volker Fingerle	
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Borrelia burgdorferi			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Carbapenemase-Genes 544

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension						**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: not applicable			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Carbapenemases			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Chlamydia pneumoniae 540

EQAS/PT Properties **Samples:** 4 samples of 1 ml **Sample Properties:** Lyophilised cell suspension						**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Chlamydia pneumoniae			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Chlamydia trachomatis 531

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension						**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** not applicable **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Chlamydia trachomatis			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Chlamydia trachomatis & Neisseria gonorrhoeae 530

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension **Additional Information:** Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.						**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Chlamydia trachomatis and Neisseria gonorrhoeae			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Clostridium difficile (Toxin Gene) 545

EQAS/PT Properties
Samples: 4 samples of 0.3 ml
Sample Properties: Lyophilised cell suspension
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Prof. Dr. rer. nat. Udo Reischl

Deputy EQAS/PT Experts:
PD Dr. Andreas Hiergeist

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
PCR or other procedures for nucleic acid amplification/detection of Clostridium difficile toxin-genes

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Coxiella burnetii & Bacillus anthracis 542

EQAS/PT Properties
Samples: 4 samples of 0.3 ml
Sample Properties: Lyophilised cell suspension

EQAS/PT Experts:
Prof. Dr. rer. nat. Udo Reischl

Deputy EQAS/PT Experts:
PD Dr. med. Dimitrios Frangoulidis
PD Dr. rer. nat. Gregor Grass

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
PCR or other procedures for nucleic acid amplification/detection of Coxiella burnetii

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
and Bacillus anthracis

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - EHEC / STEC 534

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension						**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of EHEC / STEC			**Not subject to Rili-BÄK** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Francisella tularensis & Brucella spp. 543

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension						**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** Dr. med. vet. Heiner von Buttlar Prof. Dr. rer. nat. Holger C. Scholz
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Francisella tularensis			**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** and Brucella spp.			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Helicobacter pylori 533

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension	**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Helicobacter pylori	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Legionella pneumophila 536

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension	**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Legionella pneumophila	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Listeria spp. 538

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension						**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Listeria spp.			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - MRSA or cMRSA 539

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension **Additional Information:** For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.						**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of MRSA / cMRSA			**Not subject to Rili-BÄK:** not applicable			
Shipping Information: Shipping not cooled			**Safety Information:** Process as patient sample material			
Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Mycoplasma pneumoniae 541

EQAS/PT Properties
Samples: 4 samples of 0.3 ml
Sample Properties: Lyophilised cell suspension

EQAS/PT Experts:
Prof. Dr. rer. nat. Udo Reischl

Deputy EQAS/PT Experts:
PD Dr. Andreas Hiergeist

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
PCR or other procedures for nucleic acid amplification/detection of Mycoplasma pneumoniae

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Nov.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-11			27-11-05

Bacterial Genome Detection - PCR/NAT Multiplex Detection Method for Gastrointestinal Pathogens 548

EQAS/PT Properties
Samples: 4 samples of 0.3 ml
Sample Properties: Lyophilised cell suspension
Max. number of sample sets: 1
Additional Information:

- In order to take into account the usually very different pathogen coverage of commercially available multiplex PCR/NAT concepts, each of the parameters listed above is certified separately as part of the evaluation.
- Only results from multiplex PCR/NAT test systems with a precisely specified test/kit designation are accepted.
- The parallel use of singleplex PCR/NAT detection methods for individual pathogens in the panel is not certified. The relatively broad spectrum of pathogen-specific EQA programmes for bacterial genome detection PCR/NAT is still available for this purpose.
- Mixtures of 0 to 4 of the different pathogens specified in the panel are to be expected in the respective individual samples.

EQAS/PT Experts:
Prof. Dr. rer. nat. Udo Reischl

Deputy EQAS/PT Experts:
PD Dr. Andreas Hiergeist

Requirement for EQAS/PT according to Rili-BÄK:
Validity Certificate: 12 months
Parameter / Analytes:
Clostridium difficile (toxin-producing)
Enterohemorrhagic
E. coli (EHEC / STEC)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Aeromonas spp.
Campylobacter spp.
Enterohemorrhagic
E. coli (EHEC / STEC)
Enterotoxigenic E. coli (ETEC)
Enteropathogenic E. coli (EPEC)
Enteroaggregative E. coli (EAEC)
Escherichia coli O157
Plesiomonas spp.
Salmonella spp.
Shigella/EIEC
Vibrio spp.
Yersinia enterocolitica

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Nov.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-11			27-11-05

Bacterial Genome Detection - Salmonella enterica 537

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension	**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Salmonella enterica	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Urogenital Panel 547

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension	**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of specific DNA: Selection of Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma parvum, Ureaplasma urealyticum, Trichomonas vaginalis, Gardnerella vaginalis, Treponema pallidum
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Nov.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci) 546

EQAS/PT Properties
Samples: 4 samples of 0.3 ml
Sample Properties: Lyophilised cell suspension
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

EQAS/PT Experts:
Prof. Dr. rer. nat. Udo Reischl

Deputy EQAS/PT Experts:
PD Dr. Andreas Hiergeist

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
PCR or other procedures for nucleic acid amplification/detection of Vancomycin restant enterococci (VRE)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Nov.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-11			27-11-05

Bacteriological Infection Serology

Infection Serology - Bartonella Antibodies 326

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
polyvalent (qualitative)
polyvalent (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgA (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline:					27-06-11	
Sample Shipment:					27-08-10	
Closing Date:					27-08-27	

Infection Serology - Bordetella pertussis Antibodies 317

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgM (qualitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
						Oct.
Registration Deadline:						27-08-13
Sample Shipment:						27-10-12
Closing Date:						27-10-29

Infection Serology - Borrelia burgdorferi Antibodies 332

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
- For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
- A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
polyvalent (qualitative)
IgG (qualitative)
IgG (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
IgG-Blot
IgM-Blot

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample materia

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-04			27-10-29

Infection Serology - Brucella Antibodies 327

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
polyvalent (qualitative)
polyvalent (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline:					27-06-11	
Sample Shipment:					27-08-10	
Closing Date:					27-08-27	

Infection Serology - Campylobacter Antibodies 319

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
IgG (qualitative)
IgG (semiquantitative)
IgM (qualitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			
Registration Deadline:			27-03-19			
Sample Shipment:			27-05-18			
Closing Date:			27-06-04			

Infection Serology - Chlamydia pneumoniae (Chlamydophila) Antibodies 314

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgA (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-04			27-10-29

Infection Serology - Chlamydia trachomatis Antibodies 312

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
IgG (qualitative)
IgG (semiquantitativ)
IgA (qualitative)
IgA (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-04			27-10-29

Infection Serology - Chlamydia trachomatis Direct Detection (ELISA / PCR) 313

EQAS/PT Properties **Samples:** 2 samples of 0.4 ml **Sample Properties:** Urine **Max. number of sample sets:** 1	**EQAS/PT Experts:** Prof. Dr. med. K.-P. Hunfeld **Deputy EQAS/PT Experts:** Ulyana Gräf
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Direct detection of Chlamydia trachomatis antigen (ELISA, PCR)	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** diagnostic comment
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29

Infection Serology - Chlamydia trachomatis Direct Detection (Slide) 316

EQAS/PT Properties **Samples:** 2 slides **Sample Properties:** Slides **Max. number of sample sets:** 1	**EQAS/PT Experts:** Prof. Dr. med. K.-P. Hunfeld **Deputy EQAS/PT Experts:** Ulyana Gräf
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Direct detection of Chlamydia trachomatis antigen (dir. IFA)	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** diagnostic comment
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			June			**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29

Infection Serology - Coxiella burnetii Antibodies 325

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
IgG - Phase I (qualitative)
IgG - Phase I (semiquantitative)
IgG - Phase II (qualitative)
IgG - Phase II (semiquantitative)
IgA (qualitative)
IgM (qualitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
						Oct.
Registration Deadline:						27-08-13
Sample Shipment:						27-10-12
Closing Date:						27-10-29

Infection Serology - Diphtheria Toxoid Antibodies 318

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
AB against Diphtherie toxoid (qualitative)
AB against Diphtherie toxoid ((semi-)quantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-04			27-10-29

Infection Serology - Francisella tularensis Antibodies 328

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
polyvalent (qualitative)
polyvalent (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgA (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline:					27-06-11	
Sample Shipment:					27-08-10	
Closing Date:					27-08-27	

Infection Serology - Helicobacter pylori Antibodies 334

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgA (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-04			27-10-29

Infection Serology - Leptospira Antibodies 329

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
polyvalent (qualitative)
polyvalent (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline:					27-06-11	
Sample Shipment:					27-08-10	
Closing Date:					27-08-27	

Infection Serology - Mycoplasma pneumoniae Antibodies 324

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgM (qualitative)
polyvalent (qualitative)
polyvalent (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
						Oct.
Registration Deadline:						27-08-13
Sample Shipment:						27-10-12
Closing Date:						27-10-29

Infection Serology - Procalcitonin 320

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Procalcitonin (qualitative)
Procalcitonin (semi-quantitative)
Procalcitonin (quantitative)
Diagnostic comments

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-04			27-10-29

Infection Serology - Rheumatoid Factor 323

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: quarterly
Validity Certificate: 6 months
Parameter / Analytes:
Rheumatoid factor (RF) (qualitative)
Rheumatoid factor (RF) (quantitative)

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Jan.		June		Aug.	Oct.
Registration Deadline:	26-11-13		27-03-19		27-06-11	27-08-13
Sample Shipment:	27-01-12		27-05-18		27-08-10	27-10-12
Closing Date:	27-01-29		27-06-04		27-08-27	27-10-29

Infection Serology - Rickettsia Antibodies 330

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.4 ml **Sample Properties:** Serum **Max. number of sample sets:** 1 **Additional Information:** For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.	Prof. Dr. med. K.-P. Hunfeld **Deputy EQAS/PT Experts:** Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable	Not subject to Rili-BÄK **Validity Certificate:** 24 months **Parameter / Analytes:** polyvalent (qualitative) polyvalent (semiquantitative) IgG (qualitative) IgG (semiquantitative) IgM (qualitative) IgM (semiquantitative) diagnostic comment
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline: **Sample Shipment:** **Closing Date:**					27-06-11 27-08-10 27-08-27	

Infection Serology - Salmonella Antibodies 331

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
typhi, O-Antigen (qualitative)
typhi, O-Antigen (semiquantitative)
typhi, OH-Antigen (qualitative)
typhi, OH-Antigen (semiquantitative)
enteritidis, OH-Antigen (qualitative)
enteritidis, OH-Antigen (semiquantitative)
typhimurium, OH-Antigen (qualitative)
typhimurium, OH-Antigen (semiquantitative)
paratyphi B, OH-Antigen (qualitative)
paratyphi B, OH-Antigen (semiquantitative)
Group A, O-Antigen (qualitative)
Group A, O-Antigen (semiquantitative)
Group B, O-Antigen (qualitative)
Group B, O-Antigen (semiquantitative)
Group C, O-Antigen (qualitative)
Group C, O-Antigen (semiquantitative)
polyvalent (qualitative)
IgA (qualitative)
IgG (qualitative)
IgM (qualitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-04			27-10-29

Infection Serology - Streptococcal AB 321

EQAS/PT Properties **Samples:** 2 samples of 0.4 ml **Sample Properties:** Serum **Max. number of sample sets:** 1	**EQAS/PT Experts:** Prof. Dr. med. K.-P. Hunfeld **Deputy EQAS/PT Experts:** Ulyana Gräf
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** anti-streptolysin O (ASO) (qualitative) anti-streptolysin O (ASO) (quantitative) anti-streptodornase (aDNase) (qualitative) anti-streptodornase (aDNase) (quantitative)	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29

Infection Serology - Tetanus Toxoid Antibodies 310

EQAS/PT Properties **Samples:** 2 samples of 0.4 ml **Sample Properties:** Serum **Max. number of sample sets:** 1 **Additional Information:** For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.	**EQAS/PT Experts:** Prof. Dr. med. K.-P. Hunfeld **Deputy EQAS/PT Experts:** Ulyana Gräf
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** AB against Tetanus toxoid (qualitative) AB against Tetanus toxoid ((semi-)quantitative) diagnostic comment
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29

Infection Serology - Treponema pallidum Antibodies 311

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
TPHA (qualitative)
TPHA (semiquantitative)
TPPA (qualitative)
TPPA (semiquantitative)
polyvalent (qualitative)
IgG (qualitative)
FTA-Abs IgG (semiquantitative)
FTA-Abs IgM (qualitative)
FTA-Abs IgM (semiquantitative)
IgG (semiquantitative)
IgM (qualitative)
IgG - Immunoblot
IgM - Immunoblot
FTA-Abs IgG (qualitative)

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
AB against Cardiolipin (qualitative)
AB against Cardiolipin (semiquantitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-06-04			27-10-29

Infection Serology - Yersinia Antibodies 315

EQAS/PT Properties
Samples: 2 samples of 0.4 ml
Sample Properties: Serum
Max. number of sample sets: 1
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. K.-P. Hunfeld

Deputy EQAS/PT Experts:
Ulyana Gräf

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
enterocolitica O3 (qualitative)
enterocolitica O3 (semiquantitative)
enterocolitica O9 (qualitative)
enterocolitica O9 (semiquantitative)
pseudotuberculosis (qualitative)
pseudotuberculosis (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgM (qualitative)
diagnostic comment

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04			

Human Microbiome

Bacterial Genome Detection - Molecular Genetic Analysis of the Human Microbiome 580

EQAS/PT Properties
Samples: 4 samples of 0.5 mL
Sample Properties: Stool suspension
Max. number of sample sets: 1

EQAS/PT Experts:
Prof. Dr. Dr. rer. nat. André Gessner

Deputy EQAS/PT Experts:
Prof. Dr. rer. nat. Udo Reischl

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
NGS-Analysis (next generation sequencing)

Shipping Information:
- Cooled shipping
- Delivered with dry ice!
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 5 Days!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			Aug.			
Registration Deadline: Sample Shipment: Closing Date:			27-04-16 27-06-15 27-08-20			

Conventional Bacteriology

Bacteriology (3 Samples) 411

EQAS/PT Properties
Samples: 3 samples
Sample Properties: Lyophilised strains + Bouillon
Additional Information:

- Participants in the EQA schemes in bacteriology will get a certificate for Gram staining when successful in this part.
- **Additional participation in EQA scheme No. 413 ´Gram Stain´ is not required.**
- Participants will be notified in advance in case the panel of tested antibiotics will be changed:

Ampicillin	Oxacillin
Ampicillin/Sulbactam	Trimethoprim/Sulfamethoxazol
Cefpodoximproxetil	Fosfomycintrometamol
Ceftazidim	Nitrofurantoin Pivmecillinam
Ciprofloxacin	Nitroxolin
Levofloxacin Penicillin	Gentamicin
Meropenem	

EQAS/PT Experts:
Prof. Dr. med. Dirk Schlüter

Deputy EQAS/PT Experts:
Dr. med. Marc Lindenberg
Dr. med. Stefan Ziesing

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Cultivation, identification and susceptibility testing of fast-growing bacteria and accompanying bacterial flora of the urogenital tract, incl. yeasts
Gram staining

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
	Jan.		Mar.	July		Nov.
Registration Deadline:	26-11-20		27-01-08	27-04-30		27-09-03
Sample Shipment:	27-01-19		27-03-02	27-06-29		27-11-02
Closing Date:	27-01-29		27-03-12	27-07-09		27-11-12

Bacteriology (5 Samples) 412

EQAS/PT Properties
Samples: 5 samples of 1 mL
Sample Properties: Lyophilised strains
Additional Information:
- Participants in the EQA schemes in bacteriology will get a certificate for Gram staining when successful in this part.
- **Additional participation in EQA scheme No. 413 ´Gram Stain´ is not required.**
- Participants will be notified in advance in case the panel of tested antibiotics will be changed:

Ampicillin
Cefotaxim
Ceftazidim Cefuroxim
Ciprofloxacin
Erythromycin Gentamicin High Level
Meropenem
Levofloxacin Linezolid
Oxacillin
Penicillin Piperacillin/Tazobactam
Trimethoprim/Sulfamethoxazol
Tobramycin Vancomycin

EQAS/PT Experts:
Prof. Dr. med. Dirk Schlüter

Deputy EQAS/PT Experts:
Dr. med. Marc Lindenberg
Dr. med. Stefan Ziesing

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Cultivation, identification and susceptibility testing of bacteria Gram staining

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
	Feb.				Sep.	
Registration Deadline:	26-12-04				27-07-02	
Sample Shipment:	27-02-02				27-08-31	
Closing Date:	27-02-12				27-09-10	

Bacteriology - Gram Stain 413

EQAS/PT Properties
Samples: 3 samples
Sample Properties: Slides
Additional Information:
Participants of the EQA schemes in bacteriology No. 411 or 412 will get a certificate for gram staining if they are successful in this part.

EQAS/PT Experts:
Prof. Dr. med. Dirk Schlüter

Deputy EQAS/PT Experts:
Dr. med. Marc Lindenberg
Dr. med. Stefan Ziesing

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Gram staining

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline:		27-01-08				27-08-06
Sample Shipment:		27-03-09				27-10-05
Closing Date:		27-03-19				27-10-15

Mycobacteriology

Mycobacterial Diagnostics - Cultivation 422

EQAS/PT Properties
Samples: 5 samples of 1 mL
Sample Properties: Artificial sputum, mixed with accompanying flora and possibly Mycobacterium tuberculosis complex or Non tuberculous Mycobacteria
Max. number of sample sets: 1

EQAS/PT Experts:
Dr. Sönke Andres

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Cultivation of Mycobacteria
Differentiation of Tuberculosis Bacteria

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		May			Nov.	
Registration Deadline:		27-01-15			27-07-09	
Sample Shipment:		27-03-16			27-09-07	
Closing Date:		27-05-28			27-11-19	

Mycobacterial Diagnostics - Drug Susceptibility Testing of Mycobacterium tuberculosis 425

EQAS/PT Properties
Samples: 5 samples of 1 mL
Sample Properties: Mycobacterium tuberculosis complex suspensions for phenotypic resistance testing (incl. second-line drugs)
Max. number of sample sets: 1
Additional Information:
- Note: EQA scheme containing infectious substances according to UN2814, infectious substances category A.
- Each registration for this group must confirm that the test is performed in a laboratory with security level S3 and with appropriately qualified personnel.

EQAS/PT Experts:
Dr. Sönke Andres

Deputy EQAS/PT Experts:
N.N.

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Susceptibility Testing of Tuberculosis Bacteria

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		May			Nov.	
Registration Deadline:		27-01-15			27-07-09	
Sample Shipment:		27-03-16			27-09-07	
Closing Date:		27-05-28			27-11-19	

Mycobacterial Diagnostics - Drug Susceptibility Testing of Nontuberculous Mycobacteria 427

EQAS/PT Properties
Samples: 5 samples of 1 mL
Sample Properties: Suspensions of Nontuberculous Mycobacteria
Max. number of sample sets: 1

EQAS/PT Experts:
Dr. Sönke Andres

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Susceptibility Testing of Nontuberculous Mycobacteria

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		May			Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-05-07			27-07-09 27-09-07 27-10-29	

Mycobacterial Diagnostics - Identification 423

EQAS/PT Properties
Samples: 5 samples of 1 mL
Sample Properties: Mycobacterial suspensions (non-tuberculous mycobacteria or Mycobacterium bovis BCG)
Max. number of sample sets: 1

EQAS/PT Experts:
Dr. Sönke Andres

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Identification of Mycobacteria

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		May			Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-05-07			27-07-09 27-09-07 27-10-29	

Mycobacterial Diagnostics - Microscopy 421

EQAS/PT Properties	EQAS/PT Experts:
Samples: 6 samples **Sample Properties:** Slides **Max. number of sample sets:** 1	Dr. Sönke Andres **Deputy EQAS/PT Experts:** N.N
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Microscopic Detection of Mycobacteria	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Apr.			Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-04-02			27-07-09 27-09-07 27-09-24	

Mycobacterial Diagnostics - Molecular Drug Susceptibility Testing of tuberculosis bacteria 426

EQAS/PT Properties	EQAS/PT Experts:
Samples: 5 samples of 1 mL **Sample Properties:** Suspensions of inactivated Mycobacterium tuberculosis complex strains for molecular resistance testing **Max. number of sample sets:** 1	Dr. Sönke Andres **Deputy EQAS/PT Experts:** N.N
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Susceptibility Testing of Tuberculosis Bacteria	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-04-23			27-07-09 27-09-07 27-10-15	

Mycobacterial Diagnostics - NAT Mycobacterium tuberculosis 424

EQAS/PT Properties **Samples:** 5 samples of 1 mL **Sample Properties:** Artificial sputum, with accompanying flora and in individual cases mixed with Mycobacterium tuberculosis Complex **Max. number of sample sets:** 1	**EQAS/PT Experts:** Dr. Sönke Andres **Deputy EQAS/PT Experts:** N.N
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Nucleic Acid Amplification of Tuberculosis Bacteria	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Apr.			Sep.	
Registration Deadline: **Sample Shipment:** **Closing Date:**		27-01-15 27-03-16 27-04-02			27-07-09 27-09-07 27-09-24	

Mycology

Fungal Genome Detection - Pneumocystis jirovecii 560

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Lyophilised cell suspension	**EQAS/PT Experts:** Prof. Dr. rer. nat. Udo Reischl **Deputy EQAS/PT Experts:** PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** PCR or other procedures for nucleic acid amplification/detection of Pneumocystis jirovecii
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			June			Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Genome Detection of Dermatophytes 492

EQAS/PT Properties
Samples: 4 samples of 0.05 ml
Sample Properties: Lyophilised strains

EQAS/PT Experts:
PD Dr. rer. nat. et med. habil Cornelia Wiegand

Deputy EQAS/PT Experts:
Dr. rer. med. Silke Uhrlaß
Prof. Dr. med. Pietro Nenoff

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other procedures for Genome detection of dermatophytes

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline:		27-01-08			27-07-09	
Sample Shipment:		27-03-09			27-09-07	
Closing Date:		27-04-02			27-10-01	

Mycology Dermatophytes, Yeasts, Mould Fungus 491

EQAS/PT Properties
Samples: 4 samples
Sample Properties: Strains
Additional Information:
Living strains of causative agents or contaminantes will be sent, that had been isolated from patients with skin mycoses or mucosal fungal infections.

EQAS/PT Experts:
PD Dr. rer. nat. et med. habil Cornelia Wiegand

Deputy EQAS/PT Experts:
Dr. rer. med. Silke Uhrlaß
Prof. Dr. med. Pietro Nenoff
Prof. Dr. med. Dipl.-Biol. Gerhard Haase

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Identification of dermatophytes, yeasts and moulds

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline:		27-01-08			27-07-09	
Sample Shipment:		27-03-09			27-09-07	
Closing Date:		27-04-23			27-10-22	

Mycology Mucorales, Yeasts, Coelomycetes, Hyphomycetes, Basidiomycetes 490

EQAS/PT Properties
Samples: 5 samples
Sample Properties: Strains

EQAS/PT Experts:
Prof. Dr. med. Dipl.-Biol. Gerhard Haase

Deputy EQAS/PT Experts:
Dr. rer. nat. Walter Geißdörfer

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Cultivation and species identification of fungi (Mucorales, ascomycetes, yeast-like species, coelomycetes, hyphomycetes, basidiomycetes) known to cause mucosal, organ, systemic, or traumatic mycoses in humans, as well as contaminants that may be present in human specimens. Furthermore, a preliminary medical commentary should be provided to evaluate the respective fungus in the specified context.

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
	Feb.				Oct.	
Registration Deadline:	26-11-20				27-07-16	
Sample Shipment:	27-01-19				27-09-14	
Closing Date:	27-02-12				27-10-08	

Mycoserology - Candida (Antigen and Antibodies) 480

EQAS/PT Properties
Samples: 2 samples of 0.5 mL
Sample Properties: Liquid serum
Additional Information:
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. med. Michael S. Weig

Deputy EQAS/PT Experts:
PD Dr. rer. nat. Oliver Bader

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Candida IgA (qual)
Candida IgG (qual)
Candida IgM (qual)
Candida antigen (qual)
Candida total AB (qual)

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
	Feb.				Oct.	
Registration Deadline:	26-11-20				27-07-16	
Sample Shipment:	27-01-19				27-09-14	
Closing Date:	27-02-05				27-10-01	

Mycoserology - Cryptococcus neoformans/ - gattii Antigen 481

EQAS/PT Properties
Samples: 2 samples of 0.4 mL
Sample Properties: Liquid serum
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
PD Dr. med. Volker Rickerts

Deputy EQAS/PT Experts:
Ilka McCormick Smith

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Detection of Cryptococcus neoformans / Cryptococcus gattii Antigen

Not subject to Rili-BÄK
Validity Certificate: 12 months

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
	Feb.				Oct.	
Registration Deadline:	26-11-20				27-07-16	
Sample Shipment:	27-01-19				27-09-14	
Closing Date:	27-02-05				27-10-01	

Parasite Diagnostics

Detection of Toxoplasma DNA (PCR) 457

EQAS/PT Properties
Samples: 4 samples
Sample Properties: Stabilized amniotic fluid (and/or EDTA blood or other fluids), buffer

EQAS/PT Experts:
Prof. Dr. Marc Hübner

Deputy EQAS/PT Experts:
Prof. Dr. med. Achim Hörauf

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Toxoplasma gondii (DNA) - qualitative

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	

Molecular Genetic Detection of Protozoa in Stool 458

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.5 mL **Sample Properties:** Lyophilisate **Max. number of sample sets:** 1	Prof. Dr. med. Egbert Tannich **Deputy EQAS/PT Experts:** Prof. Dr. Iris Bruchhaus
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Cryptosporidium spp. (DNA) - qualitative Entamoeba histolytica (DNA) - qualitative Giardia duodenalis (DNA) - qualitative
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Parasite Microscopy (Blood) 456

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of thin or thick blood smear **Sample Properties:** Slides **Max. number of sample sets:** 1	Prof. Dr. Marc Hübner **Deputy EQAS/PT Experts:** Prof. Dr. med. Achim Hörauf
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Blood parasites - specification	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12			27-06-11 27-08-10 27-08-27	

Parasite Serology - Amoebiasis and Echinococcosis 455

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples variable volumes **Sample Properties:** Serum / Plasma	Prof. Dr. Marc Hübner **Deputy EQAS/PT Experts:** Prof. Dr. med. Achim Hörauf

Requirement for EQAS/PT according to Rili-BÄK: yearly	Not subject to Rili-BÄK
Validity Certificate: 24 months **Parameter / Analytes:** Antibodies against Echinococcus Antibodies against Entamoeba histolytica	**Validity Certificate:** 24 months **Parameter / Analytes:** diagnostic comment of an echinococcus infection
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
						Oct.
Registration Deadline: Sample Shipment: Closing Date:						27-08-06 27-10-05 27-10-22

Parasite Serology - Malaria and Schistosomiasis 454

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples variable volumes **Sample Properties:** Serum / Plasma **Additional Information:** For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.	Prof. Dr. Marc Hübner **Deputy EQAS/PT Experts:** Prof. Dr. med. Achim Hörauf

Requirement for EQAS/PT according to Rili-BÄK: yearly	Not subject to Rili-BÄK
Validity Certificate: 24 months **Parameter / Analytes:** Antibodies against Plasmodium Antibodies against Schistosoma	**Validity Certificate:** 24 months **Parameter / Analytes:** Comprehensive Diagnostic Evaluation of a Plasmodium Infection Comprehensive Diagnostic Evaluation of a Schistosoma Infection
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			

Parasite Serology - Toxoplasmosis 452

EQAS/PT Properties
Samples: 2 samples variable volumes
Sample Properties: Serum / Plasma
Additional Information:
- For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
- A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

EQAS/PT Experts:
Prof. Dr. Marc Hübner

Deputy EQAS/PT Experts:
Prof. Dr. med. Achim Hörauf

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Antibodies against Toxoplasma gondii

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Comprehensive diagnostic evaluation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22

Virtual Parasite Microscopy (Blood) 906

EQAS/PT Properties
Samples: Images of at least 2 clinical cases
Sample Properties: Digital slides
Max. number of sample sets: 1

EQAS/PT Experts:
Prof. Dr. med. Egbert Tannich

Deputy EQAS/PT Experts:
Prof. Dr. Iris Bruchhaus
Prof. Dr. med. Achim Hörauf
Prof. Dr. Marc Hübner

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Blood parasites - specification

Not subject to Rili-BÄK: not applicable

Shipping Information:
- Available online in digital microscopy! - No shipment!
- In March and September: Prof. Hübner, Bonn; in May and October: Prof. Tannich, Hamburg

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Virtual Parasite Detection (Stool) 907

EQAS/PT Properties **Samples:** Images of slides with feacal smears of at least 2 clinical cases **Sample Properties:** Digital slides **Max. number of sample sets:** 1	**EQAS/PT Experts:** Prof. Dr. med. Egbert Tannich **Deputy EQAS/PT Experts:** Prof. Dr. Iris Bruchhaus
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Stool parasites - specification	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Available online in digital microscopy! - No shipment!	**Safety Information:** Process as patient sample material

Dates	**Q1**		**Q2**	**Q3**		**Q4**
			May			**Oct.**
Registration Deadline: **Sample Shipment:** **Closing Date:**			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

VIRUS DIAGNOSTICS

Virus Genome Detection

Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag) 410

EQAS/PT Properties
Samples: 5 samples of 0.5 ml
Sample Properties: Liquid cell culture material (inactivated)
Additional Information:

- Note: When performing tests using your own swab, please note that the provided sample volume of 0.5 ml is generally sufficient for performing one SARS-CoV-2 test, one influenza virus test, and one RSV test. However, depending on the absorbency of the swab used, a second tube may be necessary.
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: entfällt

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
The samples are suitable to detect influenza A/B antigen, RSV A/B antigen, and SARS-CoV-2 antigen.

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Information will be updated at the end of autumn.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses 370

EQAS/PT Properties

Samples: 6 samples of 1.5 ml

Sample Properties: Lyophilised cell culture material or allantoic fluid

Additional Information:

- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
  Note for laboratories from non-EU countries:
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Referenzzentrum für Influenza, Robert Koch-Institut, Berlin; Friedrich-Loeffler-Institut, Bundesforschungsinstitut für Tiergesundheit, Nationales Referenzlabor für Aviäre Influenza, Insel Riems

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual

Validity Certificate: 12 months

Parameter / Analytes:

- This program may be completed with currently circulating influenza viruses.
- Please note: these EQA samples are not suitable for virus propagation and immune fluorescence tests for antigen detection. Some of the samples can contain chemically inactivated avian influenza A viruses.
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for influenza A and B viruses and antigen testing
- Option for typing of seasonal and avian influenza A viruses

Not subject to Rili-BÄK: not applicable

Shipping Information:

- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.				Nov.
Registration Deadline:		27-01-08				27-09-03
Sample Shipment:		27-03-09				27-11-02
Closing Date:		27-03-26				27-11-19

Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus 359

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Cooperation with: Institut für Virologie und Immunbiologie, Universität Würzburg; Institut für Virologie, Universitätsklinikum Düsseldorf; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Dr. Axel Schubert

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for RSV RNA and RSV antigen testing

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Adenoviruses 371

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material

EQAS/PT Experts:
PD Dr. med. Albert Heim

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for adenovirus DNA
- Determination of species of adenovirus
- Typing of adenovirus

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - BK Polyomavirus (BKPyV / BKV) 364

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma or suspension of urine
Additional Information:
Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln

EQAS/PT Experts:
Dr. Steffi Silling

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for BK virus DNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Borna Viruses 404

EQAS/PT Properties
Samples: 4 samples of 1.5 ml* or 0.5 ml**
Sample Properties: *Lyophilised cell culture material (inactivated) or ** lyophilised RNA eluate
Additional Information:
Cooperation with: Friedrich-Loeffler-Institut, Bundesforschungsinstitut für Tiergesundheit, Institut für Virusdiagnostik, Insel Riems

EQAS/PT Experts:
Prof. Dr. med. Jonas Schmidt-Chanasit

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Bornaviruses - RNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Chikungunya Virus 392

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma and cell culture material (inactivated)
Additional Information:
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

EQAS/PT Experts:
Prof. Dr. med. Jonas Schmidt-Chanasit

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK:
Validity Certificate: not applicable
Parameter / Analytes:

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CHIKV RNA

Shipping Information:
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Coronaviruses incl. SARS-CoV-2 340

EQAS/PT Properties
Samples: 6 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2-RNA, MERS-CoV-RNA and other human coronavirus RNA
- Option for differentiaton between SARS-CoV-2, MERS-CoV and other human coronaviruses (samples which contain SARS-CoV-2 and MERS-CoV, repectively, are inactivated)

Not subject to Rili-BÄK: not applicable

Shipping Information:
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Cytomegalovirus Program 1 365

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma or cell culture material

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CMV DNA

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Cytomegalovirus Program 2 - additional Training Program (can only be ordered with program 365) 368

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma
Additional Information:

- The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3.
- The training program (368) can only be ordered together with the corresponding main EQA scheme (365) for March.
- Separate certificates will be issued for the training program (368) and the main EQA scheme (365, subject to Rili-BÄK-B3).
- Cooperation with: Nationale Konsiliarlabore für Cytomegalievirus (CMV): Institut für Virologie, Universitätsklinikum Ulm; Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CMV DNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline:		27-01-08				
Sample Shipment:		27-03-09				
Closing Date:		27-03-26				

Virus Genome Detection - Cytomegalovirus Resistance Determination 349

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma or cell culture material
Additional Information:
Cooperation with: Nationale Konsiliarlabore für Cytomegalievirus (CMV): Institut für Virologie, Universitätsklinikum Ulm; Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for CMV resistance determination

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
					Oct.	
Registration Deadline:					27-06-25	
Sample Shipment:					27-08-24	
Closing Date:					27-10-01	

Virus Genome Detection - Dengue Viruses 369

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma or cell culture material (inactivated)
Additional Information:
Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

EQAS/PT Experts:
Prof. Dr. med. Jonas Schmidt-Chanasit

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for denguevirus RNA
- Typing of denguevirus

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Enteroviruses 372

EQAS/PT Properties **Samples:** 4 samples of 1.5 ml **Sample Properties:** Lyophilised cell culture material	**EQAS/PT Experts:** Dr. med. Martin Obermeier **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** • Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for enterovirus RNA • Typing of enterovirus	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19

Virus Genome Detection - Epstein Barr Virus 376

EQAS/PT Properties **Samples:** 4 samples of 1.5 ml **Sample Properties:** Lyophilised cell culture material	**EQAS/PT Experts:** Prof. Dr. Holger F. Rabenau **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for EBV DNA	**Not subject to Rili-BÄK** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: **Sample Shipment:** **Closing Date:**				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19

Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests 430

EQAS/PT Properties
Samples: 3 samples of 1.5 ml
Sample Properties: Lyophilised suspension of feces or cell culture material
Additional Information:

- The RiliBÄK requirements (Guidelines of the German Medical Association on quality assurance in medical laboratory testing / Bundesärztekammer) will be used to detect the pathogens listed below. This EQA scheme will include each of the pathogens mentioned below at least once a year. Participation in both EQA scheme terms is recommended.
- **Please note: Only results of multiplex tests will be accepted for EQA scheme 430**
- This multiplex EQA scheme is not suitable for (i) ´singleplex´ PCRs, (ii) tests for antigen detection, (iii) testing of sensitivity and (iv) typing. For this purpose, we refer to the INSTAND EQA schemes for the corresponding viruses.
- This program will be completed with currently circulating virus variants.

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of gastrointestinal adeno, astro, entero, noro, parecho, rota and sapoviruses, respectively.

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of gastrointestinal adeno, astro, entero, noro, parecho, rota and sapoviruses, respectively.

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Hepatitis A Virus 377

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma

EQAS/PT Experts:
Dr. Axel Schubert

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HAV RNA

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Hepatitis B Virus Genotyping 396

EQAS/PT Properties **Samples:** 4 samples of 1.5 ml **Sample Properties:** Lyophilised plasma **Additional Information:** Cooperation with: WHO Collaborating Centre for Blood Products and IVD-Devices, Paul-Ehrlich-Institut, Langen	**EQAS/PT Experts:** Dr. med. Martin Obermeier **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) incl. sequencing for HBV genotyping
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
						Nov.
Registration Deadline:						27-09-03
Sample Shipment:						27-11-02
Closing Date:						27-11-19

Virus Genome Detection - Hepatitis B Virus Program 1 361

EQAS/PT Properties **Samples:** 4 samples of 1.5 ml **Sample Properties:** Lyophilised plasma	**EQAS/PT Experts:** Dr. med. Martin Obermeier **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: bi-annual **Validity Certificate:** 12 months **Parameter / Analytes:** Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HBV DNA	**Not subject to Rili-BÄK:** not applicable
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Hepatitis B Virus Program 2 - additional Training Program (can only be ordered with program 361) 378

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma
Additional Information:
- The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3.
- The training program (378) can only be ordered together with the corresponding main EQA scheme (361) for March.
- Separate certificates will be issued for the training program (378) and the main EQA scheme (361, subject to Rili-BÄK-B3).

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HBV DNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26				

Virus Genome Detection - Hepatitis B Virus Resistance Determination 397

EQAS/PT Properties
Samples: 4 samples à 0.1 ml* or à 1.5 ml**
Sample Properties: *Plasmids in water or **lyophilised plasma

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HBV resistance determination

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
					Oct.	
Registration Deadline: Sample Shipment: Closing Date:					27-06-25 27-08-24 27-10-01	

Virus Genome Detection - Hepatitis C Virus Geno-/Subtyping 375

EQAS/PT Properties
Samples: 3-4 samples of 1.5 ml
Sample Properties: Lyophilised serum/plasma
Additional Information:
Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf; Medizinisches Infektiologiezentrum Berlin

EQAS/PT Experts:
Prof. Dr. med. Jörg Timm

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: yearly
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV geno- and subtype differentiation

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
					Sep.	
Registration Deadline:					27-06-25	
Sample Shipment:					27-08-24	
Closing Date:					27-09-10	

Virus Genome Detection - Hepatitis C Virus Program 1 362

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma

EQAS/PT Experts:
Prof. Dr. med. Jörg Timm

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV RNA

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Hepatitis C Virus Program 2 - additional Training Program (can only be ordered with program 362) 379

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma
Additional Information:
- The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3.
- The training program (379) can only be ordered together with the corresponding main EQA scheme (362) for March.
- Separate certificates will be issued for the training program (379) and the main EQA scheme (362, subject to Rili-BÄK-B3).
- Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf

EQAS/PT Experts:
Prof. Dr. med. Jörg Timm

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV RNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26				

Virus Genome Detection - Hepatitis C Virus Resistance Determination 399

EQAS/PT Properties
Samples: 2-3 samples of 0.5 ml
Sample Properties: Serum/plasma (non-lyohilised)
Additional Information:
- Please note: Only tests in the gene region NS5A will be offered in this EQA scheme. Resistance tests in the gene region NS3 will no longer be offered due to lack of clinical relevance.
- Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf; Medizinisches Infektiologiezentrum Berlin

EQAS/PT Experts:
Prof. Dr. med. Jörg Timm

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HCV resistance determination

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
					Oct.	
Registration Deadline: Sample Shipment: Closing Date:					27-06-25 27-08-24 27-10-01	

Virus Genome Detection - Hepatitis D Virus 400

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma
Additional Information:
Cooperation with: WHO Collaborating Centre for Blood Products and IVD-Devices, Paul-Ehrlich-Institut, Langen

EQAS/PT Experts:
Prof. Dr. Holger F. Rabenau

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HDV RNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Hepatitis E Virus 380

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised serum/plasma or suspension of feces
Additional Information:
Cooperation with: Nationales Konsiliarlabor für Hepatitis-A-Virus (HAV) und Hepatitis-E-Virus (HEV), Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg

EQAS/PT Experts:
Dr. Axel Schubert

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: ´bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HEV RNA

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2 363

EQAS/PT Properties
Samples: 6 samples of 1.5 ml
Sample Properties: Lyophilised plasma or cell culture material

EQAS/PT Experts:
Prof. Dr. Holger F. Rabenau

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for differentiation of HSV 1 and HSV 2 DNA

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19

Virus Genome Detection - HIV-1 (RNA) Program 2 - additional Training Program (can only be ordered with program 360) 382

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma
Additional Information:
- The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3.
- The training program (382) can only be ordered together with the corresponding main EQA scheme (360) for March.
- Separate certificates will be issued for the training program (382) and the main EQA scheme (360, subject to Rili-BÄK-B3).
- Cooperation with: Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-1 (RNA)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26				

Virus Genome Detection - HIV-1 (RNA) Program 1 360

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-1 (RNA)

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - HIV-1 Drug Resistance Determination - Standard Program for Protease and Reverse Transcriptase Inhibitors 383

EQAS/PT Properties
Samples: 4 samples of 1.5 ml* or 0.1 ml**
Sample Properties: *Plasma or **Plasmids in water (non-lyophilised)
Additional Information:
Cooperation with IMD Labor Frankfurt; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main; Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen; Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln; Medizinisches Infektiologiezentrum Berlin

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
- Please note: The samples will contain plasmids and heat-inactivated cell culture supernatant viruses respectively!
- Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HIV-1 drug resistance determination of protease inhibitors and reverse transcriptase inhibitors

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Oct.	
Registration Deadline:					27-06-25	
Sample Shipment:					27-08-24	
Closing Date:					27-10-01	

Virus Genome Detection - HIV-1 Drug Resistance Determination - additional Program for Integrase Inhibitors and Tropism Determination 384

EQAS/PT Properties
Samples: 2 samples of 1.5 ml
Sample Properties: Plasma (non-lyophilised)
Additional Information:
Cooperation with IMD Labor Frankfurt; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main; Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen; Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln; Medizinisches Infektiologiezentrum Berlin

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
- Please note: The samples will contain heat-inactivated cell culture supernatant viruses!
- Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HIV-1 drug resistance determination of integrase inhibitors and determination of tropism

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Oct.	
Registration Deadline:					27-06-25	
Sample Shipment:					27-08-24	
Closing Date:					27-10-01	

Virus Genome Detection - HIV-2 (RNA) 395

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised serum/plasma
Additional Information:
Cooperation with: Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-2 (RNA)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Human Herpesvirus 6 (HHV-6) 405

EQAS/PT Properties **Samples:** 4 samples of 1.5 ml **Sample Properties:** Lyophilised cell culture material **Additional Information:** Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf	**EQAS/PT Experts:** Prof. Dr. med. Jörg Timm **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human herpesvirus 6 (HHV-6) - DNA
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Human Herpesvirus 8 (HHV-8) 406

EQAS/PT Properties **Samples:** 4 samples of 1.5 ml **Sample Properties:** Lyophilised cell culture material **Additional Information:** Cooperation with: Institut für Virologie, Medizinische Hochschule Hannover	**EQAS/PT Experts:** Dr. med. Martin Obermeier **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human herpesvirus 8 (HHV-8) - DNA
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline:		27-01-08				
Sample Shipment:		27-03-09				
Closing Date:		27-03-26				

Virus Genome Detection - Human Metapneumovirus 385

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Dr. rer. nat. Kerstin Knies

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human metapneumovirus RNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Human Papillomaviruses (HPV) 373

EQAS/PT Properties
Samples: 5 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material or biopsy material
Additional Information:
Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln

EQAS/PT Experts:
Dr. Steffi Silling

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and hybridization for HPV DNA
- Differentiation of ‚high risk' and ‚low risk' types, and typing of ‚high risk' HPV and ‚low risk' HPV

Not subject to Rili-BÄK not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Human Rhinoviruses 393

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Dr. rer. nat. Kerstin Knies

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HRV RNA
- Typing of human rhinovirus

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - JC Polyomavirus (JCPyV / JCV) 394

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material or suspension of urine
Additional Information:
Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln

EQAS/PT Experts:
Dr. Steffi Silling

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for JC virus DNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Measles Virus 386

EQAS/PT Properties	EQAS/PT Experts:
Samples: 4 samples of 1.5 ml **Sample Properties:** Lyophilised cell culture material **Additional Information:** Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin	Prof. Dr. med. Martin Enders **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual	Not subject to Rili-BÄK: not applicable
Validity Certificate: 12 months **Parameter / Analytes:** • Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for measles virus RNA • Typing of measles virus	
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				July		Dec.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-07-09		27-12-03

Virus Genome Detection - MPXV / Orthopoxviruses 418

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material (MPXV inactivated)
Additional Information:
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Konsiliarlabor für Pockenviren, Robert Koch-Institut, Zentrum für Biologische Gefahren und Spezielle Pathogene, ZBS 1 - Hochpathogene Viren, Berlin

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable
Validity Certificate:
Parameter / Analytes:

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
MPXV (DNA) - quantitative
MPXV (DNA) - qualitative
MPXV (DNA) - clade identification
Orthopoxviruses (DNA) – quantitative
Orthopoxviruses (DNA) – qualitative
Orthopoxviruses (DNA) – type identification

Shipping Information:
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Mumps Virus 387

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for mumps virus RNA
- Typing of mumps virus

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				July		Dec.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-07-09		27-12-03

Virus Genome Detection - Norovirus 381

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised suspension of feces
Additional Information:
Cooperation with: Nationales Konsiliarlabor für Noroviren, Robert Koch-Institut, Berlin; Nationales Konsiliarlabor für Hepatitis-A-Virus (HAV) und Hepatitis-E-Virus (HEV), Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg; Institut für Virologie, Medizinische Hochschule Hannover

EQAS/PT Experts:
Dr. Axel Schubert

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for norovirus RNA with the option for differentiation in genogroup I and II

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.				Nov.
Registration Deadline:		27-01-08				27-09-03
Sample Shipment:		27-03-09				27-11-02
Closing Date:		27-03-26				27-11-19

Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens NEW! 435

EQAS/PT Properties
Samples: 5 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material

EQAS/PT Experts:
Prof. Dr. med. Jonas Schmidt-Chanasit

Deputy EQAS/PT Experts:
N.N

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for qualitative detection of Zika-, Dengue-, Chikungunya-, Japanese encephalitis- and Oropouche virus-RNA and Plasmodium spp.

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	Nov.
Registration Deadline:		27-01-08			27-06-25	27-09-03
Sample Shipment:		27-03-09			27-08-24	27-11-02
Closing Date:		27-03-26			27-09-10	27-11-19

Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests 433

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
- We will include the listed pathogens in this EQAS/PT program at least once a year. We therefore recommend participating in both rounds of the EQAS/PT program.
- We will accept only results from multiplex tests for this proficiency testing program.
- This multiplex proficiency testing program is not suitable for (i) “singleplex” PCRs, (ii) antigen detection tests, (iii) sensitivity assessments, and (iv) typing. For these purposes, please refer to the corresponding INSTAND proficiency testing programs for the respective viruses.
- The program includes currently circulating virus variants.

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: not applicable
Parameter / Analytes:
Polymerase Chain Reaction (PCR) and other nucleic acid amplification techniques (NAT) for the simultaneous qualitative detection of cytomegalovirus, enteroviruses, Epstein-Barr virus, herpes simplex virus type 1, herpes simplex virus type 2, and varicella-zoster virus.

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase Chain Reaction (PCR) and other nucleic acid amplification techniques (NAT) for the simultaneous qualitative detection of adenoviruses, human herpesvirus 6, and parechovirus.

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Parainfluenza Viruses 388

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Dr. rer. nat. Kerstin Knies

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for parainfluenza virus RNA
- Typing of parainfluenza virus

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Parechovirus 407

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
Cooperation with: Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Parechovirus (RNA)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Genome Detection - Parvovirus B19 367

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for parvovirus B19 DNA

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Rabies Virus (Tollwutvirus) 390

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised samples (inactivated, vaccine)
Additional Information:
INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rabies virus RNA

Shipping Information:
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Sep.	
Registration Deadline:					27-06-25	
Sample Shipment:					27-08-24	
Closing Date:					27-09-10	

Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests 431

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
- The pathogens listed will be included in this EQAS/PT at least once a year. We therefore recommend participating in both EQAS/PT rounds.
- **For this EQAS/PT (No. 431), only results from multiplex tests will be accepted.**
- This multiplex EQA scheme is not suitable for (i) ´singleplex´ PCRs, (ii) tests for antigen detection, (iii) testing of sensitivity and (iv) typing. For this purpose, we refer to the INSTAND EQA schemes for the corresponding viruses.
- The program is rounded out with virus variants currently in circulation
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of respiratory adeno, entero, influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated), respectively.
- Some of the samples can contain chemically inactivated avian influenza A viruses.

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of respiratory boca, corona, human metapneumo, human rhino, parecho, parainfluenza.

Shipping Information:
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Respiratory Virus Panel 2 432

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
- This EQAS/PT program is not suitable for (I) antigen detection tests, (II) sensitivity testing, and (III) typing. For these purposes, please refer to the corresponding INSTAND proficiency testing programs for the respective viruses.
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- The program is rounded out with virus variants currently in circulation.

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated).
- Some of the samples can contain chemically inactivated avian influenza A viruses.

Not subject to Rili-BÄK: not applicable

Shipping Information:
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Rotaviruses 401

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised suspension of feces
Additional Information:
Cooperation with: Nationales Konsiliarlabor für Rotaviren, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Dr. Axel Schubert

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rotavirus RNA
- Typing of rotavirus

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Genome Detection - Rubella Virus 389

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rubella virus RNA
- Typing of rubella virus

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				July		Dec.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-07-09		27-12-03

Virus Genome Detection - SARS-CoV-2 409

EQAS/PT Properties
Samples: 5 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material
Additional Information:
Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Information will be updated at the end of autumn.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - SARS-CoV-2 sequence analysis 417

EQAS/PT Properties
Samples: 3-5 samples of 1.5 ml
Sample Properties: Lyophilised cell culture material (inactivated)
Additional Information:
Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité – Universitätsmedizin Berlin; Medizinisches Infektiologiezentrum Berlin;
Abt. Methodenentwicklung und Forschungsinfrastruktur, Robert Koch-Institut, Berlin

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Differentiation of SARS-CoV-2 variants with clinical relevance using whole genome sequencing
  Please note:
- Submitted sequences are evaluated for sequence quality both in the S gene and separately in the whole genome.

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Apr.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-04-09			27-09-24	

Virus Genome Detection - Torque Teno Virus (TTV) 408

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma
Additional Information:
Cooperation with: Institut für Virologie, Uniklinik Köln

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 24 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Torque teno virus (TTV) DNA

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
					Sep.	
Registration Deadline: Sample Shipment: Closing Date:					27-06-25 27-08-24 27-09-10	

Virus Genome Detection - Varicella Zoster Virus 366

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma or cell culture material

EQAS/PT Experts:
Prof. Dr. Holger F. Rabenau

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for VZV DNA

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19

Virus Genome Detection - West Nile Virus 391

EQAS/PT Properties
Samples: 6 samples of 1.5 ml
Sample Properties: Lyophilised plasma and cell culture material (inactivated)
Additional Information:
Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

EQAS/PT Experts:
Prof. Dr. med. Jonas Schmidt-Chanasit

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for West Nile virus RNA
- Typing of West Nile virus (Lineage determination)

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Information will be updated at the end of autumn.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Zika Virus 403

EQAS/PT Properties
Samples: 4 samples of 1.5 ml
Sample Properties: Lyophilised plasma or cell culture material (inactivated)
Additional Information:
Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

EQAS/PT Experts:
Prof. Dr. med. Jonas Schmidt-Chanasit

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Zika virus RNA
- Typing of Zika virus (Lineage determination)

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Immunology

Virus Immunology - Borna Viruses (Ab) 415

EQAS/PT Properties **Samples:** 10 samples of 100 µl **Sample Properties:** Liquid serum/plasma **Additional Information:** Cooperation with WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg	**EQAS/PT Experts:** Prof. Dr. med. Jonas Schmidt-Chanasit **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Anti-borna virus IgG
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
				June		
Registration Deadline: **Sample Shipment:** **Closing Date:**				27-04-09 27-06-08 27-06-25		

Virus Immunology - Chikungunya Virus (Ab) 402

EQAS/PT Properties **Samples:** 4 samples of 0.3 ml **Sample Properties:** Liquid serum (inactivated in case of chikungunya virus RNA positive samples) **Additional Information:** Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg	**EQAS/PT Experts:** Prof. Dr. med. Jonas Schmidt-Chanasit **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Anti-CHIKV IgG Anti-CHIKV IgG - avidity Anti-CHIKV IgM
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Sep.	
Registration Deadline: **Sample Shipment:** **Closing Date:**					27-06-25 27-08-24 27-09-10	

Virus Immunology - Cytomegalovirus (Ab) 351

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Anti-CMV IgG, Anti-CMV IgG - avidity, Anti-CMV IgM

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Immunology - Dengue Viruses (Ab and NS1 Antigen) 350

EQAS/PT Properties
Samples: 4 samples of 0.3 ml
Sample Properties: Liquid serum (inactivated in case of dengue virus RNA positive ples)
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

EQAS/PT Experts:
Prof. Dr. med. Jonas Schmidt-Chanasit

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Anti-dengue virus IgG, Anti-dengue virus IgM, dengue virus-NS1 Ag, clinical interpretation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

Virus Immunology - Epstein Barr Virus (Ab) 352

EQAS/PT Properties
Samples: 2 samples of 0.6 ml
Sample Properties: Liquid serum
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- The following parameters are not considered for the ´certificate´ (only stated in the ´certificate of participation´): anti-EA IgG, anti-EA IgA, anti-EA IgM, anti-EA, anti-VCA IgA, anti-EBV IgA and strip-immunoblot anti-EBV IgA

EQAS/PT Experts:
Prof. Dr. Holger F. Rabenau

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Antibodies against EBV with and without differentiation of antigen specificity (incl. avidity) and heterophilic antibodies clinical interpretation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19

Virus Immunology - Hantaviruses (Ab) 355

EQAS/PT Properties
Samples: 4 samples of 0.5 ml
Sample Properties: Liquid serum (inactivated in case of Hantavirus RNA positive sa
Additional Information:
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Cooperation with: Labor Berlin, Charite-Vivantes GmbH

EQAS/PT Experts:
Prof. Dr. Jörg Hofmann

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
- Antibodies against hantaviruses (IgG and IgM) and differentiation of serotype specific antibodies
- Status of hantavirus infection

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26			27-06-25 27-08-24 27-09-10	

Virus Immunology - Hepatitis A Virus (Ab) 343

EQAS/PT Properties
Samples: 4 samples of 0.5 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Dr. Axel Schubert

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Anti-HAV IgG / Anti-HAV total
Anti-HAV IgM

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, Anti-HBe) 344

EQAS/PT Properties
Samples: 5 samples of 1.5 mL
Sample Properties: Liquid serum
Additional Information:

- Please note: Note: The EQA schemes for hepatitis B virus immunology have been restructured to incorporate diagnostic scenarios. Instead of individual samples for each parameter, samples with simulated diagnostic scenarios will be sent out in the future. Since only a few laboratories perform testing for anti-HBc-IgM, this parameter has been moved to the separate Program 345. All other parameters of HBV serology are grouped together in this Program 344.
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
HBsAg
Confirmation test HBsAg
Anti-HBs
Anti-HBc
HBeAg
Anti-HBe

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Diagnostic interpretation

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM) 345

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Anti-HBc IgM

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) 346

EQAS/PT Properties
Samples: 4 samples of 0.5 ml
Sample Properties: Liquid serum/plasma
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Prof. Dr. med. Jörg Timm

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Screening test anti-HCV and combined detection anti-HCV and HCV antigen
HCV antigen
Complementary test (blot) anti-HCV

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Immunology - Hepatitis D Virus (Ab) 347

EQAS/PT Properties **Samples:** 2 samples of 0.5 ml **Sample Properties:** Liquid serum/plasma	**EQAS/PT Experts:** Prof. Dr. Holger F. Rabenau **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Anti-HDV IgG / Anti-HDV total Anti-HDV IgM
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	**Q1**		**Q2**	**Q3**		**Q4**
				June		**Nov.**
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - Hepatitis E Virus (Ab) 348

EQAS/PT Properties **Samples:** 2 samples of 0.4 ml **Sample Properties:** Liquid serum	**EQAS/PT Experts:** Dr. Axel Schubert **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Anti-HEV IgG Anti-HEV IgM
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	**Q1**		**Q2**	**Q3**		**Q4**
				June		**Nov.**
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - Herpes Simplex Viruses (Ab) 354

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Prof. Dr. Holger F. Rabenau

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Anti-HSV 1/2 IgG
Anti-HSV 1/2 IgG - avidity
Anti-HSV 1 IgG
Anti-HSV 1 IgG - avidity
Anti-HSV 2 IgG
Anti-HSV 2 IgG - avidity
Anti-HSV 1/2 IgM
Anti-HSV 1 IgM
Anti-HSV 2 IgM

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - HIV-1 p24 Antigen 337

EQAS/PT Properties
Samples: 2 samples of 0.75 ml
Sample Properties: Liquid serum
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
HIV-1 p24 Ag
HIV-1 p24 Ag Confirmation test

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Immunology - HIV-1/HIV-2 (Ab) 335

EQAS/PT Properties
Samples: 4 samples of 0.75 ml
Sample Properties: Liquid serum/plasma
Additional Information:
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

EQAS/PT Experts:
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Screening test anti-HIV-1 / anti-HIV-2 (3rd and 4th Generation)
Confirmation test (blot and other confirmatory test) anti-HIV-1 / anti-HIV-2
Confirmation test (blot and other confirmatory test) anti-HIV-1
Confirmation test (blot and other confirmatory test) anti-HIV-2

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Immunology - HTLV-1/HTLV-2 (Ab) 339

EQAS/PT Properties
Samples: 4 samples of 0.5 ml
Sample Properties: Liquid serum/plasma
Additional Information:
Cooperation with: Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Screening test anti-HTLV-1 / anti-HTLV-2
Confirmation test (Blot and other confirmation test) anti-HTLV-1 / anti-HTLV-2

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - Measles Virus (Ab) 357

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Anti-measles virus IgG
Anti-measles virus IgG - avidity
Anti-measles virus IgM

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - Mumps Virus (Ab) 356

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Anti-mumps virus IgG
Anti-mumps virus IgG - avidity
Anti-mumps virus IgM

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - Parvovirus B19 (Ab) 342

EQAS/PT Properties **Samples:** 4 samples of 0.5 ml **Sample Properties:** Liquid serum/plasma	**EQAS/PT Experts:** Prof. Dr. med. Martin Enders **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 12 months **Parameter / Analytes:** Anti-parvovirus B19 IgG Anti-parvovirus B19 IgG - avidity Anti-parvovirus B19 IgM
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - Rabies Virus (Tollwutvirus) (Ab) 336

EQAS/PT Properties **Samples:** 2 samples of 0.5 ml **Sample Properties:** Liquid serum/plasma (vaccinee)	**EQAS/PT Experts:** Dr. med. Martin Obermeier **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel
Requirement for EQAS/PT according to Rili-BÄK: not applicable	**Not subject to Rili-BÄK** **Validity Certificate:** 24 months **Parameter / Analytes:** Anti-rabies Virus
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Sep.	
Registration Deadline:					27-06-25	
Sample Shipment:					27-08-24	
Closing Date:					27-09-10	

Virus Immunology - Rubella Virus (Ab) 341

EQAS/PT Properties
Samples: 2 samples of 0.8 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Prof. Dr. med. Martin Enders

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Anti-rubella virus IgG
Anti-rubella virus IgG - avidity
Anti-rubella virus IgM

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - SARS-CoV-2 (Ab) 416

EQAS/PT Properties
Samples: 4 samples of 0.5 ml
Sample Properties: Liquid serum/plasma

EQAS/PT Experts:
Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Anti-SARS-CoV-2 total (without differentiation of IgG, IgA and IgM)
Anti-SARS-CoV-2 IgG
Anti-SARS-CoV-2 IgG avidity (not certified)
Anti-SARS-CoV-2 IgA (not certified)
Anti-SARS-CoV-2 IgM (not certified)
Anti-SARS-CoV-2 Surrogate neutralizing antibodies

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab) 358

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Dr. Axel Schubert

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable

Not subject to Rili-BÄK
Validity Certificate: 12 months
Parameter / Analytes:
Anti-TBE/FSME virus IgG
Anti-TBE/FSME virus IgG - avidity
Anti-TBE/FSME virus IgM

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - Varicella Zoster Virus (Ab) 353

EQAS/PT Properties
Samples: 2 samples of 0.5 ml
Sample Properties: Liquid serum

EQAS/PT Experts:
Prof. Dr. Holger F. Rabenau

Deputy EQAS/PT Experts:
Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual
Validity Certificate: 12 months
Parameter / Analytes:
Anti-VZV IgG Anti-VZV IgG - avidity Anti-VZV IgM

Not subject to Rili-BÄK: not applicable

Shipping Information:
Shipping not cooled

Safety Information:
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19

Virus Immunology - Zika Virus (Ab) 338

EQAS/PT Properties	EQAS/PT Experts:
Samples: 2 samples of 0.3 ml **Sample Properties:** Liquid serum (inactivated in case of Zika virus RNA positive samples) **Additional Information:** Cooperation with:WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg	Prof. Dr. med. Jonas Schmidt-Chanasit **Deputy EQAS/PT Experts:** Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: not applicable	Not subject to Rili-BÄK **Validity Certificate:** 24 months **Parameter / Analytes:** Anti-ZIKV IgG Anti-ZIKV IgG - avidity Anti-ZIKV IgM
Shipping Information: Shipping not cooled	**Safety Information:** Process as patient sample material

Dates	Q1		Q2	Q3		Q4
					Sep.	
Registration Deadline: **Sample Shipment:** **Closing Date:**					27-06-25 27-08-24 27-09-10	

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. med. Nicolas Ahsen, von

Zentrallaboratorien der Kliniken Bremen-Mitte, Bremen-Nord, Bremen-Ost und Links der Weser
Gesundheit Nord Klinikverbund Bremen gGmbH
Klinikum Links der Weser
Senator-Weßling-Straße 1, Bremen

T +49 421 879 4557
E nicolas.vonahsen@gesundheitnord.de

Frau MSc. Simone Ahting

Institut für Humangenetik
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Str. 55, Leipzig

T +49 341 97 20596
E simone.ahting@medizin.uni-leipzig.de

Herr Dr. Sönke Andres

Forschungszentrum Borstel
Nationales Referenzzentrum für Mykobakterien
Parkallee 38, Borstel

T +49 4537 188 6480
E sandres@fz-borstel.de

Herr PD Dr. rer. nat. Oliver Bader

Institut für Medizinische Mikrobiologie und Virologie
Universitätsmedizin Göttingen
Kreuzbergring 57, Göttingen

T +49 551 3965403
E obader@gwdg.de

Herr Dr. med. Harald Bartsch

Gemeinschaftspraxis für Pathologie Traunstein

Cuno-Niggl-Str. 3, Traunstein

T +49 211-1592 13 0
E harald.bartsch@instand-ringversuch.de

Herr Prof. Dr. med. Hannsjörg Baum

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 0
E hannsjoerg.baum@instand-ringversuch.de

Herr Dr. rer. nat. Martin Blüthner

MVZ Labor PD Dr. Volkmann und Kollegen SE & Co. eGbR

Gerwigstrasse 67, Karlsruhe

T +49 721 85000 225
E bluethner@laborvolkmann.de

Herr Dr. Gernot Brauers

Uniklinikum Düsseldorf

Moorenstr. 5, Düsseldorf

T +49 211-1592 13 0
E gernot.brauers@med.uni-duesseldorf.de

Frau Prof. Dr. Iris Bruchhaus

Bernhard-Nocht-Institiut für Tropenmedizin

Bernhard-Nocht-Straße 74, Hamburg

T +49 40 285380-472
E bruchhaus@bnitm.de

Herr Dr. med. vet. Heiner Buttlar, von

Institut für Mikrobiologie der Bundeswehr

Neuherbergstraße 11, München

T +49 992692 3894
E heinervonbuttlar@bundeswehr.org

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. rer. nat. Morten O. Christensen

Gerinnungszentrum Rhein-Ruhr
Ambulanz und Fachlaboratorium für
Gerinnungserkrankungen/Hämophilie
Königstraße 13, Duisburg

T +49 203 348 336 24
E morten.christensen@gzrr.de

Frau Dr. rer. biol. hum. Andrea Dick

LMU Klinikum
Abteilung für Transfusionsmedizin, Zelltherapeutika und
Hämostaseologie
Elisabeth-Winterhalter-Weg 15, München

T +49 89 44007 7403
E andrea.dick@med.uni-muenchen.de

Herr Prof. Dr. rer. nat. Dr. med. Jürgen Durner

Labor Becker MVZ GbR

Führichstr. 70, München

T +49 89 450 917 349
E j.durner@labor-becker.de

Herr Prof. Dr. med. Martin Enders

Labor Prof. G. Enders & Kollegen, MVZ
Medizinische Diagnostik
Rosenbergstr. 85, Stuttgart

T +49 711-6357 120
E martin.enders@instand-ringversuch.de

Frau Dr. ssa Rosanna Falbo

University Department of Laboratory Medicine
University Milano Bicocca
Piazza dell'Ateneo Nuovo, 1, Milano
Italien
T +39 362-385312
E rosanna.falbo@asst-brianza.it

Herr Dr. rer. nat. Manfred Falck

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211 178 355 20
E manfred.falck@instand-ringversuch.de

Herr Dr. med. Volker Fingerle

Nationales Referenzzentrum für Borrelien
Bayerisches Landesamt für Gesundheit und
Lebensmittelsicherheit (LGL)
Veterinärstraße 2, Oberschleißheim

T +49 9131 6808 5870
E volker.fingerle@lgl.bayern.de

Herr Prof. Dr. med. Willy A. Flegel

Chief, Laboratory Services Section
DTM/CC/NIH
, Bethesda MD 20892-1184
USA
T +1 301 5947 401
E willy.flegel@instand-ringversuch.de

Herr Dr. rer. nat. Ralf-Rüdiger Flörke

Am Lindenbruch 48, Essen

T +49 160 2131 052
E ralf.floerke@instand-ringversuch.de

Herr PD Dr. med. Dimitrios Frangoulidis

Institut für Mikrobiologie der Bundeswehr

Neuherbergstraße 11, München

T +49 89 992692 3869
E dimitriosfrangoulidis@bundeswehr.org

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. Roman Fried

MQ Zürich, Universitätsspital Zürich
Institut für Klinische Chemie
Rämistrasse 100, Zürich
Schweiz
T +41 44 255 3518
E roman.fried@usz.ch

Frau Dr. med. Claudia Frömmel

MDI Limbach Berlin GmbH

Aroser Allee 84, Berlin

T +49 30 443364 535
E claudia.froemmel@instand-ringversuch.de

Herr Prof. Dr. med. Winfried Gassmann

St. Marienkrankenhaus
Medizinische Klinik III
Kampenstr. 51, Siegen

T +49 271 231 1300
E w.gassmann@mariengesellschaft.de

Herr Dr. rer. nat. Walter Geißdörfer

Mikrobiologisches Institut - Klinische Mikrobiologie,
Immunologie und Hygiene
Universitätsklinikum Erlangen
Wasserturmstraße 3-5, Erlangen

T +49 9131 85 22668
E walter.geissdoerfer@uk-erlangen.de

Herr Prof. Dr. Dr. med. André Gessner

Institut für Klinische Mikrobiologie und Hygiene
Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11, Regensburg

T +49 941 944 6400
E andre.gessner@ukr.de

Frau Ulyana Gräf

Krankenhaus Nordwest
Zentralinstitut für Labormedizin, Mikrobiologie &
Krankenhaushygiene
Steinbacher Hohl 2-26, Frankfurt

T +49 69-7601 3646
E graef.ulyana@khnw.de

Herr PD Dr. rer. nat. Gregor Grass

Institut für Mikrobiologie der Bundeswehr

Neuherbergstraße 11, München

T +49 992692 2806
E gregorgrass@bundeswehr.org

Herr Prof. Dr. med. Kai Gutensohn

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 160 1549548
E kai.gutensohn@instand-ringversuch.de

Herr Prof. Dr. med. Gerhard Haase

Labordiagnostisches Zentrum - Bereich Mikrobiologie
Universitätsklinikum RWTH Aachen
Pauwelsstraße 30, Aachen

T +49 241 8089 515/510
E ghaase@ukaachen.de

Herr Prof. Dr. med. Dr. rer. nat. Ekkehard Haen

Klinische Pharmakologie am Lehrstuhl für Psychiatrie
und Psychotherapie
und am Lehrstuhl für Pharmakologie und Toxikologie der
Universität und am Institut AGATE gGmbH
Nelkenweg 10, Pentling

T +49 178 204 3288
E ekkehard.haen@klinik.uni-regensburg.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. med. Dr. phil. Torsten Haferlach

MLL Münchner Leukämielabor GmbH

Max-Lebsche-Platz 31, München

T +49 89 99017 100
E torsten.haferlach@mll.com

Herr Dr. Gerulf Hänel

Klinikum der Universität München
Labor für Leukämiediagnostik
Marchioninistr. 15, München

T +49 89 - 2180 76835
E haenel@genzentrum.lmu.de

Herr Prof. Dr. Dr. med. Fabian Hauck

LMU Klinikum
Dr. von Haunersches Kinderspital
Lindwurmstr. 4, München

T +49 89 4400-53931
E fabian.hauck@med.uni-muenchen.de

Herr PD Dr. med. Albert Heim

Institut für Virologie
Medizinische Hochschule Hannover
, Hannover

T +49 511-5324311
E adenovirus@gmx.de

Frau PD Dr. rer.nat. Julia Hentschel

Institut für Humangenetik
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Str. 55, Leipzig

T +49 341 97 11349
E julia.hentschel@instand-ringversuch.de

Herr PD Dr. Andreas Hiergeist

Institut für Klinische Mikrobiologie und Hygiene
Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11, Regensburg

T +49 941 944 16465
E andreas.hiergeist@ukr.de

Frau Dr. med. Britta Höchsmann

Institut für Klinische Transfusionsmedizin und
Immungenetik Ulm (IKT)

Helmholtzstraße 10, Ulm

T +49 731 150 560
E b.hoechsmann@blutspende.de

Herr Prof. Dr. Jörg Hofmann

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 30 8105 4300
E joerg.hofmann@instand-ringversuch.de

Herr Prof. Dr. med. Stefan Holdenrieder

Institut für Laboratoriumsmedizin
TUM Universitätsklinikum - Deutsches Herzzentrum
München
Lazarettstraße 36, München

T +49 89 1218 1011
E stefan.holdenrieder@instand-ringversuch.de

Herr Prof. Dr. med. Achim Hörauf

Institut für Medizinische Mikrobiologie, Immunologie und
Parasitologie
Universitätsklinikum Bonn
Sigmund-Freud-Straße 25, Bonn

T +49 228 287 15675
E immip.office@ukbonn.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. Marc Hübner

Universitätsklinikum Bonn
Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie (IMMIP)
Venusberg-Campus 1, Bonn

T +49-228-287-19177
E huebner@uni-bonn.de

Herr Prof. Dr. med. Andreas Humpe

Klinikum der Universität München, Campus Großhadern
Abteilung für Transfusionsmedizin, Zelltherapeutika und Hämostaseologie
Marchioninistraße 15, München

T +49 89 4400 7 3701
E andreas.humpe@med.uni-muenchen.de

Herr Prof. Dr. med. Klaus-Peter Hunfeld

Zentralinstitut für Labormedizin, Mikrobiologie & Krankenhaushygiene
Krankenhaus Nordwest
Steinbacher Hohl 2-26, Frankfurt am Main

T +49 69 7601 4349
E hunfeld.klaus-peter@khnw.de

Frau Dr. rer. nat. Eva-Maria Jacobsen

Diagnostische Laboratorien der Universitätsklinik für Kinder- und Jugendmedizin Ulm

Eythstr. 24, Ulm

T +49 731 500 57202
E eva-maria.jacobsen@uniklinik-ulm.de

Frau Dr. Patricia KaiserP

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 210
E kaiser@instand-ev.de

Herr Dr. rer. nat. Rolf KaiserR

Institut für Virologie
Universität und Universitätsklinikum zu Köln
Fürst-Pückler-Straße 56, Köln

T +49 221 478-85808
E rolf.kaiser@uk-koeln.de

Herr Dr. rer. nat. Martin Kammel

Institut für Qualitätssicherung in der Virusdiagnostik - IQVD

Potsdamer Chaussee 80, Berlin

T +49 30 8105 4300
E m.kammel@iqvd.de

Herr Dr. med. Günther Kappert

Gerinnungszentrum Rhein-Ruhr

Königstraße 13, Duisburg

T +49 203 348 336 0
E guenther.kappert@gzrr.de

Herr Prof. Dr. med. Wolfgang Kern

MLL Münchner Leukämielabor GmbH

Max-Lebsche-Platz 31, München

T +49 89 99017 200
E wolfgang.kern@mll.com

Frau Irina Keßel

MVZ Düsseldorf-Centrum GbR

Immermannstraße 65A, Düsseldorf

T +49 162 211 4792
E irina.kessel@instand-ringversuch.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. Michael Kirschfink

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 0
E kirschfink@uni-hd.de

Frau Dr. rer. nat. Kerstin Knies

Universität Würzburg - Institut für Virologie und Immunbiologie
c/o INSTAND e.V.
Ubierstr. 20, Düsseldorf

T +49 211-1592 13 0
E kerstin.knies@uni-wuerzburg.de

Herr Dr. Uwe Kölsch

IMD Institut für Medizinische Diagnostik Berlin-Potsdam GbR

Nicolaistraße 22, Berlin-Steglitz

T +49 30 77001322
E u.koelsch@imd-berlin.de

Herr Dipl.-Ing. (FH) Udo Kramer

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 220
E kramer@instand-ev.de

Herr Prof. Dr. med. Karl-Anton Kreuzer

Universitätsklinikum Köln
Innere Medizin I
Kerpener Straße 62, Köln

T +49 221 478 97626
E karl-anton.kreuzer@uni-koeln.de

Herr Dr. med. Hartmut Kroll

Institut für Transfusionsmedizin Dessau
DRK-Blutspendedienst NSTOB
Altener Damm 50, Dessau

T +49 340 54141 110
E hartmut.kroll@bsd-nstob.de

Herr Dr.-Ing. Nils Lachmann

Charité-Universitätsmedizin Berlin, ZTB-Zentrum für Transfusionsmedizin
und Zelltherapie Berlin gGmbH, Gewebetypisierung am Campus Virchow-Klinikum
Augustenburger Platz 1, Berlin

T +49 30 450 665 098
E nils.lachmann@instand-ringversuch.de

Herr Dr. med. Marc Lindenberg

Medizinische Hochschule Hannover
Institut für Medizinische Mikrobiologie und Krankenhaushygiene
Carl-Neuberg-Straße 1, Hannover

T +49 511 532 19521
E lindenberg.marc@mh-hannover.de

Herr Dr. med. Benedikt Lohr

St. Vincenz-Krankenhaus Limburg

Auf dem Schafsberg, Limburg

T +49 6431-292 7620
E benedikt.lohr@instand-ringversuch.de

Frau Dr. rer. nat. Eva Lorsy

Universitätsklinikum Köln

Kerpener Straße 62, Köln

T +49 221 478 98828
E eva.lorsy@instand-ringversuch.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. med. Peter B. Luppa

Institut für Laboratoriumsmedizin
TUM Universitätsklinikum Rechts der Isar
Ismaninger Straße 22, München

T +49 211-1592 13 0
E p.luppa@tum.de

Herr Dr. med. Thomas Lutz

MVZ Düsseldorf-Centrum GbR

Immermannstraße 65A, Düsseldorf

T +49 211 27101 1326
E lutz@zotzklimas.de

Frau Dr. Marie Mayrhofer

MVZ Labor PD Dr. Volkmann und Kollegen SE & Co. eGbR

Gerwigstrasse 67, Karlsruhe

T +49 721 85000 226
E m.mayrhofer@laborvolkmann.de

Frau Ilka McCormick Smith

Robert Koch-Institut
FG 16 Erreger von Pilz- und Parasiteninfektionen und Mykobakteriosen
Seestraße 10, Berlin

T +49 30 18754 2184
E mccormick-smithl@rki.de

Frau Dr. med. Adriana Méndez

Kantonsspital Baden AG

, Baden
Schweiz
T +41 56 486 26 41
E adriana.mendez@ksb.ch

Herr Prof. Dr. med. Matthias Nauck

Institut für Klinische Chemie und Laboratoriumsmedizin
Universitätsmedizin Greifswald
Körperschaft des öffentlichen Rechts
Ferdinand-Sauerbruch-Straße, Greifswald

T +49 3834 86 5500
E matthias.nauck@med.uni-greifswald.de

Herr Dr. med. Thomas Nebe

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 621 4373 2991
E instand@instand-ev.de

Herr Prof. Dr. med. Pietro Nenoff

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof. Dr. P. Nenoff, T. Löwe, E. von Rein
Mölbiser Hauptstraße 8, Rötha/OT Mölbis

T +49 34347 6191-0
E p.nenoff@labopart.de

Herr Dr. rer. nat. Stefan Neubeck

Medizinische Universität Lausitz □ Carl Thiem
Institut für Laboratoriumsmedizin
Thiemstraße 111, Cottbus

T +49 355 46 3304
E s.neubeck@mul-ct.de

Herr Dr. med. Christoph Niederau

MVZ Labor Dortmund Leopoldstraße GmbH

Leopoldstraße 10, Dortmund

T +49 231 860 27 0
E christoph.niederau@labor-dortmund.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. med. Martin Obermeier

MVZ medizinisches Infektiologiezentrum Berlin AG

Oudenarder Strasse 16, Berlin

T +49 30-34409104-66
E obermeier@mvz-mib.de

Frau Dr. Michaela Patz

Universitätsklinikum Köln

Kerpener Straße 62, Köln

T +49 221 478 32569
E michaela.patz@uk-koeln.de

Frau Prof. Dr. med. Dipl.-Biol. Astrid Petersmann

Universitätsmedizin Oldenburg, Klinikum Oldenburg AöR
Universitätsinstitut für Klinische Chemie und Laboratoriumsmedizin
Rahel-Straus-Str. 10, Oldenburg

T +49 441-403-2601
E astrid.petersmann@instand-ringversuch.de

Herr Prof. Dr. Zoltan Prohaszka

Semmelweis University
Department of Internal Medicine and Hematology
Szentkirályi st. 46, Budapest
Ungarn
T +361 3251379
E prohaszka.zoltan@semmelweis.hu

Herr Prof. Dr. Holger F. Rabenau

Institut für Medizinische Virologie
Universitätsklinikum Frankfurt
Paul-Ehrlich-Str. 40, Frankfurt

T +49 211-1592 13 0
E holger.rabenau@instand-ringversuch.de

Herr Dr. med. Roland Reibke

Klinik Bad Trissl GmbH
Abteilung für Innere Medizin I und Palliativmedizin
Bad-Trissl-Straße 73, Bad Trissl

T +49 80 33 20-285
E roland.reibke@klinik-bad-trissl.de

Herr Prof. Dr. rer. nat. Udo Reischl

Institut für Klinische Mikrobiologie und Hygiene
Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11, Regensburg

T +49 941 944 6450
E udo.reischl@instand-ringversuch.de

Herr Prof. Dr. med. Karl H. Reuner

Medizinische Universität Lausitz □ Carl Thiem
Institut für Laboratoriumsmedizin
Thiemstraße 111, Cottbus

T +49 355 46-2480
E k.reuner@mul-ct.de

Herr PD Dr. med. Volker Rickerts

Robert Koch-Institut
FG 16 Erreger von Pilz- und Parasiteninfektionen und Mykobakteriosen
Seestraße 10, Berlin

T +49 30 18754 2208
E rickertsv@rki.de

Herr Florian Ridders

Klinische Pharmakologie am Lehrstuhl für Pharmakologie und Toxikologie der Universität

Universitätsstr. 31, Regensburg

T +49 941 943 4766
E florian.ridders@klinik.uni-regensburg.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. med Martin Roskos

MVZ SYNLAB Leverkusen GmbH

Paracelsus Straße 13, Leverkusen

T +49 214 374 - 24892
E martin.roskos@synlab.com

Herr Prof. Dr. med. Ulrich Sachs

Justus-Liebig-Universität Gießen
Institut für Klinische Immunologie und Transfusionsmedizin
Langhansstraße 7, Gießen

T +49 641 985 41514
E ulrich.sachs@instand-ringversuch.de

Herr Prof. Dr. med. Ulrich Sack

Universitätsklinikum Leipzig AöR
Institut für Klinische Immunologie
Johannisallee 30, Leipzig

T +49 341 972 5500
E ulrich.sack@instand-ringversuch.de

Herr Dr. med. Richard Schabath

Praxis für Hämatologie und Onkologie Berlin Mitte

Friedrichstraße 113A, Berlin

T
E richard@schabath.de

Herr Prof. Dr. rer. nat. Ingo Schellenberg

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 120
E schellenberg@instand-ev.de

Herr Prof. Dr. med. Dirk Schlüter

Medizinische Hochschule Hannover
Institut für Medizinische Mikrobiologie und Krankenhaushygiene
Carl-Neuberg-Straße 1, Hannover

T +49 511 532 0
E dirk.schlueter@instand-ringversuch.de

Herr Prof. Dr. med. Jonas Schmidt-Chanasit

Bernhard-Nocht-Institut für Tropenmedizin
Nationales Referenzzentrum für tropische Infektionserreger Kooperationszentrum der WHO für Arboviren
Bernhard-Nocht-Strasse 74, Hamburg

T +49 40 285380 271
E schmidt-chanasit@bnitm.de

Frau Dr. rer. nat. Heike Schneider

Institut für Klinische Chemie und Pathobiochemie
TUM-Klinikum Rechts der Isar AöR
Ismaninger Straße 22, München

T +49 89 4140 5252
E heike.schneider@instand-ringversuch.de

Herr Prof. Dr. rer. nat. Holger C. Scholz

Robert Koch-Institut
Abteilung ZBS 2
Nordufer 20, Berlin

T +49 211-1592 13 0
E scholzh@rki.de

Frau Dr. rer. nat. Susanna Schubert

Institut für Humangenetik
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Str. 55, Leipzig

T
E susanna.schubert@instand-ringversuch.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. Axel Schubert

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-15 92 13 720
E schubert@instand-ev.de

Herr Dr. Torsten J. Schulze

Institut Springe
Eldagsener Straße 38, Springe

T +49 5041 772 □ 533
E torsten.schulze@bsd-nstob.de

Frau Dr. Steffi Silling

Nationales Referenzzentrum für Papillom- und Polyomaviren
Institut für Virologie Uniklinik Köln
Fürst-Pückler-Straße 56, Köln

T +49 221-47885811
E steffi.silling@instand-ringversuch.de

Herr Prof. Dr. med. Michael Spannagl

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 125
E m.spannagl@instand-ev.de

Herr Prof. Dr. med. Werner Steimer

Institut für Laboratoriumsmedizin
TUM Klinikum Rechts der Isar
Ismaningerstraße 22, München

T +49 89 30659957
E werner.steimer@instand-ringversuch.de

Frau Prof. Dr. Marion Subklewe

Ludwig-Maximilians-Universität München
Gene Center Laboratory for Translational Cancer Immunology
Feodor-Lynen-Straße 25, München

T +49 89 - 4400 73133
E marion.subklewe@med.uni-muenchen.de

Herr Prof. Dr. med. Egbert Tannich

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 0
E egbert.tannich@hamburg.de

Herr Prof. Dr. med. Jörg Timm

Universitätsklinikum Düsseldorf
Heinrich-Heine-Universität
Moorenstr. 5, Düsseldorf

T +49 211-81-12225
E joerg.timm@med.uni-duesseldorf.de

Frau M.Sc. Luisa Toll

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 380
E toll@instand-ev.de

Herr Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Max-Planck-Institut für Psychiatrie

Kraepelinstraße 2-10, München

T +49 89 30622 8035
E manfred.uhr@instand-ringversuch.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Frau Dr. rer. med. Silke Uhrlaß

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof. Dr. P. Nenoff, T. Löwe, E. von Rein
Mölbiser Hauptstraße 8, Rötha/OT Mölbis

T +49 34347 6191-259
E s.uhrlass@labopart.de

Herr PD Dr. med. Franz F. Wagner

DRK-Blutspendedienst NSTOB

Eldagsener Straße 38, Springe

T +49 5041 772 172
E fwagner@bsd-nstob.de

Herr Prof. Dr. med. Michael S. Weig

Institut für Medizinische Mikrobiologie
Universitätsmedizin Göttingen
Kreuzbergring 57, Göttingen

T +49 551 39 67099
E mweig@gwdg.de

Herr Dr. med. Christof Weinstock

DRK-Blutspendedienst Baden-Württemberg
Hessen gemeinnützige GmbH
Helmholtzstraße 10, Ulm

T +49 731 150 600
E c.weinstock@blutspende.de

Frau Dr. Nathalie Weiss

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 211-1592 13 430
E weiss@instand-ev.de

Herr Prof. Dr. med. Folker Wenzel

Fakultät Medical and Life Sciences
Campus Villingen-Schwenningen
Jakob-Kienzle-Str. 17, Villingen-Schwenningen

T +49 7720 307 4358
E wenzel@instand-ev.de

Frau PD Dr. rer. nat. et med. habil Cornelia Wiegand

Klinik für Hautkrankheiten Universitätsklinikum Jena
Dermatologisches Forschungslabor
Am Klinikum 1, Jena

T +49 3641 9328878
E c.wiegand@med.uni-jena.de

Herr Dr. med. Georg Wittmann

Labor Becker MVZ eGbR

Führichstr. 70, München

T +49 89 450917-395
E g.wittmann@labor-becker.de

Frau Sükran Zaralioglu

Charité-Universitätsmedizin Berlin, ZTB-Zentrum für Transfusionsmedizin
und Zelltherapie Berlin gGmbH, Gewebetypisierung am Campus Virchow-Klinikum
Augustenburger Platz 1, Berlin

T +49 30 450 665 098
E suekran.zaralioglu@charite.de

Frau Prof. Dr. med. Inga Zerr

Nationales Referenzzentrum für TSE
Klinik für Neurologie Universitätsmedizin Göttingen
Robert-Koch-Straße 40, Göttingen

T +49 551 39 61805
E ingazerr@med.uni-goettingen.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. med. Stefan Ziesing

Medizinische Hochschule Hannover
Institut für Medizinische Mikrobiologie und Krankenhaushygiene
Carl-Neuberg-Straße 1, Hannover

T +49 511 532 4344
E ziesing.stefan@mh-hannover.de

Herr Dr. rer. nat. Thomas Zimmermann

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof. Dr. P. Nenoff, T. Löwe, E. von Rein
Wurzener Straße 5, Dresden

T +49 351 210799 211
E th.zimmermann@labopart.de

INDEX

SYMBOL

(d-)Methamphetamine (urine) (176) 151

1

1,25 dihydroxy vitamin D (290) 159
1,25-OH Cholecalciferol (serum) (290) 159
1-39 ACTH (298) 105
1-84 PTH (301) 106
10-OH-Carbamazepine (192, 860) 128, 136
17-beta-Estradiol (302) 109
17-Hydroxyprogesterone (dried blood spots) (785) 125
17-Hydroxyprogesterone (serum / plasma) (309) 111

2

21-hydroxylase deficiency (DNA) (773) 33
25-Hydroxy-Cholecalciferol (290) 159
25-Hydroxy-Vitamin-D (290) 159
25-OH CCF (Vitamin D) (290) 159

3

3-Methoxytyramine (175) 155

4

4-Hydroxyproline (710) 113

5

5-HIAA (175) 155
5-Hydroxyindolea acid (175) 155

9

9-OH-Risperidone (862) 137

A

A - Subtyping (Machine-based, whole blood) (237, 83, 83
A - Subtyping (serum / erythrocytes suspension) (231, 232) 81, 81
A B 0 - system (DNA) (235) 26
A B 0 characteristics, Rhesus type (Machine-based, whole blood) (237, 238) 83, 83
A B 0 characteristics, Rhesus type (serum / erythrocytes suspension) (231, 232) 81, 81
a1-Antitrypsine (241) 143
a1-AT S-Locus (743) 28
a1-AT Z-Locus (743) 28
a1-Globulins (141) 120
a1-Globulins (electrophoresis, Serum) (102) 115
a1-Glycoprotein (241) 143
A1298C (DNA) (747) 42
A1298C (whole blood, Dna) (732) 42
A149P (793) 27
A174D (793) 27
a1PI (743) 28
a2-Globulins (141) 120
a2-Globulins (electrophoresis, Serum) (102) 115
a2-Makroglobulin (241) 143
A20 (plasma) (509) 103
AAT (743) 28
ACE (630) 113
ACE INS/DEL (DNA) (763) 28
acetaminophen (194) 135
Acid phosphatase (100) 115
Acid-fast bacilli (Slide) (421) 188
ACT (286) 102
activated clotting time (286) 102
Activated partial thromboplastin time (221, 230, 280, 94, 95, 102,
Acute myeloid leukemia (798) 57
Adenoviruses (cell culture lysate) (371, 431, 433) 199, 221, 224
Adenoviruses (suspensions of feces) (430) 206
ADHS-Treatment (879) 135
aDNase (321) 181
Adrenal Gland (298) 105
Aeromonas spp (548) 168
AFP (Pregnancy) (306) 107
AFP (tumor marker) (292) 149
Alanine (710) 113
ALAT (100, 810) 115, 145
Albumin (CSF) (460) 124
Albumin (electrophoresis, Serum) (102) 115
Albumin (POCT: Abaxis Piccolo) (810) 145
Albumin (serum) (100, 141) 115, 120
Albumin (urine) (171, 182) 156, 158
Albumin quotient (CSF / serum) (460) 124
Alcohol (750, 751) 119, 152
ALDOB (793) 27
Aldolase (serum) (100) 115
Aldolase B (A149P, A174D, N334K) (DNA) (793) 27
Aldolase B (DNA) (793) 27
Aldosterone (serum) (304) 105
Aldosterone (urine) (179) 155
Alkaline Phosphatase (100, 810) 115, 145
Allergy Diagnostic (basophils, EDTA-whole blood) (653) 70
Allergy Diagnostic (IgE, serum) (720) 62
allo-Isoleucine (710) 113
alpha-1-Microglobulin (urine) (182) 158
alpha-2-macroglobulin (urine) (182) 158
alpha-Aminoadipic acid (710) 113
alpha-Amylase (POCT: Abaxis Piccolo) (810) 145
alpha-Amylase (serum) (100) 115
alpha-Amylase (urine) (173) 157
Alpha-Fetoprotein (306) 107

INDEX

alpha-Globin (DNA) (794) 27
alpha1-Antitrypsin (743) 28
alpha1-proteinase-Inhibitor (743) 28
Alprazolam (876) 133
ALT (100, 810) 115, 145
Alternative pathway (246) 80
Aluminium (plasma) (206) 147
Aluminium (urine) (205) 153
AMH (297) 106
Amicacin (197) 138
Amino Acid Analysis (710) 113
Aminolaevulinic acid (urine) (180) 154
Amiodarone (190) 126
Amisulpride (861, 873) 131, 136
Amitriptyline (serum) (199, 203, 863) 137, 140, 141
Amitriptyline (urine) (204) 153
AML-Panel (NGS) (798) 57
Ammonia (118) 114
Amoebiasis (455) 194
Amphetamine (urine) (174) 150
Ampicillin (890) 127
AMR (544) 162
Amyloid ß Peptid 40 (Aß40) (466) 121
Amyloid ß Peptid 42 (Aß42) (466) 121
Amyloid ß Peptid Ratio (Aß 42/40) (466) 121
ANA (251) 64
ANCR (DNA) (786) 45
Androstendion (309) 111
Angelmann syndrome (AS) (DNA) (786) 45
Angiotensin Converting Enzym Apolipoprotein (DNA) (763) 28
Angiotensin-Converting-Enzyme (630) 113
Anthrax (542) 164
Anti -P450 C17 -Hydroxylase (263) 63
Anti - Acetylcholin Receptors (269) 66
Anti - Actin (253) 66
Anti - Adrenal Cortex (263) 63
Anti - Amphiphysin 1 (265) 67
Anti - Asialoganglioside (AGA1) (267) 68
Anti - Borna virus (415) 230
Anti - BPAg-1 (259) 63
Anti - BPAg-2 (259) 63
Anti - C1 inhibitor (250) 77
Anti - Cardiolipin (IgG) (275) 62
Anti - Cardiolipin (IgM) (275) 62
Anti - CCP (cyclic citrulline peptide) (273) 69
Anti - CHIKV (cell culture lysate) (402) 230
Anti - CMV (serum) (351) 231
Anti - deamidated Gliadin (271) 65
Anti - dengue virus (serum) (350) 231
Anti - Desmoglein-1 (259) 63
Anti - Desmoglein-3 (259) 63
Anti - Desmoplakin I/II (259) 63
Anti - Desmosomes (serum) (259) 63
Anti - DFS70/LEDGF (251) 64
Anti - Disialoganglioside (GD1a) (267) 68
Anti - Disialoganglioside (GD1b) (267) 68
Anti - ds-DNA (251) 64
Anti - Endomysium (271) 65
Anti - Glia Cell Nuclear Antibody (AGNA) (265) 67
Anti - Gliadin (271) 65
Anti - glomerular basement membrane (GBM) (serum) (257) 69
Anti - Glutamic Acid Decarboxylase (GAD) (261) 65
Anti - H+/K+-ATPase (253) 66
Anti - HAV (serum) (343) 233
Anti - HBc (serum) (344) 233
Anti - HBc-IgM (serum) (345) 234
Anti - HBe (serum) (345) 234
Anti - HBs (serum) (344) 233
Anti - HCV (serum) (346) 234
Anti - HDV (serum) (347) 235
Anti - Hemidesmosomes (259) 63
Anti - HEV (serum) (348) 235
Anti - HIV-1 (serum) (335) 237
Anti - HIV-2 (serum) (335) 237
Anti - HSV (serum) (354) 236
Anti - HTLV-1 (serum) (339) 237
Anti - HTLV-2 (serum) (339) 237
Anti - HuD (serum) (265) 67
Anti - Insulin (IAA) (261) 65
Anti - Islet Cells (ICA) (261) 65
Anti - Jo 1 (Histidyl-tRNA-Synthetase) (255) 64
Anti - MCV (mutated citrullinated Vimentin) (273) 69
Anti - measles virus (serum) (357) 238
Anti - Microsomes (LKM 1) (253) 66
Anti - Mikrosomen (295) 110
Anti - Mitochondria (253) 66
Anti - Monosialoganglioside (GM1) (267) 68
Anti - Monosialoganglioside (GM2) (267) 68
Anti - Monosialoganglioside (GM3) (267) 68
Anti - MPO (257) 69
Anti - Mullerian hormone (297) 106
Anti - mumps virus (serum) (358) 241
Anti - Musclespecific Receptor Tyrosinkinase (MuSK) (269) 66
Anti - Myelin-associated Glycoprotein (MAG) (267) 68
Anti - Neuronal Nuclei (265) 67
Anti - P450 C21 -Hydroxylase (263) 63
Anti - P450 ssc -Hydroxylase (263) 63
Anti - Parietal Cells (253) 66
Anti - parvovirus B19 (serum) (342) 239
Anti - PM / Scl (255) 64
Anti - PR3 (257) 69
Anti - Purkinje Cells (265) 67
Anti - Quadrosialoganglioside (GQ1b) (267) 68
Anti - rabies Virus (serum) (336) 239
Anti - Ri / Nova 1 (265) 67
Anti - rubella virus (serum) (341) 240
Anti - Skeletal Muscle (269) 66
Anti - Sm (255) 64
Anti - Sm (D) (255) 64
Anti - Smooth Muscle (253) 66
Anti - SOX1 (265) 67
Anti - SSA / Ro (255) 64
Anti - SSA / Ro (52kD - Proteins) (255) 64

INDEX

Anti - SSA / Ro (60kD - Proteins) (255)	64
Anti - SSB / La (255)	64
Anti - streptodornase (serum) (321)	181
Anti - streptolysin O (serum) (321)	181
Anti - Ta (Ma 2) (265)	67
Anti - TBE/FSME (serum) (358)	241
Anti - Titin (269)	66
Anti - Topoisomerase-1 (Scl 70) (255)	64
Anti - TPO (295)	110
Anti - Transglutaminase IgA (271)	65
Anti - Trisialoganglioside (GT1b) (267)	68
Anti - Tyreoglobulin (295)	110
Anti - Tyrosine Phosphatase (IA2) (261)	65
Anti - U1 -snRNP (Anti - U1 -70K) (255)	64
Anti - VZV (serum) (353)	241
Anti - Yo (CDR62) (265)	67
Anti - ZIKV (serum) (338)	242
Anti - Zinc Transporter 8 (ZnT8A) (261)	65
Anti - ß2-Glycoprotein (IgG) (275)	62
Anti - ß2-Glycoprotein (IgM) (275)	62
anti nuclear antibodies (251)	64
Anti- DNA double stranded (251)	64
Anti-DGP (271)	65
anti-Microsome (295)	110
anti-Thyroglobulin (295)	110
anti-TPO (295)	110
Antiarrhytmics (190)	126
Antibacterials (193, 890)	126, 127
antibiotic resistance (544)	162
Antibiotics (193)	126
Antibodies (452)	195
Antibodies against Bartonella henselae (serum) (326)	170
Antibodies against Bordetella pertussis (serum) (317)	171
Antibodies against Borrelia (serum) (332)	171
Antibodies against Brucella (serum) (327)	172
Antibodies against campylobacter (serum) (319)	172
Antibodies against Chlamydia pneumoniae (serum) (314)	173
Antibodies against Chlamydia trachomatis (serum) (312)	173
Antibodies against Coxiella burnetii (serum) (325)	175
Antibodies against diphtheria toxoid (serum) (318)	175
Antibodies against EBV (serum) (352)	232
Antibodies against Echinococcus (455)	194
Antibodies against Entamoeba histolytica (455)	194
Antibodies against Francisella (serum) (328)	176
Antibodies against hantaviruses (serum) (355)	232
Antibodies against Helicobacter pylori (serum) (334)	176
Antibodies against Leptospira (serum) (329)	177
Antibodies against mycoplasma pneumoniae (serum) (324)	177
Antibodies against Plasmodium (454)	194
Antibodies against Rickettsia (serum) (330)	179
Antibodies against salmonella (serum) (331)	180
Antibodies against Schistosoma (454)	194
Antibodies against tetanus toxoid (serum) (310)	181
Antibodies against Toxoplasma gondii (452)	195
Antibodies against Treponema pallidum (serum) (311)	182
Antibodies against Yersinia (serum) (315)	183
Antibody ID (Machine-based, whole blood) (237, 238)	83, 83
Antibody ID (serum / erythrocytes suspension) (232)	81
Antibody Identification (232, 237, 238)	81, 83, 83
Antibody quantitation (Machine-based, whole blood) (238)	83
Antibody quantitation (serum / erythrocytes suspension) (232)	81
Antibody Screening (Machine-based, whole blood) (237, 238)	83, 83
Antibody Screening (serum / erythrocytes suspension) (231, 232)	81, 81
Antibody titer (232)	81
anticoagulant (230, 282, 501, 502, 503, 504, 505)	94, 94, 96, 97,
Anticonvulsants (191, 192, 871, 872)	127, 128, 128,
Antifungals (198, 602)	129, 130
Antimon (lyophilized whole blood) (208)	146
Antimon (serum) (207)	147
Antiphospholipid Syndrome (275)	62
Antipsychotic Drugs (200, 200, 873, 873, 874, 874, 875, 875)	130, 130, 131, 131, 131, 131, 132, 132
Antithrombin (225, 285)	95, 95
Antithrombin (DNA) (792)	29
Antivirals (850)	132
AP (100)	115
AP (POCT: Abaxis Piccolo) (810)	145
APC resistance (288)	100
Apixaban (504)	94
Apo B (DNA) (771)	30
Apo E (Genotyp 2, 3, 4) (DNA) (744)	30
Apo-E (734)	29
ApoB (151, 771)	30, 119
ApoB (DNA) (771)	30
ApoE (151)	119
ApoE (genotype 2, 3, 4) (DNA) (744)	30
ApoE (genotype 2, 3, 4) (whole blood) (734)	29
Apolipoprotein A1 (151)	119
Apolipoprotein B (151)	119
Apolipoprotein E (744)	30
Apolipoprotein E (DNA) (744)	30
Apolipoprotein E (serum / plasma) (151)	119
Apolipoprotein E (whole blood) (734)	29
Apolipoprotein E (whole blood, Dna) (734)	29
APS (275)	62
aPTT (Argatroban) (230)	94
aPTT (Plasma) (221, 280, 285)	95, 102, 104
aPTT (whole blood) (286)	102
Argatroban (Argatroban) (230)	94
Arginine (710)	113
Argininosuccinic acid (710)	113
Aripiprazole (860)	136
Arsenic (lyophilized whole blood) (208)	146
Arsenic (plasma) (206)	147
Arsenic (urine) (205)	153
ASAT (100, 810)	115, 145
Ascorbic acid (urine) (171)	156

INDEX

Ascorbic acid (Vitamin C) (plasma) (296)	159
Asialotransferrin (750)	119
ASO (serum) (321)	181
Asparagine (710)	113
Aspartic acid (710)	113
AST (100, 810)	115, 145
Astroviruses (suspensions of feces) (430)	206
ASXL1 Nomenclature (798)	57
AT (plasma) (225)	95
AT3 (DNA) (792)	29
Atazanavir (850)	132
Atomoxetine (879)	135
ATP 7 B: H 1069 Q (DNA) (745)	34
Auto-anti C1q (245)	78
Auto-anti FH (249)	78
auto-anti-C1 inhibitor (250)	77
Autoantibodies against nuclei (251, 251)	64, 64
Autoimmune Dermatitis (259)	63
Autoimmune Diseases 01 - Connective Tissue Diseases (ANA) (251)	64
Autoimmune Diseases 02 - Hepatic Syndromes (253)	66
Autoimmune Diseases 03 - Connective Tissue Diseases (ENA) (255)	64
Autoimmune Diseases 04 - Vasculitis/Glomerulopathies (257)	69
Autoimmune Diseases 05 - Autoimmune Dermatitis (259)	63
Autoimmune Diseases 06 - Diabetes mellitus (261)	65
Autoimmune Diseases 07 - Autoimmune Endocrinopathies (263)	63
Autoimmune Diseases 08 - Paraneoplastic Neuropathies (265)	67
Autoimmune Diseases 09 - Peripheral Neuropathies (267)	68
Autoimmune Diseases 10 - Myasthenia gravis (269)	66
Autoimmune Diseases 11 - Gluten-Sensitive Enteropathies (271)	65
Autoimmune Diseases 12 - Rheumatoid Arthritis (273)	69
Autoimmune Diseases 13 - Antiphospholipid Syndrome (275)	62
Autoimmune Endocrinopathies (263)	63
autoprothrombin IIA (788)	31
Avian Influenza (cell culture lysate) (370)	198
Avidity - Anti-CHIKV IgG (cell culture lysate) (402)	230
Avidity - Anti-CMV IgG (serum) (351)	231
Avidity - Anti-HSV IgG (serum) (354)	236
Avidity - Anti-measles virus IgG (serum) (357)	238
Avidity - Anti-mumps virus IgG (serum) (356)	238
Avidity - Anti-parvovirus B19 IgG (serum) (342)	239
Avidity - Anti-rubella virus IgG (serum) (341)	240
Avidity - Anti-TBE/FSME virus IgG (serum) (358)	241
Avidity - Anti-VZV IgG (serum) (353)	241
Avidity - Anti-ZIKV IgG (serum) (338)	242
AZF (DNA) (788)	31
Azoospermia factor (788)	31

B

b-Alanine (710)	113
B-cells (cellular products) (617)	93
B-Cells (EDTA-Vollblut) (651)	74
B-Lymphocytes (213)	90
Bacillary angiomatosi (326)	170
Bacillus anthracis (Bacterial genome) (542)	164
Bacterial Genome Detection (548)	168
Bacterial identification (412)	185
Bacteriology (411, 412)	184, 185
Bacteriology (Slide (fixed)) (413)	185
Bacteriology - Gram Stain (Slide (fixed)) (413)	185
Barbiturate-phenobarbiturate (urine) (174)	150
Bartonella henselae (antibody, serum) (326)	170
Basidiomycetes (living cultures) (490)	191
Basophil Activation Test (653)	70
Basophilic Granulocytes (whole blood) (612)	88
Bb (247)	79
Becker muscular dystrophy (BMD) (DNA) (780)	37
Benzodiazepine Lorazepam (urine) (177)	151
Benzodiazepines (serum) (876, 877, 878)	133, 133, 134
Benzoylecgonine (urine) (174)	150
Beryllium (serum) (207)	147
beta-2-Microglobulin (serum) (292)	149
beta-2-Microglobulin (urine) (182)	158
beta-Globin (DNA) (794)	27
beta-Globulins (electrophoresis, Serum) (102)	115
beta-Globulins (Serum) (141)	120
Bilirubin (newborn, serum) (110)	125
Bilirubin (POCT: Abaxis Piccolo) (810)	145
Bilirubin (serum) (100)	115
Bilirubin (urine) (171)	156
Biochemistry (100)	115
Biogene Amines (plasma) (185)	114
Biogene Amines (urine) (175)	155
Biotin (Vitamin H) (290)	159
Bismuth (207)	147
BK polyomavirus (BKPyV or BKV) (plasma / urine) (364)	200
BK Virus (plasma / urine) (364)	200
BK virus-associated nephropathy (364)	200
bleeding tendency (670, 671, 672, 673, 674, 675, 676, 677, 678)	49, 49, 50, 50, 51, 51, 52, 52, 54
Blood Cell Count (QBC systems) (209)	87
Blood Cell Count (stabilized control blood) (211)	86
blood coagulation factor XIV (788)	31
Blood Gas Analysis (POCT OPTI Systems) (163)	145
Blood Gas Analysis (POCT) (161, 162)	144, 144
blood grouping (231, 232, 237)	81, 81, 83
Blood parasites (blood smear) (456)	193
Blood parasites (pictures) (906)	195
Blood Smear Analysis (blood smear) (212)	87
BNP (761)	112
Bocaviruses (cell culture lysate) (431)	224
BoDV (404, 415)	200, 230

INDEX

Bone Marrow Cytology (bone marrow aspirate (digital image)) (218)	88
Bordetella pertussis (antibody, serum) (317)	171
Bordetella pertussis (Bacterial genome) (532)	161
Borna Viruses (cell culture lysate) (404)	200
Borna Viruses (serum) (415)	230
Borrelia burgdorferi (Ab) (antibody, serum) (332)	171
Borrelia burgdorferi (Bacterial genome) (535)	161
Borrelia IgG Antibody Index (AI) calculation (CSF) (465)	123
Borrelia IgG Antibody Index (CSF) (465)	123
Borrelia specific quotient (CSF) (465)	123
BRAF (795)	57
BRAF Nomenclature (795)	57
BRAF p.V600 (795, 795)	57, 57
BRAF V600 (liquid biopsy) (752)	35
BRCA1 (DNA) (779)	31
BRCA2 (DNA) (779)	31
breast and ovarian cancer (DNA) (779)	31
Brivaracetam (871)	128
Bromazepam (878)	134
Brucella (antibody, serum) (327)	172
Brucella spp. (Bacterial genome) (543)	165
Brucellosis (543)	165
Bruton tyrosine kinase (796)	58
BTK (796)	58
BTK Nomenclature (796)	58
BTK p.C481 (796)	58
Buprenorphine (urine) (176)	151

C

c-ANCA (serum) (257)	69
C-Peptide (serum / plasma) (300)	108
C-Reactive Protein (241)	143
C-Reactive Protein (antibody, serum) (322)	143
C. difficile (545)	164
C1 inhibitor: activity (246)	80
C1 inhibitor: proteine (246)	80
C1-Inhibitor (plasma) (225)	95
C1q proteine (246)	80
C282Y (DNA) (741)	39
C282Y (whole blood, Dna) (733)	40
C3 - nephritic factor (248)	79
C3-Complement (246)	80
C3-Complement (plasma) (241)	143
C3a (247)	79
C3d (247)	79
C4-Complement (246)	80
C4-Complement (plasma) (241)	143
CA 125 (292)	149
CA 15-3 (292)	149
CA 19-9 (292)	149
CA 72-4 (292)	149
Cadmium (lyophilized whole blood) (208)	146
Cadmium (plasma) (206)	147
Cadmium (urine) (205)	153
Caffeine (870)	138
CAH (DNA) (773)	33
Calcitonin (Calcium metabolism) (301)	106
Calcitonin (Tumor marker) (299)	149
Calcium (POCT: Abaxis Piccolo) (810)	145
Calcium (serum) (100)	115
Calcium (urine) (173)	157
Calcium Metabolism (301)	106
Calprotectin (130)	148
CALR (DNA) (768)	59
Campylobacter (548)	168
Campylobacter (antibody, serum) (319)	172
Candida antibodies (480)	191
Candida antigen (serum) (480)	191
Candidiasis (480)	191
Capillary Zone Electrophoresis (102)	115
CAR-T-Cells (822)	85
Carbamacepine (195)	139
Carbamazepine-epoxide (192)	128
carbamezepine (195)	139
Carbapenemase genes (microbiological samples) (544)	162
Carbapenemase-Genes (Bacterial genome) (544)	162
Cardiac markers (760)	112
Cariprazine (875)	132
Cat-scratch disease (326)	170
CCR5-Gene (DNA) (764)	32
CD107a expression (NK and T cell blasts) (657)	76
CD16+ (651)	74
CD19+ (651)	74
CD21low/CD38low B cells (651)	74
CD3+ (651)	74
CD34 (whole blood) (217, 660)	92, 93
CD34+ events (whole blood) (217)	92
CD4 (213)	90
CD4+ (651)	74
CD45+ (cellular products) (617)	93
CD45+ events (whole blood) (217)	92
CD56+ (651)	74
CD8 (213)	90
CDI (545)	164
CEA (292)	149
CEBPA (CDS) Mutation(s) (798)	57
CEBPA Nomenclature (798)	57
Cefepime (890)	127
Ceftazidime (890)	127
Celiac disease (271)	65
Cellular Immunodeficiency Diagnostic (EDTA-whole blood) (651)	74
Cerebrospinal Fluid Analysis (467, 468)	121, 122
Cerebrospinal Fluid Analysis (CSF + serum) (460, 462, 463)	123, 124, 124
Cerebrospinal Fluid Analysis (CSF) (464, 465, 466)	121, 122, 123
Cerebrospinal Fluid Analysis 01 - Protein Analysis (CSF + serum) (460)	124

INDEX

Cerebrospinal Fluid Analysis 02 - Oligoclonal IgG (CSF + serum) (462)	124
Cerebrospinal Fluid Analysis 03 - MRZ Reaction (CSF + serum) (463)	123
Cerebrospinal Fluid Analysis 04 - Lactate/ Glucose (CSF) (464)	122
Cerebrospinal Fluid Analysis 05 - Neuroborreliosis (CSF + serum) (465)	123
Cerebrospinal Fluid Analysis 06 - Dementia Markers (CSF) (466)	121
CFTR Common Mutations (DNA) (778)	32
CFTR gene (DNA) (778)	32
CGG-Repeat (DNA) (781)	39
CHE (100)	115
chemokine receptor (764)	32
Chikungunya Virus (cell culture lysate) (402)	230
Chikungunya Virus (plasma) (392)	201
Chimerism Diagnostics (618)	26
Chlamydia (312, 313, 314, 316, 530, 531)	163, 163, 173, 173, 174, 174
Chlamydia pneumoniae (antibody, serum) (314)	173
Chlamydia pneumoniae (Bacterial genome) (540)	162
Chlamydia trachomatis (antibody, serum) (312, 313)	173, 174
Chlamydia trachomatis (Bacterial genome) (530, 531)	163, 163
Chlamydia trachomatis (Slide (fixed)) (316)	174
Chloramphenicol (198)	130
Chlordiazepoxide (876)	133
Chloride (POCT OPTI Systems) (163)	145
Chloride (POCT) (161)	144
Chloride (POCT: Abaxis Piccolo) (810)	145
Chloride (serum) (100)	115
Chloride (urine) (173)	157
Chlorprotixene (875)	132
Cholesterol (100, 151)	115, 119
Cholesterol (POCT: Abaxis Piccolo) (810)	145
Cholinesterase (100)	115
Chromatographic analysis (188)	152
Chromium (lyophilized whole blood) (208)	146
Chromium (plasma) (206)	147
Chromium (urine) (205)	153
Chromium release assay (657)	76
chronic lymphocytic leukemia (820)	86
Citalopram (860)	136
Citrulline (710)	113
CK (100)	115
CK (POCT: Abaxis Piccolo) (810)	145
CK-MB (760)	112
Classical pathway (246)	80
CLL-MRD Immunophenotyping (820)	86
Clobazam (878)	134
Clobazepam (878)	134
Clomipramine (serum) (199, 203, 863)	137, 140, 141
Clomipramine (urine) (204)	153
Clonazepam (877)	133
Clostridium difficile (Bacterial genome) (545)	164
Clostridium difficile (microbiological samples) (545)	164
Clostridium difficile (toxinogen) (548)	168
clotting factor (670, 671, 672, 673, 674, 675, 676, 677, 678, 790, 791, 792)	29, 45, 46, 49, 49, 50, 50, 51, 51, 52, 52, 54
Clozapine (200, 862, 863)	130, 137, 137
cMRSA (Bacterial genome) (539)	167
CMV (349, 351)	204, 231
CMV (cell culture lysate) (433)	221
CMV (plasma) (349, 365, 368)	203, 203, 204
coagulation (223, 224, 225, 226, 227, 670, 671, 672, 673, 674, 675, 676, 677, 678)	49, 49, 50, 50, 51, 51, 52, 52, 54, 95, 96, 98, 98, 99
coagulation (DNA) (790, 791)	45, 46
Cobalamin (Vitamin B12) (290)	159
Cobalt (lyophilized whole blood) (208)	146
Cobalt (plasma) (206)	147
Cobalt (urine) (205)	153
Coeliac Disease (772)	73
Coeliac disease diagnostics (serum) (271)	65
Coelomycetes (living cultures) (490)	191
Coeruloplasmin (241)	143
Collagen Receptor C807T (739)	33
Collagen receptor C807T (DNA) (739)	33
Collagen receptor GP Ia/IIa (C 807 T) (739)	33
Collagen receptor GP Ia/IIa (DNA) (739)	33
Collagenosis Screening (ANA) (serum) (251)	64
Colton system [CO] (DNA) (235)	26
Complement activation products (247)	79
Complement Analysis (245, 246, 247, 248, 249, 250)	77, 78, 78, 79, 79, 80
Complement Analysis 01 (Auto-anti-C1q) (245)	78
Complement Analysis 02 (Functions and proteins) (246)	80
Complement Analysis 03 (Complement activation products) (247)	79
Complement Analysis 04 (C3 - nephritic factor) (248)	79
Complement Analysis 05 (Auto-anti FH) (249)	78
Complement Analysis 06 (anti - C1 inhibitor) (250)	77
Complement factor H (246)	80
Complement factor I (246)	80
Concentration of Hb in reticulocytes (216)	91
congenital adrenal hyperplasia (DNA) (773)	33
Connective Tissue Diseases (ANA) (serum) (251)	64
Connective Tissue Diseases (ENA) (255)	64
Connexin 26 (DNA) (782)	34
Copper (plasma) (206)	147
Copper (serum) (100)	115
Copper (urine) (205)	153
Coproporphyrin (178)	156
Coronaviruses (409)	227
Coronaviruses (cell culture lysate) (340, 417, 431, 432)	202, 224, 225, 227
Coronaviruses (cell culture supernatants) (410, 410)	197, 197
Coronaviruses (serum) (416)	240
Cortisol (serum) (302)	109
Cortisol free (urine) (179)	155
COVID (409, 410, 416)	197, 227, 240

INDEX

Coxiella burnetii (antibody, serum) (325)	175
Coxiella burnetii (Bacterial genome) (542)	164
Creatine Kinase (100)	115
Creatinine (POCT) (161)	144
Creatinine (POCT: Abaxis Piccolo) (810)	145
Creatinine (serum) (100)	115
Creatinine (urine) (173, 182)	157, 158
Creatinine kinase (810)	145
CRP (810)	145
Cryptococcosis (481)	192
Cryptococcus gattii (serum or liquor) (481)	192
Cryptococcus neoformans (serum or liquor) (481)	192
Cryptosporidium spp. (458)	193
CSF (460, 462, 463, 464, 465, 466, 467, 468)	121, 121, 122, 122, 123, 123, 124, 124
ctDNA (liquid biopsy) (752)	35
Cultivation of mycobacteria (sputum) (422)	186
Cultivation, identification and sensitivity testing of bacteria (3 Samples) (411)	184
Cultivation, identification and sensitivity testing of bacteria (5 Samples) (412)	185
Cx26 (782)	34
Cyclosporine A (601)	134
CYFRA 21-1 (292)	149
Cyp21A2 (DNA) (773)	33
CYP21A2 gene (DNA) (773)	33
CYP2C19 (DNA) (775)	35
CYP2C9 (DNA) (775)	35
CYP2D6 (DNA) (777)	36
Cystathionine (710)	113
Cystatin-C (242)	142
Cysteine-Homocysteine-disulfide (710)	113
Cystic fibrosis (778)	32
Cystine (710)	113
Cytomegalovirus (cell culture lysate) (433)	221
Cytomegalovirus (plasma) (349, 365, 368)	203, 203, 204
Cytomegalovirus (serum) (351)	231

D

D-Dimer (226, 285)	95, 96
Dabigatran (502)	96
Darunavir (850)	132
DAT (231, 232, 237, 238)	81, 81, 83, 83
delta-9-THC-COOH (urine) (177)	151
Dementia Markers (CSF) (466)	121
Dengue fever (350, 369)	204, 231
Dengue Viruses (plasma) (369)	204
Dengue Viruses (serum) (350)	231
Dermatophytes (living cultures) (491)	190
Dermatophytes Genome Detection (Lyophilized spore suspension) (492)	190
Desalkylflurazepam (876)	133
Desethylamiodarone (190)	126
Desipramine (863)	137
Desipramine (serum) (202, 203)	139, 141
Desipramine (urine) (204)	153
Desmethyl fluoxetine (874)	131
Desmethyl olanzapine (875)	132
Desmethyl sertraline (873)	131
Desmethyldiazepam (876)	133
DFNB1 (DNA) (782)	34
DHEA (298)	105
DHEA sulfate (298)	105
DHEA-S (298)	105
Diabetes mellitus (261)	65
Diazepam (876)	133
Diego system [DI] (DNA) (235)	26
Differential Blood Count (whole blood) (612)	88
Differentiation of tuberculosis bacteria (sputum) (422)	186
Digitoxin (197)	138
Digoxin (195)	139
Dihydropyrimidin Dehydrogenase (DNA) (762)	36
Diphtheria Toxoid (antibody, serum) (318)	175
Dipstick (171)	156
Direct Antiglobulin Test (Machine-based, whole blood) (237, 238)	83, 83
Direct Antiglobulin Test (serum / erythrocytes suspension) (231, 232)	81, 81
Direct detection of Chlamydia trachomatis antigen (antigen, serum) (313)	174
Direct detection of Chlamydia trachomatis antigen (Slide (fixed)) (316)	174
Disialotransferrin (serum) (750)	119
DMD (DNA) (780)	37
Dolutegravir (serum) (850)	132
Dombrock system [DO] (DNA) (235)	26
Dopamine (plasma) (185)	114
Dopamine (urine) (175)	155
Doxepin (serum) (201, 203, 863)	137, 140, 141
Doxepin (urine) (204)	153
DPA1 (444)	70
DPB1 (444)	70
DPD (777)	36
DPYD (DNA) (762)	36
DQA1 (444)	70
DQB1 (444)	70
DRB1 (444)	70
DRB3 (444)	70
DRB4 (444)	70
DRB5 (444)	70
Drug Resistance Determination (plasma) (349, 383, 384, 397, 399)	204, 208, 210, 213, 214
Drugs of Abuse (174, 176, 177)	150, 151, 151
Duchenne muscular dystrophy (DMD) (DNA) (780)	37
Duffy system [FY] (DNA) (235)	26
Duloxetine (862)	137
Dysfibrinogenemia (676)	52
Dystrophin (DNA) (780)	37

INDEX

E

E. coli (534) 165
EBV (352, 376, 433) 205, 221, 232
Echinococcosis (serum/plasma) (455) 194
EDDP (urine) (177) 151
Edoxaban (505) 97
educational program (378, 379, 382) 208, 210, 212
Efavirenz (850) 132
Effector memory T cells (651) 74
Effector T cells (651) 74
EGFR T790M (liquid biopsy) (752) 35
EHEC (Bacterial genome) (534) 165
Elvitegravir (850) 132
Emicizumab (plasma) (506) 97
ENA (255) 64
Endocrinopathies (263) 63
Engraftment Diagnostics (618) 26
Entamoeba histolytica (458) 193
Enterohemorrhagic E. coli (EHEC / STEC) (548) 168
Enteroinvasive E. coli (EIEC) (548) 168
Enteropathogenic E. coli (EPEC) (548) 168
Enterotoxigenic E. coli (ETEC) (548) 168
Enteroviruses (cell culture lysate) (372, 431, 433) 205, 221, 224
Enteroviruses (suspensions of feces) (430) 206
Eosinophilic Granulocytes (whole blood) (612) 88
Epinephrine (175) 155
Epinephrine (plasma) (185) 114
Epinephrine (urine) (175) 155
Epstein Barr Virus (cell culture lysate) (433) 221
Epstein Barr Virus (plasma) (376) 205
Epstein Barr Virus (serum) (352) 232
Erythocyte - alleles (DNA) (235) 26
Erythrocytes (stabilized control blood) (211) 86
Erythrocytes (urine) (171) 156
Erythrocytes (whole blood) (612) 88
Erythropoiesis (bone marrow aspirate (digital image)) (218) 88
Erythropoietin (626) 108
Escherichia coli (534) 165
Escherichia coli O157 (548) 168
Escitalopram (861) 136
Eslicarbazepine (871) 128
ESR1 (liquid biopsy) (752) 35
Ethanol (700) 116
Ethosuximid (195) 139
Ethylglucuronid (751) 152
Etravirine (850) 132
Everolimus (601) 134
Expansion of trinucleotide CAG repeats (DNA) (784) 40

F

F10 (DNA) (674) 51
F11 (DNA) (675) 51
F13A1 (DNA) (677) 52
F13B (DNA) (677) 52
F5 (DNA) (670) 49
F7 (DNA) (671) 50
F8 (DNA) (672) 50
F9 (DNA) (673) 49
Factor II (223) 98
Factor IX (224) 98
Factor IX (DNA) (673) 49
Factor V (223) 98
Factor V (DNA) (670) 49
Factor V-Leiden (DNA) (740) 37
Factor V-Leiden (DNA) (740) 37
Factor V-Leiden (whole blood) (730) 38
Factor VII (223) 98
Factor VII (DNA) (671) 50
Factor VIII (227) 99
Factor VIII (DNA) (672) 50
Factor X (223) 98
Factor X (DNA) (674) 51
Factor XI (224) 98
Factor XI (DNA) (675) 51
Factor XII (224) 98
Factor XIII (224) 98
Factor XIII (DNA) (677) 52
FDP screening (222) 99
Fecal Diagnostics (130, 131) 148, 148
Fecal elastase (130) 148
Felbamate (871) 128
Ferritin (241) 143
Ferritin (CSF) (467) 121
Fertility (297) 106
fetal haemoglobin (210) 89
Fetoprotein (306) 107
FGA (DNA) (676) 52
FGB (DNA) (676) 52
FGG (DNA) (676) 52
Fibrinogen (222, 285) 95, 99
Fibrinogen (DNA) (676) 52
Fibrinogen degradation products (222) 99
Fibrinogen Receptor (749) 38
Fifth disease (342, 367) 223, 239
Flavine Adenine Dinucleotide (FAD) (291) 160
Flavine mononucleotid (FMN) (291) 160
Flowcytometry (217, 617) 92, 93
FLT3 (internal tandem duplication) (DNA) (701) 53
FLT3 (TKD) Mutation(s) (798) 57
FLT3 Nomenclature (798) 57
FLT3-ITD (DNA) (701) 53
Fluconazole (198) 130
Flucytosine (198) 130
Flunitrazepam (877) 133
Fluoride (plasma) (206) 147
Fluoride (urine) (205) 153
Fluoxetine (874) 131
Flurazepam (877) 133
Fluvoxamine (873) 131
FMR1 (DNA) (781) 39
Folate (290) 159

INDEX

Folic acid (serum) (290)	159
Follicle-stimulating hormone (297)	106
Fondaparinux (plasma) (501)	100
Food allergens (IgE against) (720)	62
Fraction CO-Hb (POCT) (162)	144
Fraction Met-Hb (POCT) (162)	144
Fraction O2-Hb (POCT) (162)	144
Fragile X (DNA) (781)	39
Fragile X syndrom (DNA) (781)	39
Francisella (antibody, serum) (328)	176
Francisella tularensis (Bacterial genome) (543)	165
Free beta-chain hCG (serum / plasma) (305)	107
Free Haemoglobin (236)	89
Free Hemoglobin (236)	89
Free light chains (243)	117
Fructosamine (146)	116
FSH (297)	106
Fungal Genome Detection (Fungal genome) (560)	189
fungal infection (480, 481)	191, 192
FXPOI (DNA) (781)	39
FXS (DNA) (781)	39
FXTAS (DNA) (781)	39

G

G6PDH (279)	117
Gabapentin (872)	129
gamma-Globulins (100, 141)	115, 120
gamma-Globulins (electrophoresis, Serum) (102)	115
Gammopathies (243)	117
Gap junction beta-2 protein (782)	34
Gardnerella (547)	169
Gastrin (300)	108
Gastrointestinal disease (381, 430)	206, 220
Gastrointestinal Virus Panel (suspensions of feces) (430)	206
Gastrointestinale Pathogene (548)	168
genome detection (424)	189
Gentamicin (197)	138
GGT (POCT: Abaxis Piccolo) (810)	145
GGT (serum) (100)	115
Giardia duodenalis (458)	193
GJB2 (782)	34
GJB2 (DNA) (782)	34
GJB2 gene (DNA) (782)	34
GJB6 (DNA) (782)	34
GJB6 gene (DNA) (782)	34
Glandular fever (352, 376)	205, 232
GLDH (100)	115
Glomerulopathies (serum) (257)	69
Glucagon (300)	108
Glucose (CSF) (464)	122
Glucose (POCT) (161, 800)	144, 146
Glucose (POCT: Abaxis Piccolo) (810)	145
Glucose (serum) (100, 111)	115, 118
Glucose (urine) (171, 173)	156, 157
Glucose quotient (CSF/Serum) (CSF) (464)	122
Glucose-6 Phosphat-Dehydrogenase (279)	117
Glutamic acid (710)	113
Glutamine (710)	113
Gluten-Sensitive Enteropathies (serum) (271)	65
Glycine (710)	113
Gold (plasma) (206)	147
GOT (POCT: Abaxis Piccolo) (810)	145
GOT (serum) (100)	115
GP Ia/IIa (DNA) (739)	33
GPI deficient cells (616)	91
GPT (POCT: Abaxis Piccolo) (810)	145
GPT (serum) (100)	115
Gram Stain (Lyophilisate) (411, 412)	184, 185
Gram Stain (Slide (fixed)) (413)	185
Granulocyte (neutrophil) antigens (234)	82
Granulocyte - alleles (DNA) (235)	26
Granulocyte antibodies (234)	82
Granulocyte Function (Oxidative Burst) (654)	77
Granulocyte Function (Phagocytosis Test) (655)	68
Granulocyte Immunology (234)	82
Granulopoiesis (bone marrow aspirate (digital image)) (218)	88
Growth Hormone (GH) (298)	105

H

H. pylori (334, 533)	166, 176
H63D (741)	39
Haematocrit (QBC systems) (209)	87
Haematocrit (stabilized control blood) (211)	86
Haematocrit (whole blood) (612)	88
Haematology 07 - Blood Smear Analysis (blood smear) (212)	87
Haematology 09 - Bone Marrow Cytology (bone marrow aspirate (digital image)) (218)	88
Haemoglobin (POCT OPTI Systems) (163)	145
Haemoglobin (POCT) (162)	144
Haemoglobin (QBC systems) (209)	87
Haemoglobin (stabilized control blood) (211)	86
Haemoglobin (whole blood) (612)	88
Haemoglobin-Haptoglobin-Complex (stool) (131)	148
Haemoglobinopathies (whole blood) (210)	89
Haloperidol (862)	137
Hantaviruses (serum) (355)	232
Haptoglobin (plasma) (241)	143
Haptoglobin (stool) (131)	148
HAV (344, 377)	206, 233
Hb-A (210)	89
Hb-A2 (210)	89
Hb-F (210)	89
Hb-S (210)	89
HBA (794)	27
HbA1c (EDTA Vollblut) (145)	118

INDEX

HBB (794)	27
HBDH (100)	115
HBeAg (serum) (345)	234
HBOC (DNA) (779)	31
HBsAg (serum) (344)	233
HBV (345, 361, 378, 396, 397)	207, 207, 208, 208, 234
hCG (urine) (171)	156
hCG intact (Pregnancy) (306)	107
hCG intact (Tumor marker) (292)	149
hCG intact (urine) (179)	155
HCT (209, 211, 612)	86, 87, 88
HCV (346, 362, 375, 379, 399)	209, 209, 210, 210, 234
HCV Antigen (serum) (346)	234
HD (784)	40
HDL-cholesterol (151)	119
HDL-cholesterol (POCT: Abaxis Piccolo) (810)	145
HDV (347, 400)	211, 235
HE4 (292)	149
Helicobacter pylori (antibody, serum) (334)	176
Helicobacter pylori (Bacterial genome) (533)	166
hematocrit (209, 211, 612)	86, 87, 88
Hematopoetic Growth Factors (626)	108
Hemoglobin (162, 163, 209, 211, 612)	86, 87, 88, 144, 145
Hemoglobin-Haptoglobin-Complex (131)	148
Hemoglobinopathies (210)	89
hemolytic anemia (279)	117
Hemopexin (241)	143
Hemophilia A (672)	50
Hemophilia B (673)	49
Hemophilia C (675)	51
hemostasis (670, 671, 672, 673, 674, 675, 676, 677, 678, 790, 791, 792)	29, 45, 46, 49, 49, 50, 50, 51, 51, 52, 52, 54
Hepatic Syndromes (serum) (253)	66
Hepatitis A Virus (plasma) (377)	206
Hepatitis A Virus (serum) (343)	233
Hepatitis B Virus (plasma) (361, 378, 396, 397)	207, 207, 208, 208
Hepatitis B Virus (serum) (344, 345)	233, 234
Hepatitis C Virus (plasma) (362, 375, 379, 399)	209, 209, 210, 210
Hepatitis C Virus (serum) (346)	234
Hepatitis D Virus (plasma) (400)	211
Hepatitis D Virus (serum) (347)	235
Hepatitis E Virus (plasma) (380)	211
Hepatitis E Virus (serum) (348)	235
Heptaprorphyrin (178)	156
HER2/new (292)	149
hereditary hemochromatosis (733, 741)	39, 40
Hereditary nonpolyposis colorectal cancer (783)	41
Herpes simplex specific quotient (CSF / serum) (463)	123
Herpes simplex virus IgG Antibody Index (CSF / serum) (463)	123
Herpes Simplex Viruses (cell culture lysate) (433)	221
Herpes Simplex Viruses (plasma) (363)	212
Herpes Simplex Viruses (serum) (354)	236
HEV (348, 380)	211, 235
Hexaporphyrin (178)	156
HFE (741)	39
HFE (C282Y, H63D, S65C) (DNA) (741)	39
HFE (C282Y, H63D, S65C) (whole blood) (733)	40
HFE: C 282 Y (733)	40
HFE: H 63 D (733)	40
HFE: S 65 C (733)	40
HGH (298)	105
HHV-6 (cell culture lysate) (405)	215
HHV-8 (cell culture lysate) (406)	215
high resolution (444)	70
Histidine (710)	113
HIV (850)	132
HIV-1 (plasma) (360, 382, 383, 384)	212, 213, 213, 214
HIV-1 (serum) (335)	237
HIV-1 Drug Susceptibility Determination (plasma) (384)	214
HIV-1 p24 Antigen (serum) (337)	236
HIV-2 (plasma) (395)	214
HIV-2 (serum) (335)	237
HLA A (441, 442, 444)	70, 72, 73
HLA Antibody Screening and Specification (445)	71
HLA B (441, 442, 444)	70, 72, 73
HLA B 57 (444)	70
HLA C (442, 444)	70, 73
HLA Crossmatching (443)	71
HLA Typing (blood samples) (441, 442)	72, 73
HLA Typing (buffy coat) (444)	70
HLA-B27 Determination (440)	72
HLA-DQ (441, 772)	72, 73
HLA-DR (441)	72
HMPV (385)	216
HNA (234)	82
HNA - system (DNA) (235)	26
HNPCC (DNA) (783)	41
Holotranscobalamine (290)	159
Homocystein (151)	119
Homovanillic acid (175)	155
HPA (749)	38
HPA - system (DNA) (235)	26
HPA 1a/1b (DNA) (749)	38
HPV (373)	216
HPV (cell culture lysate) (373)	216
hsCRP (240)	142
HSV (354, 363, 433, 463)	123, 212, 221, 236
HTLV-1 (serum) (339)	237
HTLV-2 (serum) (339)	237
HTT (DNA) (784)	40
HTT gene (DNA) (784)	40
HTT Huntingtin (DNA) (784)	40
Human brucellosis (327)	172
Human Herpesvirus (cell culture lysate) (405, 406)	215, 215
Human immunodeficiency virus (360, 382, 383, 384, 850)	132, 212, 213, 213, 214
Human immunodeficiency virus 2 (395)	214
Human immunodeficiency viruses (335, 337)	236, 237

INDEX

Human Metapneumovirus (cell culture lysate) (385)	216
Human neutrophil antigens (234)	82
Human Papilloma Viruses (cell culture lysate) (373)	216
Human Rhinoviruses (cell culture lysate) (393)	217
Human T-lymphotropic virus (339)	237
Huntingtin (DNA) (784)	40
Huntington disease (HD) (DNA) (784)	40
HVA (175)	155
Hydatid (455)	194
Hydroxy-Itraconazole (602)	129
Hydroxycarbamazepine (860)	136
Hydroxycarbazepine (192)	128
hypercholesterolemia (771)	30
Hyphomycetes (living cultures) (490)	191
Hypodysfibrinogenemia (676)	52
Hypofibrinogenemia (676)	52

I

Identification of mycobacteria (suspensions of mycobacterial strains) (423)	187
IDH1 Exon 4 Mutation(s) (798)	57
IDH1 Nomenclature (798)	57
IDH2 Exon 4 Mutation(s) (798)	57
IDH2 Nomenclature (798)	57
IgA (CSF) (460)	124
IgA (plasma) (241, 243)	117, 143
IgA (serum) (100)	115
IgA Quotient (CSF / serum) (460)	124
IgE (food allergens) (720)	62
IgE (inhaled allergens) (720)	62
IgE (insect poison allergens) (720)	62
IgE (plasma) (241)	143
IgE (serum) (720)	62
IgE (specific) (720)	62
IgG (CSF) (460)	124
IgG (plasma) (241, 243)	117, 143
IgG (serum) (100)	115
IgG (urine) (182)	158
IgG Quotient (CSF / serum) (460)	124
IgG Subclasses (serum) (244)	111
IgM (CSF) (460)	124
IgM (plasma) (241, 243)	117, 143
IgM (serum) (100)	115
IgM Quotient (CSF + serum) (460)	124
IGRA (Heparin-whole blood) (650)	75
IL28B (777)	36
Imipramine (serum) (202, 203, 863)	137, 139, 141
Imipramine (urine) (204)	153
Immature reticulocytes (216)	91
Immunogenetics (blood samples) (440, 441, 442)	72, 72, 73
Immunogenetics (buffy coat) (444)	70
Immunogenetics (serum) (443, 445)	71, 71
Immunohaematology 01 (manual performance) (231)	81
Immunohaematology 02 (manual perfomance and titer determination) (232)	81
Immunohaematology 05 (Machine-Based Analysis) (Machine-based, whole blood) (237)	83
Immunohaematology 06 - Molecular Diagnostic (DNA) (235)	26
Immunohaematology 07 (Machine-Based Analysis and titer determination) (Machine-based, whole blood) (238)	83
Immunophenotyping (bone marrow or blood smears and leukaemia or lymphoma cells) (214)	90
Immunophenotyping (cellular products) (617)	93
Immunophenotyping (whole blood) (213)	90
Immunosuppressants (lyophilized whole blood) (601)	134
Immunosuppressants (serum / plasma) (602)	129
Infectious Mononucleosis (352, 376)	205, 232
Influenza Viruses (cell culture lysate) (370, 431, 432)	198, 224, 225
Inhaled allergens (IgE against) (720)	62
INR (plasma) (221, 285)	95, 102
INR (whole blood) (286)	102
insect poison allergens (IgE against) (720)	62
Insulin (300)	108
Integrase Inhibitors (plasma) (384)	214
Interferon Gamma Release Assay (650)	75
International Normalized Ratio (221, 285)	95, 102
Iodine (plasma) (206)	147
Iodine (urine) (205)	153
ionized Calcium (POCT OPTI Systems) (163)	145
ionized Calcium (POCT) (161)	144
Iron (plasma) (206)	147
Iron (serum) (100)	115
Iron (urine) (205)	153
Iron binding capacity (100)	115
IRT (785)	125
Isoleucine (710)	113
IT15 (784)	40
Itraconazole (602)	129

J

JAK2 (768)	59
JC polyomavirus (JCPyV / JCV) (plasma / urine) (394)	217
JC Virus (plasma / urine) (394)	217

K

kappa (243)	117
Kappa Free Light Chains (CSF) (468)	122
Kell antigen (Machine-based, whole blood) (237, 238)	83, 83
Kell antigen (serum / erythrocytes suspension) (231, 232)	81, 81
Kell system [KEL] (DNA) (235)	26
Ketone bodies (urine) (171)	156
Kidd system [JK] (DNA) (235)	26
Kissing disease (352, 376)	205, 232
KIT (767)	58
Knops system [KN] (DNA) (235)	26
KRAS Codon 12 (liquid biopsy) (752)	35
KRAS Codon 13 (liquid biopsy) (752)	35
KRAS Codon 61 (liquid biopsy) (752)	35

INDEX

L

Lacosamide (871) 128
Lactase gene (DNA) (770) 41
Lactase-gene (DNA) (770) 41
Lactate (CSF) (464) 122
Lactate (POCT OPTI Systems) (163) 145
Lactate (POCT) (161) 144
Lactate (POCT: Abaxis Piccolo) (810) 145
Lactate (serum) (100) 115
Lactate Dehydrogenase (100, 810) 115, 145
Lactose (DNA) (770) 41
lactose intolerance (770) 41
Lactose intollerance (DNA) (770) 41
lambda (243) 117
Lamotrigine (191, 860) 127, 136
Landsteiner Wiener system [LW] (DNA) (235) 26
LCT (DNA) (770) 41
LDH (100) 115
LDH (POCT: Abaxis Piccolo) (810) 145
LDL-cholesterol (151) 119
LDL-cholesterol (POCT: Abaxis Piccolo) (810) 145
Lead (lyophilized whole blood) (208) 146
Lead (urine) (205) 153
Lectin pathway (246) 80
Legionella pneumophila (Bacterial genome) (536) 166
Legionellosis (536) 166
Legionnaires disease (536) 166
Leptospira (329) 177
Leptospira (antibody, serum) (329) 177
Leptospirosis (329) 177
Leucine (710) 113
Leucocytes (cellular products) (617) 93
Leucocytes (QBC systems) (209) 87
Leucocytes (stabilized control blood) (211) 86
Leucocytes (urine) (171) 156
Leucocytes (whole blood) (213, 217, 612) 88, 90, 92
leukozyte antigen (440, 441, 442, 443, 444, 445) 70, 71, 71, 72, 72, 73
Levetiracetam (191) 127
Levomepromazine (873) 131
LH (297) 106
Lime borreliosis (535) 161
Linezolid (890) 127
Lipase (100) 115
Lipids (151) 119
Lipoproteins (151) 119
Liquid Biopsy (752) 35
Listeria (538) 167
Listeria spp. (Bacterial genome) (538) 167
Listeriosis (538) 167
Lithium (100, 195) 115, 139
Liver disease (253) 66
LMW Heparin (281) 101
Lopinavir (850) 132
Lorazepam (878) 134
low molecular weight heparin (281) 101
low resolution (442) 73
Lp (a) (151) 119
LSD (urine) (176) 151
Luteinizing hormone (297) 106
Lutheran system [Lu] (DNA) (235) 26
Lyme disease (332, 535) 161, 171
Lymphocyte Proliferation Assay (656) 76
lymphocytes (651) 74
Lymphocytes (whole blood) (213, 612) 88, 90
Lymphozyte Transformation Test (LTT) (656) 76
Lynch syndrome (783) 41
Lysine (710) 113

M

Magnesium (lyophilized whole blood) (208) 146
Magnesium (POCT) (161) 144
Magnesium (POCT: Abaxis Piccolo) (810) 145
Magnesium (serum) (100) 115
Magnesium (urine) (173) 157
Malaria (serum/plasma) (454) 194
Manganese (lyophilized whole blood) (208) 146
Manganese (plasma) (206) 147
Manganese (urine) (205) 153
Maproptiline (202, 863) 137, 139
Maraviroc (850) 132
Markers of Ethanol Abuse (serum) (750) 119
Markers of Ethanol Abuse (urine) (751) 152
MCV (stabilized control blood) (211) 86
MCV (whole blood) (612) 88
MDMA (urine) (177) 151
mean cell volume (211, 612) 86, 88
mean corpuscular volume (211, 612) 86, 88
Measles specific quotient (CSF + serum) (463) 123
Measles Virus (cell culture lysate) (386) 218
Measles Virus (serum) (357) 238
Measles virus IgG Antibody Index (CSF + serum) (463) 123
mecA (539) 167
Megakaryopoiesis (bone marrow aspirate (digital image)) (218) 88
Memory T cells (651) 74
MEN2 Syndrome (DNA) (738) 56
MEN2A (DNA) (738) 56
Mercury (lyophilized whole blood) (208) 146
Mercury (urine) (205) 153
Meropenem (890) 127
MERS (cell culture lysate) (340) 202
Metanephrines (175) 155
Methadone (urine) (176) 151
Methicillin-resistant Staphylococcus aureus (539) 167
Methionine (710) 113
Methotrexate (197) 138
Methylmalonic Acid (187) 158
Methylphenidate (879) 135

INDEX

Mianserine (874)	131
Microalbumin (173)	157
Microbiome (stool) (580)	183
Microscopic detection of mycobacteria (Slide) (421)	188
Minimal residual disease (820, 821)	86, 120
Mirtazapine (861)	136
MLH1 (DNA) (783)	41
MMF (602)	129
MNS - system (DNA) (235)	26
MNS system [GYP] (DNA) (235)	26
molecular susceptibility testing of tuberculosis bacteria (suspensions of mycobacterial strains) (426)	188
Molybdaen (207)	147
Molybdenum (207)	147
Monkeypox virus / Orthopoxviruses (418)	219
Monocytes (whole blood) (612)	88
Morphology (Slide (fixed)) (413)	185
Morphology of erythrocytes (blood smear) (212)	87
Morphology of leukocytes (blood smear) (212)	87
Morphology of platelets (blood smear) (212)	87
Mould Fungus (living cultures) (491)	190
MPA (602)	129
MPL (768)	59
MPN (768)	59
MPOX (418)	219
MPXV (418)	219
MRSA (Bacterial genome) (539)	167
MSH2 (DNA) (783)	41
MSH6 (DNA) (783)	41
MTHFR (C677T, A1298C) (DNA) (747)	42
MTHFR (C677T, A1298C) (whole blood) (732)	42
MTHFR (whole blood, Dna) (732)	42
MTHFR C677T (DNA) (747)	42
MTHFR C677T (whole blood, Dna) (732)	42
Mucorales (living cultures) (490)	191
Multiple Endocrine Neoplasia Type 2A (DNA) (738)	56
Multiplex Test (cell culture lysate) (431, 432, 433)	221, 224, 225
Multiplex Test (suspensions of feces) (430)	206
Mumps Virus (cell culture lysate) (387)	220
Mumps Virus (serum) (356)	238
muscular dystrophy (780)	37
Myasthenia gravis (serum) (269)	66
Mycobacteria (Slide) (421)	188
Mycobacteria (sputum) (422, 424)	186, 189
Mycobacteria (suspensions of mycobacterial	186, 187, 187, 188
Mycobacterial diagnostics - Cultivation (sputum) (422)	186
Mycobacterial diagnostics - Drug Susceptibility Testing of nontuberculous mycobacteria (suspensions of non-mycobacterial strains) (427)	187
Mycobacterial diagnostics - Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) (425)	186
Mycobacterial diagnostics - Identification (suspensions of mycobacterial strains) (423)	187
Mycobacterial diagnostics - Microscopy (Slide) (421)	188
Mycobacterial diagnostics - Molecular Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) (426)	188
Mycobacterial diagnostics - NAT tuberculosis bacteria (sputum) (424)	189
Mycobacterial diagnostics 01 - Microscopy (Slide) (421)	188
Mycobacterial diagnostics 02 - Cultivation (sputum) (422)	186
Mycobacterial diagnostics 03 - Identification (suspensions of mycobacterial strains) (423)	187
Mycobacterial diagnostics 05 - Drug Susceptibility Testing of tuberculosis bacteria (suspensions of	186
Mycobacterial diagnostics 06 - Molecular Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) (426)	188
Mycobacterial diagnostics 07 - Drug Susceptibility Testing of nontuberculous mycobacteria (suspensions of non-mycobacterial strains) (427)	187
Mycology (living cultures) (490, 490, 491)	190, 191, 191
Mycophenolic acid (602)	129
Mycoplasma (547)	169
Mycoplasma pneumoniae (antibody, serum) (324)	177
Mycoplasma pneumoniae (Bacterial genome) (541)	168
Mycoserology (serum or liquor) (481)	192
Mycoserology (serum) (480)	191
MYD88 (766)	59
Myeloproliferative Neoplasia (768)	59
Myocardial Markers (760, 761)	112, 112
Myoglobin (760)	112

N

N-Desmethylclozapine (200, 862, 863)	130, 137, 137
N-Desmethylmethsuximide (192)	128
N334K (793)	27
Naive B cells (651)	74
Naive T cells (651)	74
Neisseria gonorrhoeae (Bacterial genome) (530)	163
Neonatal Bilirubin (110)	125
Neuroborreliosis (CSF) (465)	123
Neutrophilic Granulocytes (whole blood) (612)	88
Nevirapine (850)	132
Newborn screening (785, 785)	125, 125
Next Generation Sequencing (798)	57
Next Generation Sequencing (stool) (580)	183
NGS-Analysis (stool) (580)	183
Nickel (lyophilized whole blood) (208)	146
Nickel (plasma) (206)	147
Nickel (urine) (205)	153
Nitrazepam (877)	133
Nitrite (urine) (171)	156
NK and cytotoxic T cells function (657)	76
NK cell activation assay (CD107a) (657)	76
NK cell subpopulations (651)	74
NK cytotoxicity assay (CD107a or lysis) (657)	76
NK-cells (cellular products) (617)	93
NK-Cells (EDTA-whole blood) (651)	74
NK-cells (whole blood) (213)	90
Non-switched B cells (651)	74
non-syndromic hearing inpairment (DNA) (782)	34
Nontuberculous mycobacteria (suspensions of mycobacterial strains) (427)	187

INDEX

Norclomipramine (serum) (199, 203, 863)	137, 140, 141
Norclomipramine (urine) (204)	153
Norclozapine (862, 863)	137, 137
Nordiazepam (876)	133
Nordoxepin (serum) (201, 203, 863)	137, 140, 141
Nordoxepin (urine) (204)	153
Norepinephrine (plasma) (185)	114
Norepinephrine (urine) (175)	155
Normaproptiline (202)	139
Normetanephrine (175)	155
Noroviruses (suspensions of feces) (381, 430)	206, 220
Nortrimipramine (serum) (201, 203)	140, 141
Nortrimipramine (urine) (204)	153
Nortriptyline (serum) (199, 203, 863)	137, 140, 141
Nortriptyline (urine) (204)	153
NPM1 Exon 11 Mutation(s) (798)	57
NPM1 Nomenclature (798)	57
NSAIDs (194)	135
NSE (292)	149
NT-pro BNP (760)	112

O

O-Desmethylvenlafaxine (860, 861)	136, 136
Olanzapine (862, 875)	132, 137
Oligoclonal IgG (CSF / serum) (462)	124
Opiate (urine) (174)	150
Orgaran (282)	101
Ornithine (710)	113
Osmolality (serum) (100)	115
Osmolality (urine) (173)	157
Oxazepam (876)	133

P

p-ANCA (serum) (257)	69
P. jirovecii (560)	189
p.D816V (767)	58
p.L265P (766)	59
PAI-1 (4G/5G) (DNA) (748)	44
PAI-1 (4G/5G) (whole blood) (735)	44
PAI-1 (4G/5G) (whole blood, Dna) (735)	44
Paliperidone (862)	137
Pancreas (300)	108
Pancreas amylase (serum) (100)	115
Panel for Viral Meningitis (cell culture lysate) (433)	221
Pantothenic acid (Vitamin B5) (290)	159
PAP (785)	125
PAPP-A (serum / plasma) (305)	107
Paracetamol (194)	135
Parainfluenza Viruses (cell culture lysate) (388, 431)	222, 224
Paraneoplastic Neuropathies (serum) (265)	67
Parasite Microscopy (blood smear) (456)	193
Parasite Microscopy (stool) (451)	145
Parasites (blood smear) (456)	193
Parasites (pictures) (906, 907)	195, 196
Parasites (serum/plasma) (452, 454, 455)	194, 194, 195
Parasites (stool) (451)	145
Parechovirus (cell culture lysate) (407, 431, 433)	221, 222, 224
Parechovirus (suspensions of feces) (430)	206
Paroxetine (875)	132
Paroxysmal Nocturnal Hemoglobinuria (616)	91
Parvovirus B19 (plasma) (367)	223
Parvovirus B19 (serum) (342)	239
pCO2 (POCT OPTI Systems) (163)	145
pCO2 (POCT) (161)	144
PCR/NAT Multiplex (548)	168
Peliosis hepatis (326)	170
Pentaporphyrin (178)	156
Perampanel (871)	128
Perazine (860, 874)	131, 136
Peripheral Neuropathies (serum) (267)	68
pH (POCT OPTI Systems) (163)	145
pH (POCT) (161)	144
pH (urine) (171)	156
Pharmacogenetics (775)	35
Phenobarbital (195)	139
Phenylalanine (710)	113
Phenytoin (195)	139
Phosphate (POCT: Abaxis Piccolo) (810)	145
Phosphate (serum) (100)	115
Phosphate (urine) (173)	157
Phosphoethanolamine (710)	113
Phospholipids (151)	119
PhosphoTau Protein (pTau) (CSF) (466)	121
Photometer Controls (181)	141
PIGF (625)	109
PIK3CA (liquid biopsy) (752)	35
Pipamperone (873)	131
Piperacilline (890)	127
Pituitary (298)	105
Placental growth factor (625)	109
Plasma Cell Neoplasia-MRD Immunophenotyping (821)	120
Plasmaprotein (240, 241, 242)	142, 142, 143
Plasminogenactivator inhibitor (PAI): 4G, 5G (whole blood) (735)	44
Plasminogenactivator-Inhibitor (PAI): 4G, 5G (DNA) (748)	44
Plasminogenactivator-Inhibitor (PAI): 4G, 5G (whole blood, Dna) (735)	44
Plasmodia (454)	194
Platelet antibodies (233)	82
Platelet antigens (233)	82
Platelet Immunology (233)	82
Platelets (209, 211, 612)	86, 87, 88
Platin (206)	147
PLGF (625)	109
PML::RARA gene fusion (cDNA) (702)	54
PML::RARA qualitative (cDNA) (702)	54
PMS2 (DNA) (783)	41
Pneumocystis jirovecii (Fungal genome) (560)	189
PNH (EDTA-whole blood) (616)	91

INDEX

pO2 (POCT OPTI Systems) (163)	145
pO2 (POCT) (161)	144
POCT (100, 131, 145, 151, 171, 173, 174, 176, 177, 179, 203, 204, 209, 211, 226, 240, 286, 292, 293, 311, 321, 322, 324, 334, 337, 344, 346, 350, 352, 355, 359, 370, 410, 481, 539, 545, 546, 612, 760, 761, 800, 810)	86, 87, 88, 96, 102, 112, 112, 115, 118, 119, 141, 142, 143, 145, 146, 148, 149, 150, 150, 151, 151, 153, 155, 156, 157, 164, 167, 170, 176, 177, 181, 182, 192, 197, 198, 199, 231, 232, 232, 233, 234, 236
Porphobilinogen (urine) (180)	154
Porphyrins (178)	156
Posaconazole (198)	130
Potassium (POCT OPTI Systems) (163)	145
Potassium (POCT) (161)	144
Potassium (POCT: Abaxis Piccolo) (810)	145
Potassium (serum) (100)	115
Potassium (urine) (173)	157
Prader-Willi syndrome (PWS) (DNA) (786)	45
Prader□Labhart□Willi-Fanconi syndrome (786)	45
Preeclampsia Marker (625)	109
Pregabalin (872)	129
Pregnancy (305, 306)	107, 107
Primidon (195)	139
Pro-Gastrin-Releasing Peptide (299)	149
Pro-insuline (300)	108
PROC (DNA) (790, 791)	45, 46
PROC gene (DNA) (790)	45
Procalcitonin (serum) (320)	178
Progenitor Cells (whole blood) (217)	92
Progesterone (302)	109
Prolactin (298)	105
Proline (710)	113
PROS (791)	46
PROS1 gene (DNA) (791)	46
Prostatic acid Posphatase (100)	115
Protease Inhibitors (plasma) (384)	214
Protein (CSF) (460)	124
Protein (POCT: Abaxis Piccolo) (810)	145
Protein (serum) (100, 141)	115, 120
Protein (urine) (171, 173)	156, 157
Protein Analysis (CSF + serum) (460)	124
Protein C (DNA) (790)	45
Protein C (plasma) (225)	95
Protein S (DNA) (791)	46
Protein S (plasma) (225)	95
Prothrombin G20210A (DNA) (746)	46
Prothrombin G20210A (whole blood) (731)	47
Prothrombin G20210A (whole blood, Dna) (731)	47
Prothrombin Time (221)	102
PSA (292, 293)	149, 150
Psychostimulants (879)	135
Psychotherapeutic Drugs (860, 861, 862, 863)	136, 136, 137, 137
Pyridoxal-5-phosphate (Vitamin B6) (lyophilized whole blood) (291)	160
Pyridoxal-5-phosphate (Vitamin B6) (serum) (290)	159

Q

Q fever (325, 542)	164, 175
Querry fever (325, 542)	164, 175
Quetiapine (860, 861, 862)	136, 136, 137
Quick (plasma) (221, 285)	95, 102
Quick (whole blood) (286)	102

R

RA (273)	69
Rabies Virus (lyophilised) (390)	223
Rabies Virus (serum) (336)	239
Raltegravir (850)	132
rare erythrocyte blood group systems (DNA) (235)	26
Reboxetine (873)	131
red blood cell (RBC) morphology (212)	87
red blood cells (RBC) (171, 211, 612)	86, 88, 156
Respiratory burst (granulocytes) (654)	77
respiratory diseases (431, 432)	224, 225
respiratory infection (314)	173
Respiratory Stimulants (870, 870)	138, 138
Respiratory Syncytial Virus (cell culture lysate) (359, 432)	199, 225
Respiratory Virus Panel (cell culture lysate) (431, 432)	224, 225
RET (DNA) (738)	56
Ret Proto-Oncogene (DNA) (738)	56
Reticulated Platelets (216)	91
Reticulocyte (blood smears) (215)	92
Reticulocyte production Index (RPI) (216)	91
Reticulocytes (blood smears) (215)	92
Reticulocytes (whole blood) (216)	91
Retinol (Vitamin A) (290)	159
Retinol binding protein (urine) (182)	158
Reverse Transcriptase Inhibitors (plasma) (384)	214
RF (273, 323)	69, 178
Rh (D) Factor (Machine-based, whole blood) (237, 238)	83, 83
Rh (D) Factor (serum / erythrocytes suspension) (231, 232)	81, 81
Rh - Subtyping (Machine-based, whole blood) (237)	83
Rh - Subtyping (serum / erythrocytes suspension) (231, 232)	81, 81
Rh - Subtyping (without Cw) (Machine-based, whole blood) (238)	83
RHCE (DNA) (235)	26
RHD (DNA) (235)	26
RHD - Deletion (DNA) (235)	26
Rheumatoid Arthritis (serum) (273)	69
Rheumatoid Factor (IgA) (serum) (273)	69
Rheumatoid Factor (IgG) (serum) (273)	69
Rheumatoid Factor (IgM) (serum) (273)	69
Rheumatoid Factor (serum) (273, 323)	69, 178

INDEX

Ribavirine (850)	132
Riboflavin (Vitamin B2) (lyophilized whole blood) (291)	160
Riboflavin (Vitamin B2) (serum) (290)	159
Rickettsia (antibody, serum) (330)	179
rickettsioses (330)	179
Rilpivirin (850)	132
Risperidone (862)	137
Ritalinic acid (879)	135
Ritonavir (850)	132
Rivaroxaban (503)	103
ROMA-Score (292)	149
Rotaviruses (suspensions of feces) (401, 430, 430)	206, 206, 226
ROTEM Sigma (plasma) (509)	103
RSV (359)	199
Rubella specific quotient (CSF + serum) (463)	123
Rubella Virus (cell culture lysate) (389)	226
Rubella Virus (serum) (341)	240
Rubella virus IgG Antibody Index (CSF + serum) (463)	123
Rufinamide (871)	128
RUNX1 (CDS) Mutation(s) (798)	57
RUNX1 Nomenclature (798)	57

S

S100 (292)	149
S65C (741)	39
Salicylate (194)	135
Salicylic acid (194)	135
Salmonella (537)	169
Salmonella (antibody, serum) (331)	180
Salmonella enterica (Bacterial genome) (537)	169
Salmonellosis (331, 537)	169, 180
Sapoviruses (suspensions of feces) (430, 430)	206, 206
Sarcosine (710)	113
SARS-CoV-2 (Ag) (cell culture supernatants) (410)	197
SARS-CoV-2 (cell culture lysate) (340, 409, 417, 431)	202, 224, 227, 227
SARS-CoV-2 (cell culture supernatants) (410)	197
SARS-CoV-2 (RNA) (cell culture lysate) (409)	227
SARS-CoV-2 (serum) (416)	240
sC5b-9 (247)	79
SCC (292)	149
Schistosomiasis (serum/plasma) (454)	194
Sediment Pictures (pictures) (172)	157
Selenium (lyophilized whole blood) (208)	146
Selenium (plasma) (206)	147
Selenium (urine) (205)	153
Sepsis (320, 322)	143, 178
Serine (710)	113
Serotonin (plasma) (185)	114
Serotonin (urine) (175)	155
SERPINC1 (792)	29
SERPINC1 gene (DNA) (792)	29
Sertraline (serum) (873)	131
Serum Proteins (141)	120
sexually transmitted disease (STI) (311, 312, 313, 316, 530, 531, 547)	163, 163, 169, 173, 174, 174, 182
sexually transmitted diseases (STI) (373)	216
sexuell übertragbare Krankheiten (STI) (480)	191
SF3B1 (DNA) (797)	60
SF3B1 Exon 14-15 (DNA) (797)	60
SF3B1 Nomenclature (DNA) (797)	60
sFLT-1 (soluble fms-like tyrosine kinase-1) (625)	109
Shiga toxin-producing Escherichia coli (534)	165
Shigella spp (548)	168
sickle cells (210)	89
Sipple syndrome (738)	56
Sirolimus (601)	134
Skin antibodies (259)	63
SMA (DNA) (787)	47
SMN (DNA) (787)	47
SMN1 (DNA) (787)	47
SMN1 and SMN2 genes (DNA) (787)	47
SMN2 (DNA) (787)	47
SNRPN (DNA) (786)	45
sO2 (POCT OPTI Systems) (163)	145
Sodium (POCT OPTI Systems) (163)	145
Sodium (POCT) (161)	144
Sodium (POCT: Abaxis Piccolo) (810)	145
Sodium (serum) (100)	115
Sodium (urine) (173)	157
soluble transferrin receptor (241)	143
specific gravity (urine) (171)	156
spinal muscular atropy (DNA) (787)	47
Staining characteristics (411)	184
Staining characteristics (Slide (fixed)) (413)	185
STAT3 (DNA) (769)	60
Status of hantavirus infection (serum) (355)	232
STEC (Bacterial genome) (534)	165
Stem Cells (whole blood) (217)	92
Steroid Homones (302)	109
sTfR (241)	143
Stool parasites (pictures) (907)	196
Stool parasites (stool) (451)	145
Streptococcal AB (antibody, serum) (321)	181
Sulbactam (890)	127
Sulthiame (191)	127
Survival of motor neuron (787)	47
Susceptibility Testing of nontuberculous mycobacteria (427)	187
Susceptibility Testing of tuberculosis bacteria (425)	186
Susceptibility tests (3 Samples) (drying process) (411)	184
Susceptibility tests (5 samples) (Lyophilisate) (412)	185
Switched B cells (651)	74
Syphilis (311)	182
Systematic Toxicological Analysis (STA) (188)	152

INDEX

T

T cell subpopulations (651) 74
T cytotoxicity assay (CD107a or lysis) (657) 76
T-cells (cellular products) (617) 93
T-Cells (EDTA-whole blood) (651) 74
T-Helper Cells (EDTA-whole blood) (651) 74
T-lymphocytes (whole blood) (213) 90
T3 (294, 302) 109, 110
T4 (294, 302) 109, 110
Tacrolimus (601) 134
Taurine (710) 113
Tazobactam (890) 127
tCO2 (POCT: Abaxis Piccolo) (810) 145
TEG/ROTEM (283) 104
Teicoplanin (193) 126
Temazepam (877) 133
Testosterone (293, 302) 109, 150
Tetanus Toxoid (antibody, serum) (310) 181
Tetracyclic Antidepressants (202) 139
TgAB (295) 110
thalassemia (210) 89
Theophylline (195) 139
Thiamine total (Vitamin B1) (291) 160
Thiaminpyrophosphat (TPP) (291) 160
Threonine (710) 113
Thrombin time (222, 280, 285) 95, 99, 104
Thrombin time (Argatroban) (230) 94
Thrombocyte - alleles (DNA) (235) 26
Thrombocytes (QBC systems) (209) 87
Thrombocytes (stabilized control blood) (211) 86
Thrombocytes (whole blood) (612) 88
thromboembolism (501) 100
thrombophilia (275, 730, 731, 740, 746) 37, 38, 46, 47, 62
thrombophilia (DNA) (790, 791, 792) 29, 45, 46
Thromboplastin time (221) 102
Thrombopoietin (626) 108
thrombosis (730, 731, 740, 746) 37, 38, 46, 47
thrombosis (DNA) (790, 791, 792) 29, 45, 46
Thyreoglobulin (Special Thyroid) (301) 106
Thyreoglobulin (Tumor marker) (292) 149
Thyroglobulin (301) 106
Thyroid Gland Antibodies (295) 110
Thyroid Hormones (294, 301, 302) 106, 109, 110
thyroid-stimulating hormone (294) 110
Thyroxine (294, 302) 109, 110
Tiagabine (872) 129
TIBC (100) 115
Tick-Borne Encephalitis (serum) (358) 241
Tin (serum) (207) 147
Tobramycin (197) 138
Tocopherol (Vitamin E) (290) 159
Topiramate (872) 129
Torque Teno Virus (TTV) (plasma) (408) 228
Total Protein C (plasma) (225, 225) 95, 95
Total Tau Protein (Tau) (CSF) (466) 121
Toxin Gene (Bacterial genome) (545) 164
Toxin genes (microbiological samples) (545) 164
Toxoplasm gondii (EDTA whole blood) (457) 192
toxoplasmosis (457) 192
Toxoplasmosis (serum/plasma) (452) 195
TP53 (CDS) Mutation(s) (798) 57
TP53 (DNA) (765) 61
TP53 Nomenclature (798) 57
TPA (292) 149
TPMT (775) 35
TPS (292) 149
TPT (221) 102
TPZ (plasma) (221, 285) 95, 102
TPZ (whole blood) (286) 102
TRAb (295) 110
Trace Elements (lyophilized whole blood) (208) 146
Trace Elements (plasma) (206) 147
Trace Elements (serum) (207) 147
Trace Elements (urine) (205) 153
Training Program (plasma) (368, 378, 379, 382) 203, 208, 210, 212
TRAK/THYBIA (295) 110
transcription factor (769) 60
Transferrine (plasma) (241) 143
Transferrine (serum) (100) 115
Transferrine (urine) (182) 158
Trazodone (876) 133
Treponema (547) 169
Treponema pallidum (antibody, serum) (311) 182
Trichomonas (547) 169
Tricyclic Antidepressants (serum) (199, 201, 202, 203) 139, 140, 140, 141
Tricyclic Antidepressants (urine) (204) 153
Triglycerides (100, 151) 115, 119
Triglycerides (POCT: Abaxis Piccolo) (810) 145
Triioddotyronine (294) 110
Trijodthyronin (294, 302) 109, 110
Trimipramine (serum) (201, 203, 863) 137, 140, 141
Trimipramine (urine) (204) 153
Trockenchemie (POCT) (800) 146
Trockenchemie (POCT: Abaxis Piccolo) (810) 145
Tropism Determination (plasma) (384) 214
Troponin I (760) 112
Troponin T (760) 112
Tryptophan (710) 113
TSH (dried blood spots) (785) 125
TSH (serum / plasma) (294) 110
TSH (serum) (302) 109
Tuberculosis (Slide) (421) 188
Tuberculosis (sputum) (422) 186
Tuberculosis (suspensions of mycobacterial strains) (423, 425, 426, 427) 186, 187, 187, 188
Tuberculosis bacteria (sputum) (424) 189
Tuberculosis bacteria, genome detection (sputum) (424) 189

INDEX

Tularemia (328, 543)	165, 176
Tumor Markers (292, 293, 299)	149, 149, 150
Tumor Panel (liquid biopsy) (752)	35
tumor suppressor (765)	61
Typing of adenovirus (cell culture lysate) (371)	199
Typing of Dengue Viruses (plasma) (369)	204
Typing of enterovirus (cell culture lysate) (372)	205
Typing of human rhinovirus (cell culture lysate) (393)	217
Typing of measles virus (cell culture lysate) (386)	218
Typing of mumps virus (cell culture lysate) (387)	220
Typing of parainfluenza virus (cell culture lysate) (388)	222
Typing of rotavirus (suspensions of feces) (401)	226
Typing of rubella virus (cell culture lysate) (389)	226
Typing of seasonal and avian influenza A viruses (cell culture lysate) (370)	198
Typing of West Nile virus (cell culture lysate) (391)	229
Typing of Zika virus (cell culture lysate) (403)	229
Tyrosine (710)	113
tyrosine kinase (767)	58

U

UDP-glucuronyltransferase 1 (*28, *6) (DNA) (742)	48
UDP-glucuronyltransferase 1 (*28, *6) (whole blood) (726)	48
UDP-Glucuronyltransferase 1 (DNA) (742)	48
UDP-GT1 (742)	48
UDPG1 (*28, *6) (DNA) (742)	48
UDPG1 (*28, *6) (whole blood) (726)	48
UF Heparin (280)	104
unfractionated heparin (280)	104
Unit-Use (800)	146
Urate (100, 810)	115, 145
Urea (POCT OPTI Systems) (163)	145
Urea (POCT) (161)	144
Urea (POCT: Abaxis Piccolo) (810)	145
Urea (serum) (100)	115
Urea (urine) (173)	157
Ureaplasma (547)	169
Uric Acid (POCT: Abaxis Piccolo) (810)	145
Uric Acid (serum) (100)	115
Uric Acid (urine) (173)	157
Urinary Stone (500)	154
Urinary Stone Analyses (500)	154
Urine Chemistry (171, 173, 175, 178, 182)	155, 156, 156, 157, 158
Urine Chemistry (pictures) (172)	157
Urine Chemistry (urine) (179)	155
Urine Chemistry 06 (urine) (180)	154
Urine Protein Differentiation (171)	156
Urine Sediment Pictures (pictures) (172)	157
Urobilinogen (171)	156
Urogenital Panel (Bacterial genome) (547)	169
Uroporphorin (178)	156

V

Valine (710)	113
Valproic Acid (195)	139
Vanadium (207)	147
Vancomycin (197)	138
Vancomycin Resistant Enterococci (Bacterial genome) (546)	170
Vanillylmandelic acid (175)	155
Varicella Zoster Virus (cell culture lysate) (433)	221
Varicella Zoster Virus (plasma) (366)	228
Varicella Zoster Virus (serum) (353)	241
Varizella zoster specific quotient (CSF + serum) (463)	123
Varizella zoster virus IgG Antibody Index (CSF + serum) (463)	123
Vasculitis (serum) (257)	69
Vel system [VEL] (DNA) (235)	26
Venlafaxine (860, 861)	136, 136
Viable CD34+ events (whole blood) (217)	92
Viable CD45+ events (whole blood) (217)	92
Vibrio spp. (548)	168
Vigabatrin (872)	129
viral hemorrhagic fever (350, 355, 369, 392, 402)	201, 204, 230, 231, 232
Virilization (serum / plasma) (309)	111
virtual (172, 218, 906, 907)	88, 157, 195, 196
Virtual Parasite Microscopy (Blood) (pictures) (906)	195
Virtual Parasite Microscopy (Stool) (pictures) (907)	196
Virus Antigen Detection □ SARS-CoV-2 (Ag) (cell culture supernatants) (410)	197
Virus Detection (cell culture lysate) (370)	198
Virus Detection (Genome/Antigen) - Influenza Viruses (cell culture lysate) (370)	198
Virus Genome Detection - Adenoviruses (cell culture lysate) (371)	199
Virus Genome Detection - BK Virus (plasma / urine) (364)	200
Virus Genome Detection - Borna Viruses (cell culture lysate) (404)	200
Virus Genome Detection - Chikungunya Virus (plasma) (392)	201
Virus Genome Detection - Coronaviruses (cell culture lysate) (340)	202
Virus Genome Detection - Cytomegalovirus - additional Training Program (plasma) (368)	203
Virus Genome Detection - Cytomegalovirus Program 1 (plasma) (365)	203
Virus Genome Detection - Cytomegalovirus Susceptibility Determination (plasma) (349)	204
Virus Genome Detection - Dengue Viruses (plasma) (369)	204
Virus Genome Detection - Enteroviruses (cell culture lysate) (372)	205
Virus Genome Detection - Epstein Barr Virus (plasma) (376)	205
Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests (suspensions of feces) (430)	206

INDEX

Virus Genome Detection - Hepatitis A Virus (plasma) (377) 206
Virus Genome Detection - Hepatitis B Virus - additional Training Program (plasma) (378) 208
Virus Genome Detection - Hepatitis B Virus Genotyping (plasma) (396) 207
Virus Genome Detection - Hepatitis B Virus Program 1 (plasma) (361) 207
Virus Genome Detection - Hepatitis B Virus Susceptibility Determination (plasma) (397) 208
Virus Genome Detection - Hepatitis C Virus - additional Training Program (plasma) (379) 210
Virus Genome Detection - Hepatitis C Virus -Susceptibility Determination (plasma) (399) 210
Virus Genome Detection - Hepatitis C Virus Geno-/Subtyping (plasma) (375) 209
Virus Genome Detection - Hepatitis C Virus Program 1 (plasma) (362) 209
Virus Genome Detection - Hepatitis D Virus (plasma) (400) 211
Virus Genome Detection - Hepatitis E Virus (plasma) (380) 211
Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2 (plasma) (363) 212
Virus Genome Detection - HIV-1 (RNA) - additional Training Program (plasma) (382) 212
Virus Genome Detection - HIV-1 (RNA) Program 1 (plasma) (360) 213
Virus Genome Detection - HIV-1 Drug Susceptibility Determination (plasma) (383) 213
Virus Genome Detection - HIV-2 (RNA) (plasma) (395) 214
Virus Genome Detection - Human Herpesvirus 6 (HHV-6) (cell culture lysate) (405) 215
Virus Genome Detection - Human Herpesvirus 8 (HHV-8) (cell culture lysate) (406) 215
Virus Genome Detection - Human Metapneumovirus (cell culture lysate) (385) 216
Virus Genome Detection - Human Papilloma Viruses (cell culture lysate) (373) 216
Virus Genome Detection - Human Rhinoviruses (cell culture lysate) (393) 217
Virus Genome Detection - JC Virus (plasma / urine) (394) 217
Virus Genome Detection - Measles Virus (cell culture lysate) (386) 218
Virus Genome Detection - Mumps Virus (cell culture lysate) (387) 220
Virus Genome Detection - Norovirus (suspensions of feces) (381) 220
Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests (cell culture lysate) (433) 221
Virus Genome Detection - Parainfluenza Viruses (cell culture lysate) (388) 222
Virus Genome Detection - Parechovirus (cell culture lysate) (407) 222
Virus Genome Detection - Parvovirus B19 (plasma) (367) 223
Virus Genome Detection - Rabies Virus (Tollwutvirus) (lyophilised) (390) 223
Virus Genome Detection - Respiratory Syncytial Virus (Antigen/Genome) (cell culture lysate) (359) 199
Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests (cell culture lysate) (431) 224
Virus Genome Detection - Respiratory Virus Panel 2 for Multiplex Tests (cell culture lysate) (432) 225
Virus Genome Detection - Rotaviruses (suspensions of feces) (401) 226
Virus Genome Detection - Rubella Virus (cell culture lysate) (389) 226
Virus Genome Detection - SARS-CoV-2 (cell culture lysate) (409) 227
Virus Genome Detection - Torque Teno Virus (TTV) (plasma) (408) 228
Virus Genome Detection - Varicella Zoster Virus (plasma) (366) 228
Virus Genome Detection - West Nile Virus (cell culture lysate) (391) 229
Virus Genome Detection - Zika Virus (cell culture lysate) (403) 229
Virus Immunology - Borna Viruses (Ab) (serum) (415) 230
Virus Immunology - Chikungunya Virus (Ab) (cell culture lysate) (402) 230
Virus Immunology - Cytomegalovirus (Ab) (serum) (351) 231
Virus Immunology - Dengue Viruses (Ab and NS1 Antigen) (serum) (350) 231
Virus Immunology - Epstein Barr Virus (Ab) (serum) (352) 232
Virus Immunology - Hantaviruses (Ab) (serum) (355) 232
Virus Immunology - Hepatitis A Virus (Ab) (serum) (343) 233
Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc) (serum) (344) 233
Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM, HBeAg, Anti-HBe) (serum) (345) 234
Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) (serum) (346) 234
Virus Immunology - Hepatitis D Virus (Ab) (serum) (347) 235
Virus Immunology - Hepatitis E Virus (Ab) (serum) (348) 235
Virus Immunology - Herpes Simplex Viruses (Ab) (serum) (354) 236
Virus Immunology - HIV-1 p24 Antigen (serum) (337) 236
Virus Immunology - HIV-1/HIV-2 (Ab) (serum) (335) 237
Virus Immunology - HTLV-1/HTLV-2 (Ab) (serum) (339) 237
Virus Immunology - Measles Virus (Ab) (serum) (357) 238
Virus Immunology - Mumps Virus (Ab) (serum) (356) 238
Virus Immunology - Parvovirus B19 (Ab) (serum) (342) 239
Virus Immunology - Rabies Virus (Tollwutvirus) (Ab) (serum) (336) 239
Virus Immunology - Rubella Virus (Ab) (serum) (341) 240
Virus Immunology - SARS-CoV-2 (Ab) (serum) (416) 240
Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab) (serum) (358) 241
Virus Immunology - Varicella Zoster Virus (Ab) (serum) (353) 241
Virus Immunology - Zika Virus (Ab) (serum) (338) 242
Virusgenome-Detection SARS-CoV-2-VOC-Analysis (cell culture lysate) (417) 227
Vitamin C (171) 156
Vitamin C (plasma) (296) 159

INDEX

Vitamins (lyophilized whole blood) (291)	160
Vitamins (plasma) (187, 296)	158, 159
Vitamins (serum) (290)	159
VKORC1 (775)	35
VLDL-cholesterol (POCT: Abaxis Piccolo) (810)	145
VOC-Analysis (cell culture lysate) (417)	227
von Willebrand factor (DNA) (678)	54
von Willebrand syndrome (DNA) (678)	54
Voriconazole (198)	130
VRE (Bacterial genome) (546)	170
VWF (DNA) (678)	54
vWS (678)	54
VZV (366, 433, 463)	123, 221, 228
West Nile Virus (cell culture lysate) (391)	229
white blood cell (WBC) morphology (212)	87
white blood cells (WBC) (171, 209, 211, 213, 217, 612, 617)	86, 87, 88, 90, 92, 93, 156
Whooping cough (317, 532)	161, 171
Willebrand Factor (227)	99
WNV (391)	229
Yeasts (living cultures) (490, 491)	190, 191
Yersinia (antibody, serum) (315)	183
Yersinia enterocolitica (548)	168
Yersiniosis (315)	183
Yt system [YT] (DNA) (235)	26
Zika fever (338)	242
Zika Virus (cell culture lysate) (403)	229
Zika Virus (serum) (338)	242
Zinc (lyophilized whole blood) (208)	146
Zinc (plasma) (206)	147
Zinc (urine) (205)	153
Ziprasidone (862, 873)	131, 137
Zonisamide (872)	129
Zoonosis (325, 331, 338, 339, 340, 355, 385, 404, 535, 537, 538, 539, 542, 543)	161, 164, 165, 167, 167, 169, 175, 180, 200, 202, 216, 232, 237, 242

www.instand-international.com

INSTAND International GMBH is distributing EQA Schemes globally as a subsidiary of INSTAND e.V. and is based in Germany.

INSTAND e.V. is an interdisciplinary, non-profit, scientific-medical professional association. It operates as a reference institution according to the Guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations – Rili-BÄK. INSTAND is based in Germany and has more than 300 members worldwide. INSTAND is a member of numerous national and international professional societies and standardization committees, including DIN, CEN, and ISO. INSTAND's excellent global scientific network is a valuable tool to draw upon for research projects for quality assurance. INSTAND is accredited according to DIN EN ISO/IEC 17043.

INSTAND

INSTAND International GMBH
Address: Ubierstr. 20, 40223 Duesseldorf, Germany
Telephone: +49 211 876 3529 0
E-mail: info@instand-international.com